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Synthetic studies directed towards hunanamycin, teixobactin and 
telomycin antibiotic natural products and their analogues 
 
The emergence of bacteria resistant to all clinically approved antibiotics 
has led to a worldwide search for new drugs. Without new antibiotics many 
aspects of modern medicine would become nearly impossible.  
 
One possible solution is to use natural products which show antibacterial 
activity as the starting point for new antibiotics. Sometimes new natural 
products act upon well-known targets. However, sometimes they will show 
previously unknown modes of action. One natural product which acts upon 
a new target is hunanamycin A, a small molecule inhibitor of the riboflavin 
synthase enzyme, an enzyme not found in mammalian cells. A new 
synthesis of hunanamycin A has been achieved, using ribose as a starting 
material. The synthesis can easily be adapted to make new analogues to 
improve the activity of hunanamycin A. 
 
Teixobactin is a macrocyclic lariat depsipeptide showing excellent activity 
against Gram-positive bacteria, by targeting lipid II and III to prevent cell 
wall biosynthesis. Teixobactin is made up from a 13 membered 
depsipeptide macrocycle containing the non-proteinogenic amino acid 
enduracididine and a seven amino acid linear tail. Arginine was substituted 
for enduracididine in this research. A combination of solid phase and 
solution phase synthesis were then used in research towards teixobactin 
analogues for testing in order to improve the pharmacological properties 
and understand the structure-activity relationship. 
 
Another macrocyclic depsipeptide showing antibacterial activity is 
telomycin. A combination of solid and solution phase synthesis may also 
be used to make analogues of telomycin for structure-activity relationship.  
 
In summary, synthetic studies based on natural products showing 
antibacterial activity has been carried out in order to work towards the 
development of new antibiotics.  
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Chapter One 
1. Introduction 
 
1.1 Natural products in research 
 
Natural products are an important area of research in chemistry.1 From 
total syntheses to confirm structure and invent new methodology, to the 
extraction of novel natural products from previously untested sources, to 
medicinal chemistry based on natural products, research in this area is as 
relevant today as it was in the early era of modern chemistry. Between 
2000 and 2014 around 35% of newly approved small molecule drugs were 
derived from the unaltered natural products2, with many others using 
inspiration from nature. Of all licensed drugs only around 37% are fully 
synthetic and do not originate from a natural product in any way.3  
 
The simplest definition of a natural product is “a small molecule that is 
produced by a biological source”.4 Natural products can be further divided 
into primary and secondary metabolites.  
 
Primary metabolites are defined as biomolecules which are essential for 
metabolic processes in a cell and can usually be easily extracted in large 
quantities from many different sources.5 Therefore, they are often of little 
use to natural products research since they are well-conserved and 
produced by most or all species. They are usually not able to offer any 
selective advantage or different biological activity.  
 
Secondary metabolites are usually made in smaller quantities by fewer 
species for a specific purpose.5  Secondary metabolites include a wide 
range of molecules including polyketides, steroids, alkaloids, peptides and 
specialised carbohydrates. Natural products research is usually focused 
on secondary metabolites, since they often show interesting bioactivities.   
 
Each secondary metabolite is only produced by a certain group of 
organisms, specifically because it provides some advantage to the species 
producing them. Unlike primary metabolites, secondary metabolites are 
often made for a purpose outside of the cell they are made in. For 
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example, camphor is produced by the plant Salvia leucophylla as a seed 
germination inhibitor and pyrethrins are produced from Chrysanthemum 
cinearifolium as insecticides.5 There are many examples of natural 
products that have been used to develop a variety of useful products, 
particularly drug molecules.6  
 
1.2 Design of drug molecules 
 
Natural products often do not look like drug molecules as they feature 
complex, unexpected structures and often do not obey Lipinski’s rules.7 
Compared to other drugs, antibacterials derived from natural products 
frequently feature unique and complex structures, are often larger than the 
500 g mol-1 limit suggested by Lipinski’s rules8, are more polar and have 
more hydroxy groups than chemically designed molecules9 and often 
require high doses compared to other drugs. Despite these facts, they are 
often a source of unexpectedly good bioactivities.10  
 
As for many secondary metabolites, antibiotics are produced in nature 
because they provide a selection advantage. For example, microbes (a 
common source of antibiotics), produce antibiotics to compete against 
bacteria in the same environment.5 This is one of the major advantages of 
a total synthesis or extraction of a natural product– even if the structure is 
unexpected, the molecules made are already known to be biologically 
active.  
 
In recent years the favoured method of drug discovery has been a “target-
based” approach9 using combinatorial chemistry to make a large number 
of similar products. These molecules are tested through high throughput 
screening against targets until some are found to be “hits”. These hits can 
then be modified to be more effective. However, despite much research 
involving this technique, few licensed drugs have been made this way.2 
One theory behind the generally low success of this method is that the 
activity for drugs is not distributed evenly throughout all chemical space 
but instead is concentrated in a few areas.9 Many of these areas have 
been “discovered” by natural products, which provide a head start on 
where active drugs may be found.10   
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A third method used with great success is employing natural products as 
leads and modifying these to give the most active derivative of the 
biologically active natural product. This method combines the best parts of 
the previous two techniques: known activity from a natural product and the 
opportunity to improve this activity by analogue generation and then using 
high throughput screening.  
 
The third method has been used successfully in the development of many 
new drugs including antibiotics2 and is the approach that will be used for 
much of this project. 
 
 1.3 The definition and use of antibiotics 
 
One definition of antibiotics is “molecules that stop microbes, both bacteria 
and fungi, from growing or kill them outright”.11 This definition can cover 
both secondary metabolites produced by bacteria or other 
microorganisms, synthetic antibiotics and natural product derived 
antibiotics used as drugs.11  
 
Today, it is taken for granted by the general public that any bacterial 
infection can be cured easily by antibiotics. However, this was not always 
the case. Before their discovery, bacterial infections were often serious 
and life-threatening and so antibiotics were viewed as miracle drugs.9  
 
Immediately after their discovery (Chapter 1.4), there was much 
excitement and investment into antibiotics research with many new 
classes of antibiotics discovered.9 However, this was not sustained and 
after the 1970s the drugs already developed were thought to be sufficient 
and few new antibiotics were marketed. Resistance to current antibiotics 
began to be observed in bacteria and today even the antibiotic of last 
resort, vancomycin, now has resistant strains (vancomycin resistant 
Staphylococcus aureus).  
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1.3.1 Statistics of natural products developed into antibiotics 
 
Despite there now being a clear need for new antibiotics, fewer and fewer 
antibiotics have been registered each decade since the 1960s.12 From 
1983 to 20142 the number of new antibiotics approved by the Food and 
Drug Administration (FDA) has declined from 16 per five year period to 2 
per five year period.  
 
From 1981 until 2010 only 118 antibacterial compounds have been listed 
as New Chemical Entities and Medical Indications.12 Of these the majority 
were naturally derived (synthetic modifications based on natural products), 
26 were synthetic, 1 was a natural product made by total synthesis and 10 
were the natural products themselves. This means that over half of all new 
antibiotics in the last 30 years were derived from a natural product (with 
some modification) as is carried out in the majority of this project.  
 
From the remaining drugs the next largest group were solely synthetic as 
seen for sulfa drugs.12 Ten were also the original natural product with only 
one synthetically made but naturally derived product. Many of the new 
drugs marketed were derivatives of existing drugs and do not show new 
modes of action.    
 
1.4 Early antibiotic synthesis 
 
The most famous early antibiotic is penicillin.10 However, the first 
antibiotics to be discovered were made completely by chemical synthesis. 
Interest was first shown in dye molecules as these were thought to be able 
to selectively bind to microorganisms. Treatment with these dyes showed 
some success, with the synthetic dye methylene blue used to treat 
malaria. Synthesis of analogues based on these structures resulted in the 
first antibacterial drug to be released. This was known 
as Salvarsan (Figure 1.1) and was discovered in 1909. It was shortly 
followed by the similar but more water-soluble neosalvarsan (Figure 1.1). 
However, these drugs had serious side effects and so better alternatives 
were desperately needed.    
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Improvements also came from molecules originally designed as dyes. 
Sulfonamides were added to dyes to improve their binding, as it was 
thought that it would also increase their affinity for bacteria. Success was 
achieved when azo dyes were synthesised and tested. The most effective 
dye was found to be the red prontosil (Figure 1.1), which was 
consequently released as an antibacterial drug in 1935. After the release 
of prontosil, the active part was found to be sulfanilamide rather than the 
azo dye portion of the molecule. Therefore many analogues of 
sulfanilamide were synthesised, launching the first class of antibiotics, the 
sulfonamides.10   
 
 
 
 
Figure 1.1: The structures of the first antibiotics. 
In complete contrast, the more famous penicillin (the first β-lactam 
antibiotic) was discovered not by chemists but by microbiologists.13 It was 
noted by Alexander Fleming when colonies of Staphylococcus on culture 
became contaminated with a certain mould the bacteria underwent lysis. 
The mould, Penicillium chrysogenum, then gave its name to the first 
naturally derived antibiotic, penicillin13 (Figure 1.1). Production of 
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the "filtrate" of penicillin was initially produced from the mould itself and 
was not synthesised until after the Second World War.    
 
Initial tests on the "Mould Broth Filtrate" were carried out to test it 
as a disinfectant, rather than as an antibiotic.13 Even an 800-fold dilution 
was more effective than carbolic soap at disinfecting surfaces. Another 
advantage was its non-toxicity to humans, an ideal property for a drug.  
 
The discovery of penicillin in 192913 and the related purification of the 
natural product cephalosporin C from Cephalosporium acremonium in 
195510 led to the development of one of the most widely prescribed 
classes of antibiotics, the β-lactams. Drugs of this class are distinguished 
by the 4-membered β-lactam ring which gives the class its name. Initially 
several natural penicillins were discovered to be produced from various 
strains of Penicillium chrysogenum. However, producing many analogues 
proved to be more challenging. It was not until 195714 that the first 
chemical synthesis of a natural product penicillin (Penicillin V) was 
reported. A 1959 general synthesis of penicillins was reported as giving 
identical results for both semi-synthesis starting from penicillin G15 and 
complete total synthesis. This important discovery led to many more 
semisynthetic β-Lactam antibiotics9 with many other derivatives also made 
by total synthesis.   
 
Therefore, as shown by the examples given in Figure 1.2, although β-
lactams were originally discovered in nature they have been improved by 
chemists allowing them to produce the antibiotics of today. Due to the 
importance of these molecules many reviews have been written on their 
synthesis and properties16,17, and therefore only a brief overview has been 
given in this section.    
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Figure 1.2: Examples of a β-Lactam made by each of the possible methods.  
 
1.5 Current antibiotics 
 
Since the discovery of penicillin and sulfonamides there have been many 
new antibiotics introduced.18 As there are too many classes and individual 
drugs to comprehensively cover, a short overview will be given here, with 
a focus on drugs which target similar sites as the natural products 
researched in this project.  
 
1.5.1 Sites of action of antibiotics 
 
The vast majority of antibiotics used today have a known site of action. 
The sites of action of the drug candidates synthesised as part of this 
project are cell wall (Chapter 3), cell membrane biosynthesis (Chapter 4) 
and riboflavin biosynthesis (Chapter 2). Cell wall biosynthesis is a very 
common target, while cell membrane and riboflavin biosynthesis are more 
unusual.  
 
Other common targets (Figure 1.3) for antibiotics are protein biosynthesis 
(targeted by aminoglycosides, tetracyclines, macrolides, oxazolidinones, 
streptogramins and phenicols), RNA synthesis (rifamycin), DNA synthesis 
(quinolones) and the folic acid pathway (trimethoprim and sulfonamides). 
However due to the low frequency of finding targets for these sites, other 
areas such as ATP synthase are being considered.18 Oxazolidinones, 
sulfonamides and quinolines are fully synthetic antibiotics. However, all 
other examples shown here are based on natural products, showing their 
importance in antibiotic research.18 
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Figure 1.3: Popular targets within the bacterial cell (Adapted from Current Medicinal 
Chemistry, 2004, Vol. 11, No. 6, p776).19  
 
1.5.2 Cell wall inhibitors 
 
Despite all of the potential targets (Figure 1.3) the most commonly used 
antibiotics are cell wall inhibitors.12 Three classes discussed here are β-
Lactams, glycopeptides and lantibiotics. 
 
1.5.2.1 β-Lactams 
 
β-Lactam antibiotics (previously discussed in Section 1.4.2) inhibit 
bacterial growth by blocking the enzyme that cross-links two peptides to 
form the cell wall.11 The active site of this enzyme will typically have a 
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transpeptidase which attacks the terminal peptide bond of one of the 
peptide chains, releasing D-Ala and activating the chain to attack from the 
second peptide chain.  
 
The enzyme is blocked when the transpeptidase reacts with the lactam 
ring, rather than an amide bond on a peptide. The resulting bond is slow to 
hydrolyse and cannot be used as a substrate for cross linking with an 
amino acid, so the active site cannot be synthesis the cell wall and the 
structure of the cell is compromised.18   
 
1.5.2.2 Glycopeptides 
 
Glycopeptides (e.g. vancomycin) inhibit cell wall biosynthesis using a 
different mechanism. These antibiotics cap the uncrosslinked 
peptidoglycan and prevent crosslinking, weakening and destroying the 
structure of the cell and therefore killing it.11  
 
The most well-known member of the glycopeptides is vancomycin (Figure 
1.4), approved for clinical use in 1958.20 Many glycopeptides, such as 
vancomycin and teicoplanin are natural products that have been approved 
for use as antibiotics. However, recent trends21 for new glycopeptides 
mainly focus on either semisynthesis or chemical modification of existing 
glycopeptides10, or the use of genetic manipulation. Examples of 
semisynthetic glycopeptides recently approved by the FDA include 
telavancin and oritavancin (Figure 1.4).  
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Figure 1.4: Vancomycin (natural product) and two semi-synthetic analogues 
 
1.5.2.3 Lantibiotics 
 
Lantibiotics are a family of peptide antibiotics that may be either linear 
(Type A) or globular (Type B).22 Many lantibiotics act by interacting with 
Lipid II on the surface of cell walls to form pores, which allow proteins to 
leave the cells, although other mechanisms involving Lipid II are also 
known.23 Lantibiotics are natural products with the first member of the 
group, nisin (Figure 1.5), first discovered in the 1920s. Despite their early 
discovery, common use in preventing food spoilage and around 80 known 
members of the family, no lantibiotics have been approved as drugs.22 
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However, several natural product lantibiotics or semisynthetic derivatives 
are under consideration for development into new drugs.24   
 
 
  
 
Figure 1.5: Nisin, an example of a type A lantibiotic.  
 
1.5.3 Central metabolism 
 
There are many processes within the bacterial cell which have not yet 
been fully explored for potential targets25 and may provide useful leads for 
the development of new drugs. Many alternative targets are part of the 
central metabolism processes within the cells, which are essential for life 
and exist in all (or almost all) classes of bacteria. Central metabolism is 
often thought of as a bad choice for a target of a drug. This is due to many 
processes not only being conserved between bacteria, fungi and other 
lower species, but also being conserved in mammalian cells, causing 
major problems with selectivity. 
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However, drugs targeting central metabolism are possible since many 
currently available antibacterials26 target central metabolism. Some of the 
earliest antibacterials, sulfonamides, target the folate pathway (Figure 
1.6), part of central metabolism.  
 
Folate is used biologically for many cellular functions (e.g. DNA nucleotide 
synthesis).26,27 Folate (also known as folic acid or vitamin B9) is 
metabolised by both prokaryotes and eukaryotes by the folate pathway. 
While the structure of the folate pathway is similar for both prokaryotes 
and eukaryotes there are enough differences to selectively target 
prokaryotes.  
 
Prokaryotes cannot take up folate from their environment so have an extra 
enzyme in their pathway compared to eukaryotes. The enzyme 
dihydropteroate synthase (DHPS) produces folate and is the proven target 
of the sulfonamides, leading to the wrong product being formed by the rest 
of the pathway. Although sulfonamides are effective antibiotics, there are 
sometimes off-target effects arising from the similarity of the pathways in 
prokaryotes and mammalian cells, although DHPS is not found in 
mammalian cells. 
 
However, there are several parts of the central metabolism not found in 
mammalian cells. An example of central metabolism exclusive to 
microorganisms is the riboflavin pathway.28  
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Figure 1.6: Simplified diagram of the folate pathway. Adapted from reference26. 
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1.7 Overview to the introduction 
 
This section has introduced the concept and importance of natural product 
antibiotics and their importance for medicinal chemistry today. As shown, 
although occasional breakthroughs have been made using purely 
synthetic methods the majority of successful antibiotic drugs use natural 
products as their base or inspiration. 
 
The following three chapters will focus on the specific natural products 
studied during this project; hunanamycin (Chapter 2), teixobactin (Chapter 
3) and telomycin (Chapter 4). More detailed backgrounds to each natural 
product will be given at the start of each chapter.  
   
In many ways sulfonamides are very close to the mode of action 
of hunanamycin29 in this project - both inhibit conserved pathways that are 
common to many types of pathogen but are not found in humans and 
animals. Both are also small molecules that can be made in a few steps by 
chemical synthesis. However, in other ways there are many differences. 
Sulfa drugs are unusual in that they are fully synthetic. Hunanamycin was 
discovered in a more common way, as a secondary metabolite of a strain 
of bacteria.   
 
In contrast both teixobactin (Chapter 3) and telomycin (Chapter 4) are both 
natural products which can be used as the starting point for the 
development of antibiotics, similarly to β-lactams and glycopeptides in this 
chapter. 
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Chapter Two 
2. Total synthesis of hunanamycin A 
 
2.1.1 The riboflavin synthesis pathway 
 
A flavin (Figure 2.1.1) is "an isoalloxazine molecule carrying two methyl 
groups at the positions 7 and 8 and a further substituent at position 
N".30 Riboflavin is an example of flavin which occurs naturally in most 
cells. Flavins are usually involved in catalytic processes in cells. Riboflavin 
is classed as a vitamin (Vitamin B2) and was first discovered at the end of 
the 19th century.31  
 
 
 
Figure 2.1.1: Flavin (left) and riboflavin (right). 
 
Riboflavin is a precursor to the biologically important 
cofactors flavin mononucleotide (FMN) and flavin adenine dinucleotide 
(FAD). Flavins are capable of carrying out electron transfer processes as 
both FMN and FAD are present in oxidoreductases. However, despite the 
importance of riboflavin animals cannot synthesise this vitamin themselves 
but instead must take it up through their diet, mainly through eggs, milk, 
meat, yeast and vegetables. Riboflavin is however synthesised by bacteria 
and fungi (and also plants) so it should be possible to selectively target the 
riboflavin synthesis pathway in pathogens without affecting the animal 
host.  
In principle, targeting this pathway should be similar to the way which 
sulfonamides act on the folate pathway (Chapter 1.5.3). Sulfonamides 
have been used for many years with great success.  
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The riboflavin synthesis pathway is shown in Figure 2.1.2. Each cycle 
consumes one molecule of guanosine-5'-triphosphate (GTP) and two 
molecules of ribulose 5-phosphate.28 In the first step (catalysed by the 
enzyme lumazine synthase) intermediate A (formed from GTP) and 
ribulose 5-phosphate form intermediate B. Two equivalents of intermediate 
B then react, catalysed by the second enzyme, riboflavin synthase to form 
riboflavin. One molecule of intermediate A is formed as a side product and 
is recycled through the cycle to form another molecule of riboflavin.  
 
  
Figure 2.1.2: The riboflavin biosynthesis pathway. 
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As well as riboflavin itself other natural flavin analogues are also known. 
Among these are Cofactor F420,32 molybdopterin,30 6-Hydroxy-7,8-
dimethyl-isoalloxazine and 7-Methyl-8-hydroxyl-isoalloxazine.33 These will 
not be covered in further detail here since they were not found to have 
antibiotic activity.  
 
There is however, one naturally occurring riboflavin analogue which was 
shown to have some antibiotic activity. Roseoflavin 34 (Figure 2.1.3) is a 
natural product made by Streptomyces davawensis and was the subject of 
antibiotic research in several papers published from 1974-1982 35. The 
activity of roseoflavin and several 8-N-alkyl derivatives have been tested. 
Interestingly, they were found to have activity only against Gram-positive 
bacteria with an uptake mechanism, in contrast with hununamycin which is 
only active against bacteria without an uptake mechanism. The proposed 
mechanism of action involves roseoflavin being incorporated as a 
cofactor into enzymes which normally use riboflavin as a cofactor. Due to 
the structure of roseoflavin it has no oxidising ability, so the enzyme 
is deactivated. Although this appeared to be a good lead it was 
unfortunately found that resistance to roseoflavin appeared very rapidly. 
However, it has found a use in the industrial production of riboflavin since 
resistant bacteria produce more riboflavin.30  
 
 
Figure 2.1.3: Roseoflavin, a naturally occuring riboflavin analogue which acts as an 
antibiotic. 
 
2.1.2 A background to riboflavin inhibitors 
 
Most of the work on synthetic inhibitors of the riboflavin synthesis pathway 
has been carried out by Cushman et. al. The first paper published in 
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199936 designed inhibitors by looking at the crystal structure of lumazine 
synthase binding intermediate (A) shown below in Figure 2.1.4. 
 
 
 
 
Figure 2.1.4: The intermediate all future analogues were based on (A) and the first 
analogue predicted to inhibit riboflavin synthesis (B).  
 
Using modelling they predicted that (A) (Figure 2.1.4, 2.1.6) is an 
intermediate in the riboflavin synthesis pathway and analogues based on it 
may bind more strongly and be inhibitors of lumazine synthase.36 
Modelling was used to predict that the intermediate shown in Figure 2.1.14 
would be the most effective inhibitor of lumazine synthase. Synthesis of 
(B) showed that it had a Ki of 109 μM against lumazine synthase isolated 
from Bacillus sublilus and at the time of the paper was the most potent 
inhibitor discovered.  
 
Based on the results of this paper, further investigations37 tested a 
bisubstrate inhibitor (Figure 2.1.5). This was found to be an effective 
inhibitor with a Ki = 37 μM for lumazine synthase. However, it was not 
effective against riboflavin synthase and it was not possible to make a 
similar inhibitor for riboflavin synthase.  
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Figure 2.1.5: An inhibitor of lumazine synthase.  
 
The focus of the research was then shifted to the synthesis of inhibitors 
with different ring sizes on the fused-ring core of the molecule and 
different lengths of substituted N-alkyl chains.  
 
The first reported inhibitor of this series was based on a purinetrione  
(Figure 2.1.6).38 This was found to be a potent inhibitor with Ki of 0.61 μM 
for riboflavin synthase and 46 μM for lumazine synthase. Further work 
carried out on this substrate added alkyl chains substituted with phosphate 
at the terminal end (shown to improve inhibition in other substrates). Of 
each of the chain lengths tested (3-6 carbons), a three carbon chain was 
found to be the most effective (Ki of 3.63 μM for riboflavin synthase and 
41.4 μM for lumazine synthase).  
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. 
 Figure 2.1.6: Two inhibitors based on a purinetrione scaffold. 
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The second size of fused ring is shown in Figure 2.1.7.38 The molecule, 
2.1.9 itself is an inhibitor, but the analogues based on it (Figure 2.1.7) 
were shown to be potent inhibitors of both lumazine synthase and also to 
inhibit the riboflavin synthase enzyme.   
 
 
 
Figure 2.1.7: Inhibitors of lumazine synthase with their Ki indicated. 
 
Due to the success of the previous inhibitors pyrazolopyrimidine39 
analogues (Figure 2.1.8) have also been synthesised based on the 
previous two analogue groups. Similarly to previous analogues it has also 
been shown to be potent inhibitors. 
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Figure 2.1.8: The most effective riboflavin synthase inhibitor based on 
pyrazolopyrimidine scaffold.  
 
The crystal structure of both lumazine synthase and riboflavin synthase 
are known.36 Therefore the proposed binding of the most effective of each 
of the analogues has been shown.  
 
Although it is often mentioned that riboflavin synthesis is an attractive 
target for new antibiotics, many of the analogues here had other laboratory 
uses rather than as new drugs.30 They are also often unsuitable as 
antibiotics as they are too polar (or sometimes charged) to cross cell 
membranes effectively and the phosphate group is often broken down 
easily by phosphorylases due the frequency of the phosphate group in 
other biological molecules. 
 
2.1.3 Hunanamycin A 
 
Hunanamycin A (Figure 2.1.9) is a natural product which was isolated in 
201229 from a strain of Bacillus hunanensis in a mangrove swamp in the 
Bahamas. Bacillus hunanensis40 is a halophillic, Gram-positive 
bacteria. Screening the metabolites of this strain of bacteria led to the 
discovery of hunanamycin A. Hunanamycin A was found to have some 
antibiotic activity against yeast and some types 
of enterobacteria (including Escherichia coli), which cannot take up 
riboflavin. It has an minimum inhibitory concentration (MIC) of 
12.4 μM against Salmonella enterica. The MIC is the minimum inhibitory 
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concentration needed to prevent visible growth of the bacteria 
after overnight incubation. This MIC could be improved by the creation of 
analogues based on the core structure. 
 
 
 
 
Figure 2.1.9: The structure of hunanamycin A. Although based upon riboflavin like other 
inhibitors of riboflavin synthesis, it is not as polar as other inhibitors tested. 
 
This antibiotic could be useful as it acts only on the riboflavin synthase 
enzyme which is not present in humans or animals. Most bacteria, 
however make the vitamin themselves with some also taking up the 
vitamin through channels. It may be used as a narrow spectrum antibiotic, 
used to target a specific infection.41 
 
2.1.4 Previous synthesis of hunanamycin A 
 
A paper was published in 201342 detailing a first synthesis of hunanmycin 
A (Figure 2.1.10).This paper successfully makes hunanamycin A with the 
correct stereochemistry, with most stages giving good yields. However, it 
is difficult to make a large number of analogues from this method since it 
starts with the large fragment of 6,7-dimethyl-1,4-dihydroquinoxaline-2,3-
dione. The stereochemistry of the sugar is introduced by reactions which 
use the toxic OsO4 in the last stages. This leads to a mixture of products 
which have to be separated and also means that for each new analogue 
with slightly different stereochemistry a different method for putting the 
stereochemistry in place would need to be designed. This is a major 
disadvantage for this synthesis. 
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Figure 2.1.10: The first synthesis of hunanamycin A.  
 
A further paper on a biomimetic synthesis of hunanamycin A43 was 
published by the same group. The synthesis is started from the commonly 
available vitamin riboflavin, thought to be the molecule hunanamycin A is 
derived from biosynthetically. This synthesis (Figure 2.1.11) firstly removes 
the third ring using NaOH followed by H2O2. Prenylation and cyclisation 
are then carried out using a similar method to the first synthesis, yielding 
multiple grams of hunanamycin A. Although this synthesis is a good, high 
yielding and cost effective method of making hunanamycin A, it is not 
possible to make a large number of analogues using this method, since a 
large portion of hunanamycin A is already made. Therefore, few 
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alterations to the structure may be made. Since it is desirable to improve 
the MIC of hunanamycin A, a new synthesis is still required.   
 
 
 
Figure 2.1.11: Biomimetic synthesis of hunanamycin A. 
 
2.1.5 Conclusion 
 
Hunanamycin A is a viable candidate to develop inhibitors of riboflavin 
synthase from. Although synthesis of hunanamycin A has already been 
carried out, it would be advantageous to have another route to create 
analogues. Ribose is a very cheap and readily available starting 
material.44 Retrosynthetic analysis (Figure 2.2.1) can be carried out to with 
ribose as a starting material. This would be advantageous since it already 
has all the required stereochemistry and is cheap so would be attractive in 
an industrial synthesis. At the same time, the availability of other 
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carbohydrates would enable the preparation of analogues with different 
chain lengths and number of hydroxy groups.  
 
 
2.2.1 Proposed retrosynthesis of hunanamycin A 
 
The group which carried out the first synthesis of hunanamycin A firstly 
tried to add ribose directly to the heterocyclic core. For them this was 
ultimately unsuccessful, so the first published total synthesis of 
hunanamycin A (Figure 2.1.10) did not use ribose.42  
For the synthesis in this thesis a different approach to adding ribose will be 
used. Figure 2.2.1 shows the retrosynthetic analysis for the total synthesis 
of this molecule. The first stage of the synthesis will be addition of the 
ribityl moiety, followed by construction of the remaining, heterocyclic 
section.  
 
 
 
 
Figure 2.2.1: Retrosynthetic analysis for the synthesis of hunanamycin A. 
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2.2.2 Reductive amination using ribose 
 
Reductive amination is one method which may be used for addition of 
ribose. A previously reported45 relevant reaction using reductive amination 
to add ribose to 2.2.2 is shown in Figure 2.2.2. A good yield of 2.2.3 was 
achieved using this method. However, it has proved challenging to 
reproduce the high yields reported46,47 for the synthesis of 2.2.2, despite 
several people in the group undertaking this reaction.1
 
Figure 2.2.2: Initial route used to attempt synthesis of hunanamycin A. The first two 
reactions were adapted from reference45.  
                                                          
 Unpublished work carried out in the Ganesan group by various students and postdoctoral 
researchers between 2011 and 2014.   
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Previous work within the group* showed that it was necessary to protect 
the hydroxyls of the ribityl moiety. One of the simplest methods of 
protection is acetylation. However, the disadvantage of carrying out 
acetylation using 2.2.3 is that the more reactive amine will also be 
protected. Although this will complicate the synthesis, methods have been 
reported which selectively remove acetyl from an amine48 rather than 
hydroxyl. 
 
Two methods for acetyl protection of 2.2.3 were carried out. One used 
acetic anhydride and pyridine and the other DMAP, NEt3 and acetic 
anhydride.  Both conditions appeared to give the desired product by both 
NMR and LC-MS (Figure 2.2.3). However, the NMR showed impurities 
and appeared to show a lot of peaks which did not integrate as expected. 
A similar literature reaction47 does however also show a 1H NMR with 
many unlabelled (although minor) impurities so it may not be possible to 
purify this reaction fully.  
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Figure 2.2.3: A) 1H NMR of 2.2.4 after purification. Product is not pure, as shown by the 
highlighted regions. B) LC-MS of 2.2.4. Although the largest peak is shown to be 2.2.4, 
there is also a shoulder on the peak showing the presence of another product.  
 
The next stage of synthesis is deprotection of the Boc group. This may be 
carried out using 4M HCl in dioxane (Figure 2.2.4). The same result was 
achieved when using commercial HCl in dioxane or aqueous concentrated 
HCl dissolved in dioxane. Deprotection could also be carried out using 2,6-
lutidine and TMSOTf.  
 
Unidentified side product 
Too many aromatic peaks 
Too many methyl peaks 
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Figure 2.2.4: Proposed next stage of the synthesis, removal of the Boc protecting group. 
 
The characterization of 2.2.5 did not however, show the expected results 
for the proposed structure shown in Figure 2.2.6. The first data which 
contributed to this theory is the m/z by ESI. As shown in Figure 2.2.5 the 
expected m/z of the product is 480. However, the observed mass was 
463, corresponding to dehydration of the molecule.  
 
 
Figure 2.2.5: LC-MS of 2.2.5, showing the absence of the m/z of the proposed mass in 
the single peak shown by the UV trace.  
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The next evidence suggesting a different reaction has taken place is 
obtained from the carbon-13 NMR. Since acetylating 2.2.3 leads to 
acylation of the amine as well as the four hydroxyls on the ribityl moiety, 
there should be five carbonyl peaks in the carbon-13 spectrum. However, 
only four are seen.  
 
When viewed together the observed m/z and carbon-13 NMR suggest that 
the dehydration has taken place between the free amine and the N-Ac 
group, accelerated by the acidic conditions. The structure of the 2.2.6 can 
be further inferred from the 1H NMR where one of the methyl peaks has 
shifted to a more deshielded position, consistent with the formation of a 
benzimidazole ring.  
 
 
Figure 2.2.6: A proposed explanation for the results seen, based on “Intermediates in the 
reaction of o-phenylene-diamine with carbonyl compounds and their subsequent 
conversions”.49  
 
Summary of 2.2.2 
In summary, the difficulties with purification of 2.2.4 and the formation of 
benzimidazole upon deprotection of the Boc group of 2.2.4 mean that it 
was not viable to continue with this synthetic route.   
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2.2.3 Protection of ribose 
 
Another possible substrate for reductive amination is 2,3,4,5-hydroxyl 
protected ribose. A free aldehyde needs to remain on carbon 1, so the 
aldehyde of ribose was firstly protected (Figure 2.2.7), followed by 
protection of the hydroxyl groups and finally deprotection of the aldehyde.  
 
2.2.3.1 Protection of hydroxyls by acetylation 
 
Protection of the aldehyde can be carried out using 1,3-propanedithiol to 
give 2.2.7 in a known literature reaction. Acetylation can then be carried 
out via a common procedure (Figure 2.2.7) to give 2.2.8a in high yield and 
purity. 2.2.8a is reported as an orange syrup. However, this syrup and 
orange colour is due to trace amounts of pyridine still present in the 
product even after washing with CuSO4 solution and drying under high 
vacuum. After around three days drying under high vacuum white crystals 
were seen forming from the orange syrup, suggesting that 2.2.8a is more 
accurately reported as white crystals. For any future work the pure white 
crystals could be obtained by recrystallisation.  
 
 
 
Figure 2.2.7: Synthesis of 2,3,4,5 protected ribose. 
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In contrast to 2.2.7 and 2.2.8a, intermediate 2.2.9a was more difficult to 
purify. The method using NBS shown in Figure 2.2.7 could be used to 
make the product, with a clearly visible aldehyde peak at 9.52 ppm in the 
1H NMR spectrum providing evidence of formation. However, also seen in 
the spectrum was a singlet at 2.76 ppm which could not be assigned to 
any part of the spectrum but matched the spectrum of succinimide, formed 
as a side product from the dithiol deprotection.  
 
Several attempts were made to purify 2.2.9a but these were unsuccessful. 
One method usually suggested for removal of succinimide is to suspend 
the crude mixture in CCl4, which succinamide is not soluble in. However, 
an acetyl protected sugar is also not soluble so no purification will be 
carried out using this method.  
 
Another common method, using flash column chromatography to separate 
out the impurity and product did not work in this case because both the 
product and impurity were difficult to visualise on a silica TLC plate using 
either short or long wavelenth UV or several different stains and so it was 
difficult to know which solvent system to use and when the product was 
eluting.  
 
The final method attempted was to dissolve crude 2.2.9a in an organic 
solvent and wash with a large amount of water, which should remove the 
polar succinimide. Unfortunately, although the acetyl protecting groups 
make the ribose less polar and more organic soluble, 2.2.9ais still very 
soluble in water so the yields recovered were very low (less than 10%). 
 
2.2.3.1 Summary 
In summary, separation of succinamide and 2.2.9a was not possible, so it 
was judged necessary to change the acetyl protecting groups of 2.2.9a.  
  
2.2.3.2 Protection of hydroxyls by benzoylation 
 
The problems in purification were overcome by changing the protecting 
group. The benzoyl protecting group is less polar and so less soluble in 
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water than acetyl, although conditions to protect 2.2.7 with benzoyl to form 
2.2.8b are very similar to those used for acetyl. Protection with 4 benzyol 
groups makes 2.2.9b significantly less polar than 2.2.9a and more visible 
by TLC, so removal of succinimide by silica column was achieved after 
screening several solvent systems.  
 
Before conditions for the successful purification of 2.2.8b, other reaction 
conditions were attempted (Table 2.2.1) as initial purifications were 
unsuccessful. However, the most successful conditions were deprotection 
using NBS. Initially the deprotection was carried out at -10 °C, with 7.7 
equivalents of NBS, following a literature example.50 However, following 
the example of Gao et al.51 the number of equivalents of NBS were 
reduced to 6 and the temperature increased to room temperature. As well 
as the increased ease of reaction these conditions also led to less 
succinimide side product present in the crude product. Purification of the 
product was then carried out using flash column chromatography.  
 
 
Table 2.2.1: Conditions attempted for aldehyde deprotection of 2.2.8b to form 2.2.9b.  
 
Conditions Result 
CaCO3 (18 eq), MeI (40 
eq), MeCN: H2O (3:1) 
40 °C, 4 days52 
After 4 days the reaction 
was still not complete 
(monitored by TLC). 
30 % H2O2 (4.5 eq), 
NBu4I (10 mol%) 
AcOH, water, r.t. 53 
No product recovered.  
Hg(ClO4)2.H2O, 2,6 
lutidiene, 0 ° C, 15 
minutes54 
No product recovered.  
2,6-lutidine, NBS, 
acetone:H2O, 1 hour.55 
No product recovered. 
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2.2.5 Reductive amination using protected ribose 
 
2.2.5.1 Choice of amines for reductive amination 
 
With protected ribose successfully made, work could then be started on 
reductive amination. There are several possibilities for the choice of amine 
to use in a reductive amination. Firstly 2.2.2 may be used, as in the 
synthesis of 2.2.3. The disadvantage of this method is the difficulty 
reproducing the literature yield.  
 
Alternatively, N-prenylation of one of the amines of 4,5-dimethyl-1,2-
phenylenediamine (2.2.11) could install a precursor of the heterocycle 
before reductive amination. However, 2.2.11 is less sterically hindered 
than Boc so additional reactions may take place on the amine which 
prenylation has been carried out on.  
 
Two methods were used for the synthesis of the N-prenylated precursor to 
reductive amination. The first uses an excess of diamine to avoid double 
alkylation and the second uses mono-Boc protected diamine (Figure 
2.2.8).  
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Figure 2.2.8: Attempted synthesis of a heterocyclic fragment of hunanamycin A.  
 
The first method uses 0.5 equivalents of 3,3 dimethyl-allyl bromide and 1 
equivalent of the diamine. This reaction can be used to give the product in 
good enough purity to continue onto the next stage of the reaction.  
The other method of prenylation involves the use of the mono-Boc 
protected diamine. This method has the disadvantage of using 2.2.2 
(which has not been possible to make in high yield). However, it was 
thought that this may react more cleanly than using 4,5-dimethyl-1,2-
phenylenediamine.  
 
Two attempts of synthesising 2.2.14 using 2.2.2 were carried out. These 
used either 1 or 2 equivalents of prenyl bromide at room temperature for 
24 hours. When 2 equivalents were used only a bright yellow oil shown by 
NMR to be the doubly prenylated product was recovered. When using 1 
equivalent doubly prenylated product was the major product (22%), but 
2.2.14 was formed as the minor product in 17% yield.  
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Another possible choice for the amine is to carry out the cyclisation of the 
prenyl to form the substituted 1,2,3,4-tetrahydroquinoline derivative 2.2.12 
and then carry out reductive amination using this precursor. Unfortunately, 
despite trying many conditions (Table 2.2.2), this cyclisation was 
unsuccessful.  
 
Table 2.2.2: Attempted prenyl cyclisation conditions.  
 
 
 
The original strategy for cyclisation of 2.2.11 required the use of H2SO4 to 
attempt to generate a positive charge from the double bond of the prenyl 
Entry Conditions Result 
1 Stir for 1 hour in H2SO4 at 0 oC, 
neutralise and extract, then stir for 64 
hrs in H2SO4 at room temperature.  
Around 100% 
conversion from 
starting material. 
2 Stir in H2SO4 for 24 hours, neutralise, 
extract and stir for 48 hours in H2SO4. 
Mostly converted from 
starting material, but 
impure NMR.  
3 Stir for 1 hour in H2SO4 at 0 °C, then 
for 64 hrs at room temperature. 
A small amount of 
conversion from 
starting material. 
4 Shake in H2SO4 at 4 °C for 64 hrs Negligible reaction. 
5 Stir for 18 hours in H2SO4 , sealed 
tube at 150 oC 
Decomposed. 
6 Stir for 18 hours in H2SO4 , sealed 
tube at 80 oC 
Decomposed. 
7 Refluxing in TCE until disappearance 
of starting material.  
Decomposed. 
8 AlCl3, PhCl No reaction 
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group, which would allow Friedel-Crafts cyclisation with the aromatic ring. 
A scifinder search of similar reactions showed no examples with two 
adjacent amines on an aromatic ring but several examples with N 
substituted anilines.  
 
Following a literature procedure56 H2SO4 was added at 0 ⁰C and stirred for 
1 hour before monitoring (Table 2.2.2, entry 1). However, due to poor 
solubility no observable reaction was seen. The solution was extracted, 
the reaction repeated at room temperature and stirred for an additional 64 
hours. After this time no starting material was observed by TLC or 1H NMR 
and so the reaction was judged to be completed. However, the product 
obtained was significantly more polar than the starting material and LC-MS 
did not match the expected data for 2.2.12. Repeating this reaction without 
the extraction after 1 hour gave only a small amount of conversion from 
starting material (Table 2.2.2, entry 3).  
 
The reaction was repeated (Table 2.2.2, entry 2), but with the initial stirring 
carried out at room temperature for 24 hours, followed by extraction and 
then stirring at room temperature for a further 48 hours. This led to a 
similar result as previously observed, with the additional stirring for another 
24 hours leading only to further side reactions and a less pure product 
observed by 1H NMR. An attempt to disfavour the formation of the polar 
side product by running this reaction at 4 ⁰C showed negligible reaction 
(Table 2.2.2, entry 4).  
 
Since carrying out the reaction at lower temperatures gave only an 
unwanted side product or little reaction, several attempts (Table 2.2.2, 
entries 5 and 6) were made to heat the reaction which should increase the 
rate of protonation of 2.2.11. Unfortunately heating at either 80 or 120 ⁰C 
led only to the decomposition of 2.2.11 to 2.2.1.  
 
Due to the failure of all reactions using H2SO4, an alternative, milder 
strategy was then attempted (Table 2.2.2, entry 7).57 When refluxing 
1,1,2,2-tetrachloroethane (TCE), a small amount of HCl will be produced. 
A smaller amount of acid, generated in situ may allow Friedel-Crafts 
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cyclisation to take place without decomposition or side reactions. 
However, the 147 ⁰C temperature required to reflux TCE also led to 
decomposition of the 2.2.11 to 2.2.1.  
 
A final attempt used AlCl3 (Table 2.2.2, entry 8), a Lewis acid used in 
many Friedel-Crafts reactions and in the two published syntheses of 
hunanamycin A58,59. No reaction was observed using this acid, thought to 
be because of the coordination of the lone pair of the free amines to AlCl3.   
 
Reacting 2.2.14 with H2SO4 removed the Boc protecting group but did not 
carry out cyclisation of the prenyl group as desired. Therefore using 2.2.2 
for the prenylation stage offers no advantage over using 2.2.1.  
The final amine considered was 2.2.16. Although this commercially 
available amine has only one amine, the nitro group has a significant 
deactivating effect.   
 
2.2.5.1 Summary 
In summary, it is possible to make the prenylated precursor 2.2.11 but not 
the bicyclic precursor 2.2.12. Therefore reductive amination may be 
carried out using 2.2.11 or 2.2.2 but not 2.1.12. 
 
2.2.5.2 Reductive amination using 2,3,4,5 protected ribose 
 
Initially reductive amination was carried out using 2.2.9a contaminated 
with succinimide, as complete purification was not possible (detailed in 
Section 2.2.3). Poor results were obtained using this method (Figure 2.2.9, 
i), with disappearance of acetyl groups from the 1H NMR and starting 
material present. The result was unchanged by first stirring the aldehyde 
and amine together, followed addition of NaBH4. Using 2.2.9b rather than 
2.2.9a also showed no product formation.  
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Figure 2.2.9: Reductive amination using 2,3,4,5 protected D-ribose.  
 
Section 2.2.2 demonstrates a literature reductive amination which adds 
ribose to 2.2.2. Carrying out a similar reaction using 2.2.11 and 
unprotected ribose (Figure 2.2.10) showed the required m/z by LC-MS. 
However, a similar reaction using 2.2.9b was not successful, although a 
product with an m/z matching that of the expected imine was obtained.  
 
Several other strategies were also attempted (Figure 2.2.9) without 
success. Changing the amine to 2.2.16 (Figure 2.2.11 ii)) led to an 
unsuccessful reaction, probably due to the decreased reactivity due to the 
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nitro substituent. An additional strategy attempted was similar to a 
literature reaction used to add unprotected ribose in the pyranose form to 
2.2.1660 in section 2.2.12. However, using benzoyl protected ribose 2.2.9b 
gave only starting material.   
 
Synthesis of 2.2.20 using 2.2.1 (unprotected 4,5-dimethyl-1,2-
phenylenediamine) with 2.2.9b was successful, although the reaction was 
very low yielding. An alternative strategy is to stir 2.2.1, and 2.2.9b 
together (with molecular sieves to remove water generated) and then carry 
out the reduction after work-up of the first step (Figure 2.2.11). This gave a 
product with an m/z matching that of 2.2.19. 
 
The best ratio of reactants was 1:1 with an excess of either reactant 
showing no benefit. Although the conditions showed consumption of all 
starting materials and initial results looked promising further analysis 
showed that 2.2.19 had not been made. 
 
If 2.2.19 was produced the imine should be reduced by NaBH3CN. 
However, no consumption of starting material was observed by TLC and 
NMR with only starting material remaining. When reacted with NaBH4, 
2.2.20 was still not observed by mass spectrometry.  
 
Further evidence supporting this theory was obtained when the reaction 
shown in Figure 2.2.12 was carried out. Purification of the reaction gave a 
pure fraction with a m/z of 751. Although this would match either of the two 
molecules shown in Figure 2.2.11, NMR matches 2.2.21.  
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Figure 2.2.10: Reductive amination using fragments of the heterocyclic fragment and 
ribose.  
 
 
Figure 2.2.11: Proposed two step reductive amination.  
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Figure 2.2.12: Proposed formation of quinoxaline-2,3-dione.  
 
Starting material from this reaction was obtained from a reductive 
amination, suggesting that this reaction is not giving the expected product 
but instead the heterocycle shown in Figure 2.2.13. Therefore, given the 
results of this strategy it is best to design a different method of adding the 
ribityl moiety.  
 
 
 
 
Figure 2.2.13: Possible products from the attempted synthesis of the quinoxaline-2,3-
dione portion of hunanamycin A. 
 
2.2.5.2 Summary 
In summary no method of reductive amination has been successful in 
forming the 1,4-dihydroquinoxaline-2,3-dione core of hunanamycin A.  
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2.2.6 Reduction of protected ribose aldehyde 
 
The next method attempted to add the ribityl moiety was reduction of 
2.2.9b to an alcohol to give 2.2.23. A good leaving group could then be 
substituted, and nucleophilic substitution used to add the sugar to an 
aniline.  
 
 
 
Figure 2.2.14: Reduction of 2,3,4,5 benzoyl protected D-ribose with NaBH4.  
 
Therefore, a reduction of 2.2.9b using NaBH4 was attempted. However, 
the LC-MS of this reaction showed that as well as reducing the aldehyde, 
other reactions removing some of the benzoyl groups were also taking 
place. There is also the potential for protecting groups to move along the 
sugar by a transesterification mechanism, moving the position of the free 
hydroxyl along the carbon backbone (Figure 2.2.15). Therefore, the 
protecting group was changed from benzoyl to benzyl.  
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Figure 2.2.15: Potential mechanism of a side reaction during the synthesis of 2.2.23.  
 
Figure 2.2.16 shows the synthesis of 2.2.24 using BnBr and NaH. NBS 
could then be used to deprotect 2.2.24 in the same way as for 2.2.9b to 
give 2.2.25. Both stages gave good yields (Figure 2.2.16) and could be 
used to make multiple grams of the product of each stage.  
 
Reduction of 2.2.25 using the conditions shown in Figure 2.2.16 went to 
completion (with monitoring by TLC) after 30 minutes. After work-up NMR 
showed both conditions gave the product in good purity. However, i)61 
gave the product quantitively and ii)62 in 66% yield. Based on these results 
the conditions of i) were chosen to carry forward. 
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Figure 2.2.16: Synthesis of 2,3,4,5 benzylated ribose, followed by reduction then 
substitution of bromide leaving group in order to carry out nucleophilic substitution.   
 
2.2.7 Conversion of hydroxyl to good leaving group 
 
The hydroxyl group could potentially be converted to either tosylate63 and 
bromide64 to give a good leaving group. Bromide was chosen, with the 
Appel reaction (Figure 2.2.16) used to convert the hydroxyl to bromide. 
With 2.2.27 synthesised addition to 4,5-dimethyl-1,2-phenylenediamine (or 
a derivative) could be carried out.  
 
2.2.8 Reactions using brominated ribose 
 
Since synthesis was no longer using reductive amination, 2.2.29 was 
made as a possible nucleophile for nucleophilic substitution. Methods for 
making this molecule are known.65 66 However, modifying the synthesis by 
adding another equivalent of ethyl oxalyl chloride after 12 hours allowed 
(Figure 2.2.17) the yield to be increased from 29%67 to 88%.  
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Figure 2.2.17: Improved synthesis of 2.2.29. 
 
Nucleophilic addition of 2.2.27 to 2.2.29 is shown in Figure 2.2.18. The 
dicarbonyl group which will be used to make the quinoxaline-2,3-dione ring 
is already installed and reduction of the nitro group will result in formation 
of the ring.  
 
 
Figure 2.2.18: Nucleophilic substitution of 2.2.29 and 2.2.27.  
 
 
After using the conditions shown in Figure 2.2.18 and heating to 50 °C for 
1 day mass spectrometry of the crude product showed some formation of 
product, although the reaction did not go to completion and 2.2.27 was still 
present. In contrast, using sodium tert-butoxide as the base gave no 
product with either DMF or tert-butanol as the solvent.  
 
Although the conditions in Figure 2.2.18 showed some product formation 
in the crude mass spectrum the product could not be isolated by silica 
column and so alternative methods were sought. 
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Addition of 2.2.27 to 2.2.16 (Figure 2.2.19) yielded the expected product. 
However a modest yield of only 12% was obtained and a significant side 
product was also recovered, shown by mass spectrometry and NMR to be 
bis-alkylation. Another method68 of sugar addition shown in Figure 2.2.20 
showed only decomposition of reactants after overnight reaction.  
 
 
Figure 2.2.19: Nucleophilic substitution of 2.2.27 and 2.2.16 
 
Figure 2.2.20: An alternative route to make 2.2.31 and 2.2.32. 
 
Although further optimisation could be carried out to increase the yield of 
2.2.32, due to the discouraging results of this reaction this route was not 
continued. However, theoretically the next stage to reduce the nitro to an 
amine would use large amounts of SnCl2.2H2O, an extremely toxic 
substance. Care would need to be taken with the reagents for this stage to 
avoid removing the benzyl protecting groups, which is a possibility with 
many Pd/C nitro reductions conditions.  
 
There are several variables which could be changed to optimise this 
reaction. Since previous reactions to make 2.2.31 had the best success 
using NaH this was the base used in this reaction. However, using a base 
such as Cs2CO3 or K2CO3 may give a better yield due to the different 
mechanism of action. Using a different amine such as 2.2.2 or 2.2.11 
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could also give better results. Ultimately the moderate yield of 2.2.27 also 
discouraged continuation of this route.  
 
2.2.8 Summary 
Although the key intermediates of 2.2.30 and 2.2.32 were obtained using 
the synthesis in Figures 2.2.16 and 2.2.19, low yields and formation of 
side products led to the consideration of another route.  
 
2.2.9 Oxidation of protected ribose and addition to 4,5-dimethyl,1,2-
phenyldiamine 
 
The next approach considered was oxidation of 2.2.25 to give a carboxylic 
acid. Rather than reduction of 2.2.25 to give 2.2.26, oxidation to give 
2.2.34 would instead be carried out. The resulting carboxylic acid could 
then be coupled to the amine, using conditions predicted to be mild and 
high yielding. The resulting amide could then be reduced to an amine 
(Figure 2.2.21).  
 
Figure 2.2.21: Retrosynthetic analysis for amide coupling of sugar to diamine. 
 
Therefore, conditions to oxidise 2.2.25 to carboxylic acid 2.2.34 were 
researched. Initially, the classic conditions of  the Jones oxidation69 were 
used. A literature example using glucose was found70, although no 
examples using ribose were available. These conditions successfully 
oxidised the 2.2.25 to 2.2.34. However, although the yield increased each 
time the reaction was increased in scale, yields were still not optimal (up to 
31%). The Jones oxidation relies on large amounts of toxic CrO3 so using 
the scale from the original paper69 was not thought to be the best 
optimisation while other conditions remained to be explored.  
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Table 2.2.3: All reactions were carried out on a 2.00g (3.92 mmol) scale. 
 
 
Another chromium reagent pyridinium dichromate (PDC) was next tested. 
Although having many advantages over CrO3 including greater solubility 
and reactions typically taking place at room temperature, it shares the 
major disadvantage of the Jones oxidation, the use of stoichiometric 
amounts of chromium. Additionally, although the reaction proceeded while 
using pyridinium dichromate with wet DMF71,72 (PDC, second entry in 
Table 2.2.3) the yield was the lowest of all conditions explored.  
 
As shown in Table 2.2.3, on a 2g scale the highest yielding reaction was 
the Pinnick reaction73,74,75, which was also preferred for taking place under 
mild conditions and not generating toxic chromium containing side 
products.  
 
Ideally 2.2.24 could be deprotected to give the carboxylic acid directly. A 
method has been reported76 for deprotecting a 1,3-dithiol to give the 
corresponding carboxylic acid, using conditions similar to the Pinnick 
oxidation. Although mainly testing the success of the reaction with ketone 
derived examples, the paper also tested several aldehyde derived 1,3-
dithiols. Whether the reaction was successful was proposed to be 
determined by the identity of the substituent at the C2 carbon. For 
aldehyde derived examples the best results were given by 4-methoxy 
Conditions Yield (%) 
CrO3, H2SO4, acetone 31 
PDC, DMF, 5 hours 10 
NaClO2, NaH2PO4, tBuOH, 2-
methyl-2-butene, H2O 
69 
NaClO2, NaH2PO4, tBuOH, 2-
methyl-2-butene, H2O, 10 eq of 2-
methyl-2-butene 
85 
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substituted phenyls at the C2 position of the aldehyde, with a single alkyl 
or unsubstituted phenyl at the C2 position unsuccessful in stabilizing the 
charge of the intermediate in the proposed mechanism. Electron releasing 
groups were proposed to be more favourable but no examples with an 
ether group at C2 were explored for either aldehyde or ketone derived 
molecules. Figure 2.2.22 shows the attempted reaction using conditions 
based on this paper which proved to be ultimately unsuccessful.  
 
 
Figure 2.2.22: Proposed deprotection of dithiol 2.2.24 to give carboxylic acid 2.2.34. 
 
2.5.9.1 Coupling of carboxylic acid to 4,5-Dimethyl-1,2-phenyldiamine 
 
With the oxidation successfully completed and optimised the coupling 
could be carried out. This progressed smoothly, giving a moderate yield 
with the first conditions used77. This was optimised to give a good yield, 
shown in Table 2.2.4.  
 
Although the reference which the coupling is based on uses a slight 
excess of carboxylic acid, 1.2 equivalents of the diamine was used for 
coupling. Predictably, using a slight excess of the carboxylic acid led to the 
major product being from a side reaction rather than 2.2.35.  
In an attempt to achieve the highest possible yield, several different 
coupling agents were tested (Table 2.2.4). However, the best yielding 
coupling agents were found to be EDCI/HOBt as originally used. HATU 
appeared to be too reactive and give many side products and a messy UV 
trace on the combiflash. DCC appeared to promote the formation of a side 
product.  
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Table 2.2.4: All couplings were carried out using 1.25 mmol of 2.2.34, with couplings 
monitored by TLC. 
 
 
 
 
 
 
 
 
 
 
 
2.2.10 Construction of the heterocycle of hunanamycin A 
 
Initially, the planned order of the next part of the synthesis was N-
prenylation, followed by reduction of the amide, then formation of the 
quinoxaline-2,3-dione ring. However, there were several problems with 
this order.  
 
Firstly, it was not possible to achieve a good yield of the singly N-alkylated 
product (Figure 2.2.23). Initially a 1:1:1 ratio of 2.2.35, Cs2CO3 and prenyl 
bromide was used. Although a 23% yield of the singly prenylated product 
was isolated, 3% of the doubly prenylated product and 71% 2.2.35 was 
Coupling 
agents 
Equivalents 
of 2.2.34 
Equivalents 
of D115 
Solvent Yield 
of 
2.2.35 
(%) 
Yield of 
2.2.35 
side 
product 
(%/g) 
EDCI, 
HOBt, 
DIPEA 
1 1.2 DCM:DMF 
(2:1) 
81 1 / 0.013 
HATU, 
DIPEA 
1 1.2 DCM:DMF 
(2:1) 
58 1 / 
0.0096 
DCC, 
DMAP 
1 1.2 DCM:DMF 
(2:1) 
65 7 / 0.125 
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also isolated. Increasing the number of equivalents of Cs2CO3 to 1.5 
equivalents decreased the yield to 13% but increased the amount of 
doubly prenylated product to 10%. Carrying out the reaction under less 
concentrated conditions (2.2 x more THF) decreased the yield of product 
to 11% and also gave the comparatively large yield of 7% of doubly 
prenylated product.  
 
 
 
Figure 2.2.23: Addition of prenyl group to 2.2.35, attempted reduction of 2.2.39 amide 
and reduction of the amide of 2.2.35.  
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An alternative synthesis to make 2.2.39 is to couple 2.2.34 to 2.2.11, a 
molecule already synthesised for use in reductive amination. However, 
when coupling and purification was carried out it was found that the 
reaction gave many products with many different fractions isolated and 
2.2.39 as a negligible yield.  
 
Although it would be possible to continue this route by recycling the 
starting material recovered from the N-prenylation of 2.2.35 shown in 
Figure 2.2.23, testing of the amide reduction showed that this would be 
inadvisable. Reduction78,79 of 2.2.37 with LiAlH4 (2 eq) removed the prenyl 
group in addition to the amide reduction.    
 
In contrast, using 2 equivalents of 1M LiAlH4 to reduce 2.2.35 directly gave 
2.2.33 in up to 88% yield, with no further optimisation required.  
With 2.2.33 successfully made ring closure of the quinoxaline-2,3-dione 
ring was then carried out. Initial screening of conditions using 0.150 g of 
2.2.33 is shown in table 2.2.5. Although 2.2.40 could be formed by several 
conditions, most did not give good yields with much of the material 
decomposing in many of the reactions.  
 
The conditions giving the best yield were obtained using an unusual 
method where the reaction takes place in the rotary evaporator itself.80 
The pressure and temperature of the rotary evaporator are set so that the 
diethyl oxalate evaporates slowly. Meanwhile, the reaction takes place in 
the flask to form the quinoxaline-2,3-dione, with the side product of ethanol 
evaporating off. The products made by the original paper are not soluble in 
diethyl oxalate so can be filtered out of the reaction mixture. However, the 
4 benzyl groups of this product make it very soluble in this solvent. 
Purification is instead carried out by flash column chromatography after 
evaporation of the majority of diethyl oxalate.  
 
As can be seen by table 2.2.5, using 3 mL of diethyl oxalate gives the 
highest yield of 49%, with no starting material recovered. Using 1 mL of 
diethyl oxalate resulted in a shorter evaporation time with a lower yield, but 
with 47% of 2.2.33 also recovered.  
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Other methods which could be used to make 2.2.40, included a sealed 
tube reaction (pressure with no ethanol removal) and open flask (no 
pressure, ethanol removal). However, these all led to lower yield with a 
large amount of decomposition of material (Table 2.2.5).    
 
Table 2.2.5: Screening of conditions for formation second ring. All reactions were carried 
out on a 0.15 g scale with the exception of *which used 0.088 g.  
 
R1 R2 Conditions Yield (%) Starting 
material 
recovered 
(%) 
OEt OEt Rotary 
evaporator, 
20-0 mbar, 
3 mL 
oxalate, 
550C, 22 
hours.*  
49 0 
OEt OEt Rotary 
evaporator, 
20-0 mbar, 
1 mL 
oxalate, 
550C, 9 
hours.  
34 47 
OEt OEt Sealed 
tube, 0.13 
0 58 
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mL oxalate, 
0.87 mL 
ethanol, 55 
°C, 2 days. 
OEt OEt Sealed 
tube, 1 mL 
oxalate, 55 
°C, 2 days. 
39 0 
OEt OEt Open flask, 
1 mL, 70 
°C, 2 days. 
34 0 
OEt Cl Add oxalate 
(1.1 eq), 
DCM and 
NEt3 to 
starting 
material, 
stir at room 
temperature 
for 3 hours, 
add 1.1 eq 
of oxalate, 
stir for 
another 
hour.  
0 0 
 
Using the conditions from Table 2.2.5 which gave the most favourable 
result on a 0.30 g scale gave a decreased yield. However, increasing the 
volume of diethyl oxalate from 2 mL to 20 mL gave the best yield for 
2.2.40. A comparable yield of 70% was also achieved when this reaction 
was scaled up to a 0.67 g scale.    
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Table 2.2.6: Improved conditions for 2.2.40.  
0.30 OEt OEt 55 °C, 
rotary 
evaporator, 
20-0 mbar, 
9 hours, 2 
mL oxalate. 
23 71 
0.30 OEt OEt 55 °C, 
rotary 
evaporator, 
20-0 mbar, 
24 hours, 
20 mL 
oxalate. 
71 0 
 
The next step of N-prenylation could then be simply carried out. Using the 
conditions from chapter 2.2.5.1 (Figure 2.2.8), Cs2CO3 was chosen as the 
base due to the optimal yield achieved from the synthesis of 2.2.11. This 
reaction proceeded very smoothly and in excellent yield. Small scale 
reactions (under 100 mg) could be purified by extraction and drying under 
vacuum, since prenyl bromide and all side products are volatile. However, 
larger scales required purification by flash column chromatography. 
 
With 2.2.41 in hand the final two steps (cyclisation of the prenyl group and 
removal of benzyl protecting groups) could be carried out. Initial test 
reactions carried out showed that addition of 10 equivalents of AlCl3 to 
2.2.41 in DCE showed no starting material by TLC after stirring at room 
temperature for 4 hours. Extraction and NMR showed that the product 
obtained was not pure, with TLC in 9:1 DCM:MeOH showing several spots 
active by both long and short wavelength UV light. Mass spectrometry of 
the yellow solid resulting from a DCM:MeOH column of this reaction 
showed that it contained a mixture of hunanamycin A and singly, doubly 
and triply benzylated hunanamycin A. 
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Since the test reaction results were encouraging, the reaction was scaled 
up and again ran with 10 equivalents of AlCl3. However, this time the 
reaction was left to run overnight. Once again the resulting yellow solid 
from a DCM:MeOH column showed a mixture of benzylated hunanamycin 
A, proved by NMR. 
 
Research into removal of benzyl groups by AlCl3 showed that removal is 
often accelerated by the addition of N,N-dimethyl-aniline.81,82,83,84 
Therefore all benzylated products from the previous step were combined 
and reacted with 16 equivalents of AlCl3 and 12 equivalents of N,N-
dimethyl-aniline overnight. The major product from this reaction was singly 
benzylated hunanamycin A. Therefore, a different method of deprotection 
was tried.  
 
However, although the integral of the benzylated peaks in 1H NMR 
decreased, even after 6 days of reaction with Pd/C and H2 in THF did not 
completely remove all benzyl groups.  
Therefore, the reaction was improved by doubling the amount of AlCl3 to 
20 equivalents and stirring for 24 hours. HPLC was used to analyse the 
reaction mixture.  
 
1H NMR proved that the peak at Rt = 14.5 corresponds to hunanamycin A, 
the target molecule. NMR showed other fractions collected from the 
column showed some benzylated hunanamycin A. Since the previous 
attempt to deprotect the remaining benzyls using Pd/C and H2 in THF did 
not go to completion, the solvent was changed to MeOH and the reaction 
monitored by TLC. However, no additional product was obtained.  
 
As predicted, the HPLC trace (Figure 2.2.24) showed many peaks, with 
two major peaks (Rt = 14.5 and 15.9 minutes). The two main peaks shown 
in Figure 2.2.24 could be separated from the rest of the peaks by flash 
column chromatography. The NMR and MALDI of these products in Figure 
2.2.25 show that hunanamycin A has been made but a similar product with 
two aromatic protons rather than one has been formed. These two 
products could not be completely separated from each other by silica 
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column. Therefore, reverse phase preparative HPLC was used to separate 
them. The two products were characterised as Hunanamycin A and 
2.2.42 (Figure 2.2.24). 
 
Figure 2.2.24: Final step of synthesis to form hunanamycin A and analogue and HPLC 
showing the formation of the two major products.  
 
When the reaction is ran for 24 hours the HPLC peak of hunanamycin A 
has an integral of 66% of the total integral areas, and the combined 
isolated yield of Hunanamycin A and 2.2.42 was 26%. The reaction was 
repeated with a reaction time of 48 hours rather than 24 hours. Results 
from this reaction were almost identical to the 24 hour reaction.  
 
Therefore, 24 hours is sufficient time to provide a new route to 
hunanamycin A and a related analogue as a side product.  
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Figure 2.2.25: A) MALDI spectrum showing formation of hunanamycin A and a product 
with a m/z of 395, two mass units more than hunanamycin A. B) 1H NMR spectrum of the 
product isolated after the first purification. The aromatic region showing the two major 
products isolated is highlighted.   
 
 
2.2.11 Conclusions and future work 
 
In conclusion a new synthesis of hunanamycin A has been completed. 
The stereochemistry of the sugar is already installed by the ribose, 
avoiding the complication and expense of constructing the stereochemistry 
chemically. The total yield over 9 steps is 2%. However, over the first 8 
steps the overall yield is 24%. The first eight steps (Figure 2.2.26) are high 
yielding (over 70%) and use cheap and readily available materials.  
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Figure 2.2.26: Preferred synthetic route with yields of each step. Step 1: HCl (aq), 1,3-
propanedithiol; Step 2: i) NaH, DMF, ii) BnBr; Step 3: NBS, MeCN:H2O (4:1); Step 4: 
NaClO2, NaH2PO4, tBuOH, 2-methyl-2-butene, H2O; Step 5: i) EDCI/HOBt, ii) DIPEA, 
2.2.1; Step 6: LiAlH4, THF; Step 7: diethyloxalate, rotary evaporator; Step 8: Prenyl 
bromide, Cs2CO3, THF; Step 9: AlCl3, DCE.      
 
The yield of the final product is low (9%), partially due to the use of 
preparative HPLC to purify the final product. Ideally, future work could 
improve the yield. One possible way to achieve this is by increasing the 
scale.  
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The first 5 stages of the synthesis were proven to be scalable, with 
multiple grams of each product successfully synthesized. Synthesis of the 
next two products (2.2.35 and 2.2.33) was carried out to yield 
approximately a gram of each. Steps 7 and 8 were carried out on a scale 
of several hundred milligrams, with the largest scale synthesis of 2.2.41 
yielding 433 mg. Finally, the largest scale of step 9 was 80 mg, yielding 
only 3.5 mg (0.009 mmol).   
 
The final stage of this synthesis uses a method similar to the biomimetic 
synthesis of hunanamycin A.58 The biomimetic synthesis achieves a yield 
of around 70% for the final step. However, the AlCl3 is used only for the 
Friedel-Crafts cyclisation rather than for the removal of protecting groups. 
Therefore, the side products from the biomimetic synthesis are less 
soluble in organic solvents than hunanamycin A. Hunanamycin A can then 
be precipitated after extraction from the reaction mixture. However, for the 
reaction in Figure 2.2.24 this is not possible since many side products of 
the reaction are less polar than the products themselves. Due to the 
presence of the 4 hydroxyl groups the solubility of the final products in 
organic solvents is low. Therefore, the yield could theoretically be 
increased by increasing the scale since it could be more easily extracted 
from aqueous solutions. The biomimetic synthesis is carried out on a gram 
scale which may contribute to the higher yield.  
 
Part of the purpose of researching a new total synthesis of hunanamycin A 
was to make analogues to investigate the structure-activity relationship. A 
patent which makes several analogues of hunanamycin A has been 
published.85 This patent is based on the first synthesis of hunanamycin A42 
which starts from the heterocyclic core of hunanamycin A. Therefore, all 
analogues are made by altering the ribityl moiety. The synthesis detailed 
in this chapter allows several modifications to be made without 
significantly altering the synthetic route. 
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Figure 2.2.27: Possible modifications to hunanamycin A. 
 
For example in hunanamycin A n =1 (Figure 2.2.27) but analogues could 
vary from n = 0 to n = 7 or 8 (or potentially higher) to test the effect of a 
larger ring. R1 and R2 could be changed from two methyls to other groups 
e.g. hydrogen, ethyl, hydroxyl or halogens. This would affect the 
electronegativity of the ring as well as the effects of altering the atoms at 
that position . R3 and R4 could also be changed, possibly to incorporate 
some of the features of the previously made inhibitors of riboflavin 
synthesis.  
 
2.2.12 Synthesis using the anomeric position of ribose 
 
Although the majority of the methods attempted have used the same 
method of protection of aldehyde, followed by protection of hydroxyls, then 
deprotection of aldehyde, Figure 2.2.28 shows an alternative route was 
also briefly investigated. If successful, this method would allow the total 
synthesis in eight steps from ribose.  
 
76 
 
 
 
Figure 2.2.28: Retrosynthesetic analysis for an alternative synthesis.  
 
Figure 2.2.29 shows a possible intermediate for hunanamycin A. A method 
for making 2.2.44 was previously reported60. Following a method from a 
patent86 using a 1:1 ratio of ribose: 2.2.16 was unsuccessful. However, a 
method from a different source60 using 5 equivalents of 2.2.16 was 
successful, with much of the excess 2.2.16 isolated during the column 
purification. Initially the yield was only 11% despite using the same 
conditions and scale as the paper used. When using a freshly opened 
bottle of dry ethanol the yield was increased to 34% and then further to 
60% when using 40 mol % of ammonium chloride, recrystallised before 
use. Acetylation of 2.3.2 proceeded smoothly as reported in the 2000 
paper60 to give 2.2.44 in 83% yield. 
 
 
  
 
Figure 2.2.29: Synthesis using ribose in the pyranose form. Synthesis was adapted from 
reference 83.  
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For both 2.3.2 and 2.2.44 two isomers were isolated. For the total 
synthesis of hunanamycin A this is not a problem as the anomeric bond 
where the stereochemistry is different will eventually be converted to a 
secondary carbon when the pyranose ring is broken, making both isomers 
equivalent. Therefore although the isomers can be separated after 
acetylation, both may theoretically be used for subsequent reactions.  
Similarly to the synthesis using a linear ribityl moiety, there are two 
possible methods to form the quinoxaline-2,3-dione ring. Firstly the oxalate 
may be added to the amine (Figure 2.2.30) followed by cyclisation or 
cyclisation may be carried out at both amines simultaneously.  
 
 
Figure 2.2.30: Addition of ethyl dione to 2.2.44.  
 
The reaction to add ethyl dione did not proceed when using triethylamine 
as the base, but formation of product was observed by TLC and MALDI 
when NaH was used. Purification of the product by silica column was 
attempted. However, 2.2.29 was isolated with a yield of 33%, showing that 
2.2.46 was decomposing on the silica. Additionally, a brown oil was also 
separated which was shown to contain some product as well as a large 
amount of decomposed material. A further column of the brown oil using 
DCM:EtOAc to elute showed none of the required product.  
 
Although further purification methods were considered none appeared to 
be practical for this molecule. 2.3.2 is known to decompose at 66 °C, so 
distillation or kugelrohr distillation seem unlikely to work. Recrystallisation 
may be possible if the majority of the decomposition takes place on the 
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column but for optimum results large amounts of relatively pure 
compounds are required and optimization of conditions is a time-
consuming process. 
 
Since purification could not be carried out the next step was carried out on 
the crude. Reduction was carried out using SnCl2.2H2O. However, these 
conditions also caused the decomposition of the product. 
 
 
Figure 2.2.31: Proposed continuation of the synthesis.  
 
Reduction of 2.2.44 can be carried out using Pd/C, with literature 
examples using the product immediately after reduction directly in the next 
stage of the reaction with no characterization or purification, with mention 
made to the instability of the product.  Although this method was 
attempted, without optimization of the next stage this method is not 
practical and results were unclear.  
 
The other strategy is to break the bond at the anomeric position before 
further reactions are carried out (Figure 2.2.32). Two methods were 
attempted for this; one using NaBH4 and the other using BF3OEt2, the two 
methods found from a scifinder search for this type of reaction. The 
required product was not observed for either method. 
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Figure 2.2.32: Attempt to reduce the lactone ring to give the linear ribityl moiety.  
 
Since the results for this method have so far not been encouraging this 
route was no longer continued for total synthesis. However, although not 
useful for a total synthesis route it should be possible to adapt the method 
to give an analogue of hunanamycin A with a cyclic rather than linear 
ribityl moiety.   
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1.3 Experimental for hunanamycin A 
All chemicals and solvents were purchased from Sigma-Aldrich, Fisher 
Scientific, Fluorochem, TCI, Merck or ATGC Bioproducts and were used 
without purification unless otherwise stated. Anhydrous solvents (with the 
exception of THF) were purchased from Sigma-Aldrich in Sure Seal 
bottles. Dry THF was either purchased from Sigma-Aldrich or dried over 
sodium, using benzophenone as an indicator. 
All air and moisture sensitive reactions were carried out under an argon 
atmosphere. TLC monitoring was carried out using Merck TLC Silica Gel 
60 F254 aluminium backed plates. Plates were visualised using 254 and 
365 nm UV light and stained with ninhydrin, bromocresol or KMnO4 as 
appropriate. Flash column chromatography was carried out using either 
Davisil LC60A 40-60 micron silica gel, or using a Teledyne ISCO 
Combiflash Rf 150 with prepacked 4 g, 12 g, 20 g and 40 g Telos columns 
and repacked 100g Biotage columns. Brine was prepared as a saturated 
solution of sodium chloride in water. Solvents removed under reduced 
pressure were removed using Buchi rotary evaporators (various models). 
Melting points were carried out using a Stuart Melting point SMP10. 
Optical rotation was carried out using an ADP440 polarimeter. Optical 
rotations were carried out using either chloroform, methanol or ethanol as 
indicated. Infrared spectra were measured using a Perkin Elmer FTIR 
Spectrum Two. Absorptions are given in wave numbers (cm-1). 1H and 13C 
NMR were recorded on Bruker Ultrashield 400 Plus (400 MHz for 1H and 
100 for 13C). Splitting patterns are reported as s=singlet, d=doublet, 
t=triplet, q=quartet and m=multiplet. Chemical shifts are given in ppm and 
coupling constants in Hertz. 
Low resolution mass spectra were measured by MALDI Kratos Analytical 
Axima-CRF using either α-Cyano-4-hydroxycinnamic acid or 2,5-
Dihydroxybenzoic acid as a matrix or a Shimadzu 2010 EV. High 
resolution and all low resolution mass spectra measured by other 
techniques were carried out by the national mass spectrometry service at 
Swansea University. 
81 
 
 
(1R,2R,3R)-1-(1,3-dithian-2-yl)butane-1,2,3,4-tetrol, 2.2.7 
D-Ribose (4.00 g, 26.6 mmol) was dissolved in concentrated 
HCl (20 ml). 1,3-Propanedithiol (26.6 mmol, 2.67 mL) was then 
added via syringe and the reaction mixture stirred at room 
temperature for 10 minutes before addition of ice water (20 ml). The 
reaction mixture was monitored by TLC (1:1 EtOH:Toluene) for 6 hours 
until completion was basified by 4M aq NaOH before evaporation of water, 
using toluene and methanol to azeotrope. The crude product was purified 
on a silica column (9:1 EtOAc:MeOH to elute) to give 2.2.7 as a white solid 
(4.63 g, 19.3 mmol, 73%); [α]24.4D -19.4 (c 1.03 in MeOH)87; ṽ max/cm-1 
3342, 3256, 2982, 2949, 2933, 2907, 1470, 1435, 1405, 1103, 1080, 
1060, 1027; 1H NMR (400 MHz, DMSO-d6) δ 4.76 (d, J = 6.5, 1H); 4.43 (t, 
J = 5.5, 1 H,) 4.41 (d, J = 2.5 H, 1H), 3.66 (3 H, m, 1H), 3.55, 3.41 (m, 1H,) 
2.90 (m, 3 H), 2.74 (ddd J = 13.5, 10.9, 2.5,1H), 2.00 (m, 1H), 1.73 (m, 1H) 
; 13C NMR (101 MHz, DMSO-d6) δ 77.3, 73.7, 71.6, 62.9, 51.0, 30.1, 29.4, 
26.6. 
 
 (1R,2R,3R)-1-(1,3-dithian-2-yl)butane-1,2,3,4-tetrayl 
tetraacetate, 2.2.8a 
Pyridine (4.17 ml) was used to dissolve 2.2.7 (1.00 g, 4.17 
mmol) and the solution cooled to ice temperature. Acetic 
anhydride (62.9 mmol, 5.9 ml) was added dropwise and the reaction 
mixture stirred for 1 hour before removal of the ice bath. The reaction 
mixture was then stirred overnight at room temperature before extraction 
into EtOAc (3 x 30ml), washing with aq CuSO4 (2 x 10ml) and removal of 
solvent under reduced pressure to give 2.2.8a (1.43 g, 3.52 mmol, 84%) 
as an orange syrup; [α]25.8D 11.9 (c 1.52 in MeOH); 1H NMR (400 MHz, 
CDCl3) δ 5.76 (dd, J = 5.8, 3.5 Hz, 1H, alkyl), 5.65 (dd, J = 9.4, 3.5 Hz, 1H, 
alkyl), 5.37 (td, J = 6.4, 2.7 Hz, 1H, alkyl), 4.45 (dd, J = 12.3, 2.7 Hz, 1H, 
alkyl), 4.13 (dd, J = 12.3, 6.4 Hz, 1H, alkyl), 3.79 (d, J = 9.4 Hz, 1H, alkyl), 
3.15 – 3.05 (m, 1H, alkyl), 3.00 – 2.91 (m, 1H, alkyl), 2.71 – 2.62 (m, 1H, 
alkyl), 2.59 – 2.50 (m, 1H, alkyl), 2.14 (s, 3H, Me), 2.08 (s, 3H, Me), 2.07 
(s, 3H, Me), 2.04 (s, 3H, Me), 2.00 (m, 2H, CH2); 13C NMR (101 MHz, 
CDCl3) δ 170.8 (CO), 170.2 (CO), 169.9 (CO), 169.9 (CO), 71.2 (CH), 70.8 
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(CH), 69.5 (CH), 62.4 (CH2), 43.8 (CH), 26.4 (CH2), 26.4 (CH2), 25.2 
(CH2), 21.1 (Me), 21.0 (Me), 20.9 (Me), 20.9 (Me); m/z (ESI) 431 = 
[M+Na]+, 447 = [M+K]+.  
 
(1R,2R,3R)-1-(1,3-dithian-2-yl)butane-1,2,3,4-tetrayl tetrabenzoate, 
2.2.8b 
A solution of 2.2.7 (0.5 g, 2.08 mmol) in pyridine (2.09 mL) 
was cooled to ice temperature. Benzoyl chloride (31.5 
mmol, 3.65 mL) was added dropwise and the reaction 
mixture stirred for 1 hour before removal of the ice bath. The reaction 
mixture was then stirred overnight at room temperature before extraction 
into EtOAc (3 mL), drying (MgSO4), filtering and removal of solvent under 
reduced pressure to give 2.2.8b  as a white crystalline solid (0.904 g, 
66%): [α]24.6D 54.2 (c 1.01 in CHCl3); ṽmax/cm-1 2900, 1722, 1257, 1092, 
1067, 1024, 704, 685; 1H NMR (400 MHz, CDCl3) δ 8.06 – 7.97 (m, 4H, 
ar.), 7.96 – 7.86 (m, 4H, ar.), 7.56 – 7.27 (m, 12H, ar.), 6.46 (dd, J = 6.9, 
3.1 Hz, 1H, CH), 6.18 (dd, J = 9.6, 3.1 Hz, 1H, CH), 6.07 (td, J = 6.2, 2.7 
Hz, 1H, CH), 4.87 (dd, J = 12.3, 2.8 Hz, 1H, CH2), 4.48 (dd, J = 12.3, 6.0 
Hz, 1H, CH2), 3.99 (d, J = 9.6 Hz, 1H, CH), 3.27 – 3.17 (m, 1H, CH), 3.04 
– 2.94 (m, 1H, CH2), 2.67 (ddd, J = 14.3, 6.0, 3.2 Hz, 1H, CH2), 2.45 (ddd, 
J = 14.3, 6.2, 3.1 Hz, 1H, CH2), 2.04 – 1.86 (m, 2H, CH2); 13C NMR (101 
MHz, CDCl3) δ 166.3 (CO), 165.6 (CO), 165.5 (CO), 165.4 (CO), 133.7 
(ar.), 133.7 (ar.), 133.6 (ar.), 133.3 (ar.), 130.3 (ar.), 130.1 (ar.), 130.0 
(ar.), 129.9 (ar.), 129.7 (ar.), 129.4 (ar.), 129.3 (ar.), 129.3 (ar.), 128.8 
(ar.), 128.8 (ar.), 128.7 (ar.), 128.5 (ar.), 71.8 (CH), 71.7 (CH), 70.0 (CH), 
66.0 (CH2), 63.5 (CH2), 60.5(CH2), 43.9 (CH), 26.4 (CH2), 26.2 (CH2), 25.2 
(CH2), 15.4 (CH), 14.3 (CH); m/z (ESI)- 401, 514, 656 = [M]-.  
 
(2R,3R,4R)-5-oxopentane-1,2,3,4-tetrayl tetrabenzoate, 2.2.9b 88 
 
To a stirred solution of 2.2.8b (0.250 g, 0.381 mmol) in 4:1 
MeCN: H2O (11.2 mL) was added NBS (6 eq, 0.406g, 2.28 
mmol). The resultant bright orange solution was stirred at room 
temperature for 10 minutes. The solution was then diluted in water and 
ether and washed with sat. sodium sulphite. The organic layer was dried 
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(MgSO4), filtered and evaporated before purification by silica column 
(DCM:EtOAc) to remove succinimide to give 2.2.9b as a white solid (60%, 
0.129 g, 0.228 mmol); 1H NMR (400 MHz, CDCl3) δ 9.57 (s, 1H, CHO), 
8.14 – 8.09 (m, 2H, ar.), 8.05 – 7.97 (m, 6H, ar.), 7.65 – 7.38 (m, 12H, ar.), 
6.30 (dd, J = 9.2, 2.3 Hz, 1H, CH), 6.11 (ddd, J = 9.1, 4.7, 2.8 Hz, 1H, CH), 
5.88 (d, J = 2.3 Hz, 1H, CH), 4.91 (dd, J = 12.5, 2.8 Hz, 1H, CH), 4.52 (dd, 
J = 12.5, 4.7 Hz, 1H, CH); 13C NMR (101 MHz, CDCl3) δ 195.0 (CHO), 
166.2 (CO), 165.7 (CO), 165.1 (CO), 164.9 (CO), 134.1 (ar.), 134.0 (ar.), 
134.0 (ar.), 133.4 (ar.), 130.3 (ar.), 130.1 (ar.), 130.1 (ar.), 129.9 (ar.), 
129.5 (ar.), 128.9 (ar.), 128.8 (ar.), 128.8 (ar.), 128.6 (ar.), 128.5 (ar.), 77.6 
(CH), 70.7 (CH), 68.9 (CH), 62.7 (CH2); m/z (ESI) 445, 567 [M+H]+ , 590 
[M +Na]+, 870, 1155. 
 
N,tert-butylcarbonate-4,5-dimethyl-1,2-benzenediamine, 2.2.2  
 
Synthesised according to literature procedure45,46 
 
4,5-Dimethyl-1,2-benzenediamine (1.00 g, 7.34 mmol) 
was dissolved in water (80 ml) and NaHCO3 (1.53 g, 18.2 
mmol) was added portionwise. After 10 minutes stirring at room 
temperature Boc2O (0.801 g, 3.67 mmol) in 60 ml of THF was added and 
the mixture stirred vigarously overnight at room temperatue, before 
extraction with EtOAc (3 times). Purification was carried out on silica with 
EtOAc and petroleum ether to give a 2.2.2 (0.774 g, 3.28 mmol, 18 %) as 
a peach solid; ṽmax/cm-1 3338, 2976, 2927, 2861, 1702, 1519, 1245, 1164; 
1H NMR (400 MHz, CDCl3) δ 6.96 (1H, s, ar.), 6.51 (1H, s, ar.), 3.50 (2H, 
br. s, NH2), 2.08 (6H, s, Me),1.43 (9H, s, Boc); 13C NMR (101 MHz, CDCl3) 
δ 154.2 (C=O), 137.9 (ar.), 134.8 (ar.), 128.0 (ar.), 126.0 (ar.), 122.6 (ar.), 
119.7 (ar.), 80.5 (C=O(C)), 28.5 (t-Bu), 19.4 (Me), 19.0 (Me); m/z (ESI) 
120, 137, 181, 237.0 = [M+H]+, 259 = [M+Na]+, 495 = [2M + Na]+ .  
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1-deoxy-1-[[2-[[(1,1,-dimethylethyl carbonyl] amino-4,5-
dimethylphenyl]amino]-ribose, 2.2.3  
 
Synthesised according to literature procedure45 
 
D-Ribose (0.381 g, 2.54 mmol), 2.2.2 (0.200 g, 0.847 mmol) and 
NaBH3CN (0.080 g, 1.27 mmol) were dissolved in dry 
methanol (10mL) and heated for 48 hours at 65 °C in 
a sealed tube. The contents were transferred to a 
round bottomed flask and volatiles evaporated under 
reduced pressure. The residue was quenched with 
1M HCl (5.3 mL) followed by neutralisation by NaHCO3. The product was 
then extracted three times with EtOAc before drying (MgSO4) and 
evaporation of solvent under reduced pressure to give 2.2.3 (0.280 g, 
0.757 mmol, 89 %) as an orange crystalline solid: 1H NMR (400 MHz, 
CDCl3) δ 6.88 (1 H, s, ar.), 6.62 (1 H, s, ar.), 3.93-3.97 (1 H, m), 3.74-3.82 
(1 H, m), 3.66 (1 H, m), 3.44 (1 H, m), 3.15 (1 H, dd J = 12.8, 6.8), 2.21 (3 
H, s, Me), 2.14 (3 H, s, Me), 1.51 (9 H, s, Boc); m/z (ESI) 137.0, 181.0, 
237.0, 271.0, 315.0, 371.0  [M+H]+, 393.1 [M+Na]+. conforms to literature 
data.   
 
4,5-dimethyl-N1-(3-methylbut-2-en-1-yl)benzene-1,2-diamine, 2.2.11 
 
4,5-Dimethyl-1,2-benzenediamine (3.00 g, 22.0 mmol) 
was dissolved in THF (15 ml). K2CO3 (1.52 g, 11.0 mmol) 
was added, followed by prenyl bromide (1.27 ml, 11.0 
mmol). After overnight stirring at room temperature the 
reaction mixture was diluted with water (20 ml) and extracted with EtOAc 
(3 x 70 ml). The combined extracts were dried (MgSO4) and evaporated 
before purification on silica column (Petroleum ether:EtOAc) to yield dark 
red needle-like crystals (0.854 g, 4.18 mmol, 38 %); ṽmax/cm-1 3338, 2969, 
2919, 2859, 1604, 1519; 1H NMR (400 MHz, CDCl3) δ 6.53 (1H, s, ar.), 
6.48 (1 H, s, ar.), 5.39 (3H, m, CH), 3.66 (2 H, d J 6.8, CH2), 3.18 (3 H, br. 
s, NH), 2.19 (1 H, s, Ar-Me), 2.14 (3 H, s, Me-Ar), 1.76 (3 H, s, Me),1.72 (3 
H, s, Me); NMR (400 MHz, CDCl3) δ 135.9 (C(Me)2), 135.3 (C-Ar), 132.2 
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(C-Ar), 128.1 (Me-C(Ar)), 126.2 (Me-C(Ar)), 122.2 (CH), 118.4 (ar.), 114.2 
(Ar), 42.8 (CH2), 25.9 (Me), 19.5 (Me-Ar), 18.9 (Me-Ar), 18.2 (Me); m/z 
(ESI) 137, 205 [M+H]+, 237, 269.  
 
tert-butyl {4,5-dimethyl-2-[(3-methylbut-2-en-1-
yl)amino]phenyl}carbamate, 2.2.14 
 
tert-butyl {4,5-dimethyl-N1,N1-bis(3-methylbut-2-en-1-yl)benzene-1,2-
diamine} carbamate 
 
2.2.2 (0.15 g, 0.64 mmol) was dissolved in THF (1 ml). K2CO3 (0.088 g, 
0.64 mmol) was added, followed by prenyl bromide (0.073 ml, 
0.64 mmol). After 24 hours stirring at room temperature the 
reaction mixture was diluted with water and extracted with 
EtOAc. The combined extracts were dried (MgSO4) and 
evaporated before purification on silica column (EtOAc:Petroleum ether) to 
yield the product as a yellow solid (0.032 g, 17%) and a 
yellow oil side product (0.053 g, 22%); 1H NMR (400 MHz, 
CDCl3) δ 7.13 (s, 1H), 6.54 (s, 1H), 6.13 – 5.99 (m, 1H), 5.38 
– 5.31 (m, 1H), 3.65 (d, J = 6.7 Hz, 2H), 3.44 (s, 1H), 2.18 (s, 
6H), 1.74 (s, 6H), 1.51 (s, 9H); m/z (ESI) 137, 181, 249, 305 [M+H]+, 
387.23.  
1H NMR (400 MHz, CDCl3) δ 7.88 – 7.77 (m, 2H), 6.86 (s, 1H), 5.16 – 5.10 
(m, 2H), 3.37 (d, J = 6.8 Hz, 4H), 2.21 (s, 3H), 2.17 (s, 3H), 1.66 (s, 6H), 
1.60 (s, 6H), 1.53 (s, 9H); m/z (ESI) 137, 317, 373 [M+H]+, 405 [M+Na]+. 
 
(2R,3S,4S)-4-(5,6-dimethyl-1H-benzimidazol-2-yl)-butane-1,2,3,4-
tetrayl tetrabenzoate, 2.3.1 
Molecular sieves (3Å) were added to 2.2.1 (0.023 
g, 0.171 mmol) and 2.2.9b (0.097 g, 0.171 mmol) 
in MeCN and stirred overnight. Filtration and 
evaporation gave 2.3.1 as a yellow solid (0.074 g, 
0.108 mmol, 63%); [α]26.0D 18.5 (c 0.542 in MeOH); ṽmax/cm-1 2920, 1719, 
1601, 1451, 1247, 1091, 1068, 1025, 706; 1H NMR (400 MHz, CDCl3) δ 
8.30 – 7.97 (m, 9H, ar.), 7.87 (d, J = 7.5 Hz, 2H, ar.), 7.77 – 7.45 (m, 14H, 
ar), 7.37 – 7.24 (m, 5H, ar.), 6.96 (d, J = 3.5 Hz, 1H, ar.), 6.65 (dd, J = 6.5, 
3.8 Hz, 1H, 1’), 6.25 (s, 1H, 2’), 5.05 (d, J = 14.2 Hz, 1H, 3’), 4.69 (dd, J = 
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12.3, 5.7 Hz, 1H, 4’), 2.40 (s, 5H, Me); MALDI-TOF 683 [M+H]+, 705 
[M+Na]+.  
 
(1S,2S,3R)-1-[5,6-dimethyl-1-(3-methylbut-2-en-1-yl)-1H-benzimidazol-
2-yl]butane-1,2,3,4-tetrayl tetrabenzoate, 2.2.21 
 
A mixture of 2.2.11 (0.049 g, 0.241 mmol), 
2.2.9b  (0.15 g, 0.219 mmol) and molecular 
sieves in MeCN were stirred for 1 hour before 
addition of NaBH3CN (0.041 g, 0.656 mmol) and 
EtOH. The reaction mixture was stirred for 48 
hours at room temperature, volatiles evaporated and 1M HCl added to 
quench NaBH3CN. Neutralisation was carried out with NaHCO3 and the 
aqueous layer extracted with EtOAc. The organic layer was dried with 
MgSO4, evaporated and purified by silica column, using 10% EtOAc:DCM 
to elute a brown oil, (0.018 g, 0.023 mmol, 11%); 1H NMR (400 MHz, 
CDCl3) δ 8.12 – 8.05 (m, 2H, ar.), 7.97 – 7.85 (m, 6H, ar.), 7.60 – 7.47 (m, 
5H, ar.), 7.45-7.39 (m, 4H, ar.), 7.36-7.30 (m, 6H, ar.), 7.00 (s, 1H, ar.), 
6.77 (d, J = 7.3 Hz, 1H, CH), 6.52 (dd, J = 7.2, 3.9 Hz, 1H, CH), 6.27 (dt, J 
= 7.2, 3.7 Hz, 1H, CH), 5.14 (dd, J = 12.3, 6.1 Hz, 2H, CH), 5.02 (dd, J = 
12.1, 3.6 Hz, 1H, CH), 4.77 (dd, J = 12.1, 6.9 Hz, 2H, CH2), 2.32 (s, 3H, 
Me), 2.28 (s, 3H, Me), 1.74 (s, 3H, Me), 1.53 (s, 3H, Me); 13C NMR (101 
MHz, CDCl3) δ 166.3 (CO), 166.1 (CO), 165.5 (CO), 164.9 (CO), 133.8 
(ar.), 133.5 (ar.), 133.2 (ar.), 133.2 (ar.), 130.3 (ar.), 130.0 (ar.), 129.9 
(ar.), 129.6 (ar.), 128.7 (ar.), 128.5 (ar.), 128.4 (ar.), 110.5 (alkene), 110.2 
(alkene), 72.5 (alkyl), 71.1 (alkyl), 70.7 (alkyl), 66.6 (alkyl), 63.2 (alkyl), 
25.4 (Me), 20.7 (Me), 20.3 (Me), 18.3 (Me); m/z (NSI) 348, [M+H]+ = 751, 
783, [2M+2H]+ = 1503, 1534. 
 
(2R,3R,4R)-2,3,4,5-tetrakis(benzyloxy)-(1,3-dithian-2-yl)-butane, 2.2.24 
Under an argon atmosphere, 2.2.7 (5.01g, 20.8 mmol) 
was dissolved in dry DMF (130 mL) and NaH (60% 
dispersion in oil, 6.70 g, 167.5 mmol) added over an 
hour. After stirring for a further hour at room temperature benzyl bromide 
(14.3 ml, 120 mmol) was added dropwise. After 24 hours stirring the 
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reaction mixture was quenched with MeOH (100 ml) and water (160 ml) 
before extraction into Et2O (4 x 200 ml). The organic solvent was then 
dried (MgSO4), evaporated and the residue purified by silica column using 
EtOAc (15%) and petroleum ether to elute a light yellow oil (10.85 g, 18.06 
mmol, 89%): [α]26.0D 65.0 (c 1.05 in CHCl3); ṽmax/cm-1 3029, 2898, 1453, 
1094, 1027, 734, 696; 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.23 (m, 20H, 
ar), 4.95-4.91 (m, 1H, alkyl), 4.78-4.62 (m, 5H, alkyl), 4.55-4.53 (m, 1H, 
alkyl), 4.46 (s, 2H, alkyl), 4.06 – 3.99 (m, 2H, alkyl), 3.86 (dd, J = 6.4, 3.8 
Hz, 1H, alkyl), 3.74 – 3.63 (m, 2H, alkyl), 2.87 – 2.74 (m, 3H, alkyl), 2.67 
(ddd, J = 14.0, 11.4, 2.5 Hz, 1H, alkyl), 2.11 – 2.01 (m, 1H, alkyl), 1.96 – 
1.82 (m, 1H, alkyl); 13C NMR (101 MHz, CDCl3) δ 138.9 (ar.), 138.6 (ar.), 
138.6 (ar.), 128.4 (ar.), 128.5 (ar.), 128.4 (ar.), 128.4 (ar.), 128.1 (ar.), 
128.0 (ar.), 127.6 (ar.), 127.6 (ar.), 127.5 (ar.), 81.8 (CH), 79.3 (CH), 79.0 
(CH), 74.4 (CH2), 74.0 (CH2), 73.4 (CH2), 72.7 (CH2), 70.7 (CH2), 50.8 
(CH), 31.5 (CH2), 30.2 (CH2), 26.5 (CH2). 
 
(2R,3R,4R)-2,3,4,5-tetrakis(benzyloxy)pentanal, 2.2.25 
 
To a stirred solution of 2.2.24 (10.0 g, 16.6 mmol) in 4:1 
MeCN: H2O (450 mL) was added NBS (17.8 g, 99.9 
mmol, 6 eq). The resultant bright orange solution was 
stirred at room temperature for 15 minutes. The solution was then diluted 
in water (60 mL) and ether (300 mL) and washed with sat. sodium sulphite 
(100 mL). The organic layer was dried (MgSO4), filtered and evaporated 
before purification by silica column (DCM) to remove succinimide and give 
2.2.25 as a yellow oil (7.67 g, 15.0 mmol, 91%): [α]25.8D 27.4 (c 3.28 in 
CHCl3);  ṽmax/cm-1 3031, 2867, 1727, 1454, 1094, 1027, 734, 696; 1H NMR 
(400 MHz, CDCl3) δ 9.49 (d, J = 0.9 Hz, 1H, CHO), 7.40 – 7.20 (m, 20H, 
ar.), 4.76 – 4.64 (m, 4H, CH2), 4.62 – 4.45 (m, 7H, CH2), 4.11 (dd, J = 2.2, 
0.9 Hz, 1H, CH), 4.02 (dd, J = 8.6, 2.3 Hz, 1H, CH), 3.91 (ddd, J = 8.6, 4.5, 
2.5 Hz, 1H, CH), 3.74 – 3.68 (m, 2H, CH2), 3.64-3.60 (m, 1H, CH2), 3.42 (t, 
J = 7.0 Hz, 1H, CH2); 13C NMR (101 MHz, CDCl3) δ 201.3 (CHO), 138.4 
(ar.), 138.2 (ar.), 137.8 (ar.), 137.6 (ar.), 128.6 (ar.), 128.6 (ar.),128.5 (ar.), 
128.5 (ar.), 128.4 (ar.), 128.1 (ar.), 128.1 (ar.), 128.0 (ar.), 127.9 (ar.), 
127.8 (ar.), 127.7 (ar.), 82.6 (CH2), 80.7 (CH2), 73.5 (CH2), 73.3 (CH), 73.0 
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(CH), 72.8 (CH), 69.3 (CH); HRMS m/z: [M + H]+ Calcd for C33H35O5 
511.2479; Found 511.2474. 
 
(2S,3S,4R)-2,3,4,5-tetrakis(benzyloxy)pentan-1-ol, 2.2.26 
 
To a solution of 2.2.25 (1.22 g, 2.38 mmol) in 25 ml of 
4:1 DCM:MeOH was added NaBH4 (0.117 g, 3.10 
mmol) and the reaction monitored by TLC (4:1 Hexane:EtOAc). Upon 
completion (around 4 hours) the reaction was adjusted to pH 6 by addition 
of acetic acid, diluted with DCM (80 ml), washed with water, dried 
(MgSO4), concentrated and purified by silica column (12 g Telos column, 
10-40% EtOAc:PE) to give a clear, yellowish oil (1.14 g, 1.98 mmol, 83%): 
[α]24.4D 299 (c 0.194 in MeOH)89;  ṽmax/cm-1 3421, 2919, 1721, 1452, 1267, 
1093, 1026, 1069, 711, 697; 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.28 (m, 
20H, ar.), 4.81 – 4.65 (m, 4H, alkyl), 4.62 (s, 2H, alkyl), 4.60 – 4.50 (m, 2H, 
alkyl), 4.00 (t, J = 4.8 Hz, 1H, alkyl), 3.97-3.91 (m,1H, alkyl), 3.83 – 3.70 
(m, 5H, alkyl), 2.07 (s, 1H, alkyl); 13C NMR (101 MHz, CDCl3) δ 138.4 (ar.), 
138.3 (ar.), 138.2 (ar.), 138.2 (ar.), 128.6 (ar.), 128.5 (ar.), 128.5 (ar.), 
128.5 (ar.), 128.4 (ar.), 128.2 (ar.), 128.0 (ar.), 128.0 (ar.), 127.8 (ar.), 
127.8 (ar.), 127.8 (ar.), 127.7 (ar.), 127.7 (ar.), 127.6 (ar.), 127.0 (ar.), 79.1 
(CH), 78.9 (CH), 78.3 (CH), 74.1 (CH2), 73.4 (CH2), 72.5 (CH2), 72.0 
(CH2), 69.8 (CH2), 65.3 (CH2), 61.4 (CH2); m/z (MALDI-TOF) 535 [M+Na]+, 
551 [M+K]+, 563, 577.  
 
(2R,3R,4R)-2,3,4,5-tetrakis(benzyloxy)-1-bromopentane, 2.2.27 
 
To a solution of 2.2.26 (1.14 g, 1.98 mmol) and PPh3 (0.910 g, 
3.47 mmol) in DCM (14 ml) was added CBr4 (0.985 g, 2.97 
mmol) in DCM (12 ml). Upon completion the reaction mixture 
was partitioned between DCM and water (50 ml of each) and the DCM 
layer washed with water (x 2) and brine (x 1) before drying (MgSO4), 
evaporation and purification of the residue on silica using EtOAc (0-20%) 
and hexane to elute, giving 2.2.27 as a clear-yellow oil (0.228 g, 0.397 
mmol, 20%); [α]24.8 -121 (c 1.08 in methanol); ṽmax/cm-1 3053, 3033 (ar. 
CH), 2867 (CH), 1455 (CH2), 1265 (C-O), 736 (C-Br); 1H NMR (400 MHz, 
CDCl3) δ 7.36 – 7.26 (m, 20H, ar), 4.76 – 4.64 (m, 5H, alkyl), 4.58-4.54 (m, 
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1H, alkyl), 4.51-4.50 (m, 2H, alkyl), 3.97 – 3.88 (m, 3H, alkyl), 3.76 – 3.59 
(m, 4H, alkyl); 13C NMR (101 MHz, CDCl3) δ 138.5 (ar.), 138.4 (ar.), 138.3 
(ar.), 137.9 (ar.), 128.5 (ar.), 128.2 (ar.), 128.2 (ar.), 128.0 (ar.), 127.9 
(ar.), 127.9 (ar.), 127.8 (ar.), 127.7 (ar.), 79.3 (CH), 78.3 (CH), 78.2 (CH), 
74.1 (CH2), 73.5 (CH2), 72.5 (CH2), 72.5 (CH2), 70.1 (CH2), 33.9 (CBr); 
MALDI-TOF: 597 [M+Na]+ 599 [M+Na]+; Calcd for C33H39O4NBr 592.2057; 
Found 592.2051. 
 
(2R,3S,4S) -2,3,4,5-tetrakis(benzyloxy)-5-(4,5-dimethyl-2-nitroanilino), 
2.2.32 
To 2.2.1 (0.072 g, 0.434 mmol) in DMF (1 mL) was 
added NaH (0.434 mmol), upon which the solution 
changed from yellow/orange to blood red. Then 2.2.27 
(0.100 g, 0.174 mmol) was added in 0.1 mL of DMF and 
the solution stirred at room temperature overnight. The 
reaction mixture was extracted with EtOAc, then DCM, 
the aqueous layer neutralised with 2M HCl, then extracted with DCM. The 
combined organic layers were dried (MgSO4), evaporated and the crude 
purified by column chromatography (0-1-100% EtOAc:DCM, 12 g Telos 
column) to give 2.2.32 as an orange oil (0.0143 g, 12%): [α]24.9 -28.7 (c 
0.453 in methanol); ṽmax/cm-1 2931, 2858, 1734, 1006, 762; 1H NMR (400 
MHz, CDCl3) δ 7.93 (s, 1H, ar.), 7.41 – 7.21 (m, 20H, ar.), 6.51 (s, 1H, ar.), 
4.78 – 4.46 (m, 8H, CH2), 4.02-3.98 (m, 2H, CH), 3.88 – 3.61 (m, 3H, 
alkyl), 3.50 (m, 1H, alkyl), 3.40 (m, 1H, CH2), 2.18 (s, 3H, Me), 2.14 (s, 3H, 
Me); 13C NMR (101 MHz, CDCl3) δ 147.2 (ar.), 144.4 (ar.), 138.3 (ar.), 
137.8 (ar.), 130.0 (ar.), 128.5 (ar.), 128.5 (ar.), 128.5 (ar.), 128.3 (ar.), 
128.3 (ar.), 128.2 (ar.), 127.9 (ar.), 127.9 (ar.), 127.8 (ar.), 127.8 (ar.), 
126.5 (ar.), 124.3 (ar.), 114.7 (ar.), 78.0 (CH), 77.8 (CH), 77.4 (CH), 74.1 
(CH2), 73.6 (CH2), 72.4 (CH2), 72.4 (CH2), 69.6 (CH2), 42.8 (CNH), 20.7 
(Me), 18.7 (Me); Calcd for C41H45O6N2 661.3272; Found 661.3260. 
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N-ethoxalyl-4,5-dimethyl-2-nitroaniline, 2.2.2967 
To 4,5-dimethyl-2-nitroaniline (1.00 g, 6.02 mmol) was 
added dropwise ethyl oxalyl chloride (0.92 ml, 6.6 mmol, 1 
eq) and NEt3 in 40 ml DCM. The resulting solution was 
stirred at room temperature overnight when another 
equivalent of ethyl oxalyl chloride was added. The reaction was monitored 
until consumption of starting material. The reaction mixture was then 
poured into ice water (100 ml), extracted into DCM, washed with NaHCO3 
and 1M NaOH and the aqueous layer re-extracted with EtOAc. The 
organic layers were combined, dried and evaportated to give a light yellow 
powder (5.31 mmol, 88%); 1H NMR (400 MHz, CDCl3) δ 8.57 (s, 1H, ar.), 
8.04 (s, 1H, ar.), 4.45 (q, J = 7.1 Hz, 2H, CH2), 2.37 (s, 3H, Me), 2.31 (s, 
3H, Me), 1.44 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (101 MHz, CDCl3) δ 160.1 
(ar.), 159.8 (ar.), 154.8 (ar.), 147.06 (ar.), 134.2 (ar.), 131.0 (ar.), 126.5 
(CO), 122.7 (CO), 64.1 (CH2CH3), 20.7 (Me), 19.4 (Me), 14.1 (CH2CH3); 
TOF MS ASAP+ (100%) = 267.0978 = [M + H]+ Observed mass [M+H]+ = 
267.0978, calculated = 267.0981. 
 
(2R,3R,4R)-2,3,4,5-tetrakis(benzyloxy)pentanoic acid, 2.2.34 
To a solution of 2.2.25 (2.00 g) in tert-butyl alcohol (39 
mL) and 2-methyl-2-butene (23 mL) was added a 
mixture of sodium chlorite (7.84 g) and sodium 
dihydrogenphosphate (7.84 g) in water.  After stirring at room temperature 
and monitoring by TLC (for 1 hour), the reaction mixture was diluted with 
EtOAc (100 mL) and 0.5 M KHSO4 (40 mL). The organic layer was 
separated, and the aqueous layer was extracted with EtOAc (4 x 100 mL). 
The combined organic layer was washed with 10% NaHSO3 and brine, 
dried over Na2SO4, and evaporated.  The resulting residue was purified by 
silica gel column chromatography (hexane:EtOAc = 5:1) to give the acid 
as a yellow oil (1.43 g, 2.71 mmol, 69%): [α]22.4D -15.9 (c 1.01 in CHCl3); 
ṽmax/cm-1 2927, 2865, 1659, 1306, 701; 1H NMR (400 MHz, CDCl3) δ 7.28 
– 7.12 (m, 20H, ar.), 4.68 – 4.35 (m, 8H, alkyl), 4.30 (d, J = 2.2 Hz, 1H, 
alkyl), 4.06 (dd, J = 8.2, 2.1 Hz, 1H, alkyl), 3.86 – 3.81 (m, 1H, alkyl), 3.56 
(ddd, J = 14.9, 10.5, 3.5 Hz, 2H, alkyl); 13C NMR (101 MHz, CDCl3) δ 
173.0 (COOH), 138.3 (ar.), 138.1 (ar.), 137.8 (ar.), 137.1 (ar.), 128.6, 
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128.5 (ar.), 128.4 (ar.), 128.2 (ar.), 128.2 (ar.), 128.2 (ar.), 128.2 (ar.), 
127.9 (ar.), 127.9 (ar.), 127.7 (ar.), 127.7 (ar.), 79.6 (CH), 78.1 (CH), 77.4 
(CH), 73.8 (CH2), 73.5 (CH2), 73.2 (CH2), 72.8 (CH2), 69.0 (CH2); HRMS 
m/z: [M - H]- Calcd for C33H33O6 525.2283; Found 525.2275.   
 
(2R,3R,4R) -N-(2-amino-4,5-dimethylphenyl)- 2,3,4,5-
tetrakis(benzyloxy)pentanamide, 2.2.35 
Under argon 2.2.34 (0.658 g, 1.25 mmol) was 
dissolved in 1:2 DMF:DCM (18 mL) and 
EDAC.HCl (0.288g, 1.5 mmol) and HOBt 
(0.203g, 1.5 mmol) added at 0 °C and stirred for 
30 minutes. DIPEA (3.0 mmol, 0.52 mL) and D115 (0.204g, 1.5 mmol) 
were then added and the solution stirred until completion. 2N HCl was 
then added to acidify, followed by dilution with ether (50 mL), washing with 
water (x 3) and brine (x 1), drying (MgSO4), filtering and evaporation. 
Purification was carried out by Telos silica column to give 2.2.35 as a 
yellow-orange oil (0.655 g, 81%); [α]26.0D 141 (c 1.04 in CHCl3); ṽmax/cm- 1 
3376, 3030, 2862, 1676, 1517, 1496, 1454, 1097, 697; 1H NMR (400 MHz, 
CDCl3) δ 7.41 – 7.20 (m, 20H, ar), 6.79 (s, 1H, ar), 6.47 (s, 1H, ar), 4.82 
(d, J = 11.1 Hz, 1H, alkyl), 4.78 – 4.61 (m, 7H, alkyl), 4.58 – 4.46 (m, 4H, 
alkyl), 4.28 – 4.21 (m, 1H, alkyl), 3.99 (ddd, J = 9.1, 3.6, 2.4 Hz, 1H, alkyl), 
3.76 – 3.64 (m, 3H, alkyl), 2.12 (s, 3H, Me), 2.08 (s, 3H, Me); 13C NMR 
(101 MHz, CDCl3) δ 168.9 (NHCO), 138.6 (ar.), 138.4 (ar.), 138.1 (ar.), 
137.2 (ar.), 135.6 (ar.), 128.7 (ar.), 128.5 (ar.), 128.4 (ar.), 128.3 (ar.), 
128.3 (ar.), 128.2 (ar.), 128.2 (ar.), 128.1 (ar.), 128.1 (ar.), 128.0 (ar.), 
127.9 (ar.), 127.9 (ar.), 127.8 (ar.), 127.8 (ar.), 127.7(ar.), 127.6 (ar.), 
127.5 (ar.), 126.9 (ar.), 126.8 (ar.), 120.6 (ar.) , 118.6 (ar.), 80.9 (CH), 79.7 
(CH), 78.0 (ar.), 77.8 (ar.), 74.7 (CH2), 73.6 (CH2), 73.4 (CH2), 73.4 (CH2), 
72.9 (CH), 72.7 (CH), 72.5 (CH), 68.8 (CH), 19.4 (Me), 18.8 (Me); HRMS 
m/z: [M + H]+ Calcd for C41H45N2O5 645.3323; Found 645.3318. 
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(2R,3R,4R)-N{4,5-dimethyl-2-[(3-methylbut-2-en-1-yl)amino]phenyl}-
2,3,4,5-tetrakis(benzyloxy)pentanamide, 2.2.39 
 
A THF solution (1.5 mL) of 2.2.35 (0.10 g, 0.16 mmol) 
was prepared and CsCO3 (0.212 g, 0.16 mmol, 1 eq) 
added, followed by prenyl bromide (0.018 mL, 0.16 
mmol, 1 eq). The resulting solution was stirred at room 
temperature overnight, before extraction into EtOAc, 
washing of the organic layer with water, drying of the 
EtOAc layer over MgSO4, filtering evaporation and purification by Telos 
silica column (PE:EtOAc to elute) to give a mixture of the mono and 
diprenylated products 2.2.39 (Colourless oil, 0.0236 g, 23%), 2.2.38 (light 
yellow oil, 0.004 g, 3%): [α]23.5D 5.73 (c 3.14 in CHCl3); ṽmax/cm-1 3376, 
3030, 2862, 1679, 1521, 1496, 1453, 1096, 1027, 733, 696; 1H NMR (400 
MHz, CDCl3) δ 8.03 (s, 1H, NH), 7.42 – 7.20 (m, 20H, ar.), 6.89 (s, 1H, 
ar.), 6.53 (s, 1H, ar.), 5.07 (t, J = 6.5 Hz, 1H, CH), 4.80 (dd, J = 13.7, 8.2 
Hz, 1H, alkyl), 4.69 (dt, J = 18.1, 11.4 Hz, 5H, alkyl), 4.56 – 4.50 (m, 3H, 
alkyl), 4.26 – 4.20 (m, 1H, alkyl), 3.95 (ddd, J = 9.2, 3.7, 2.3 Hz, 1H, alkyl), 
3.68 (ddd, J = 14.4, 10.6, 3.1 Hz, 2H, alkyl), 3.45 (d, J = 6.4 Hz, 2H, alkyl), 
2.20 (s, 3H, Me), 2.11 (s, 3H, Me), 1.62 (d, J = 14.3 Hz, 6H, Me); 13C NMR 
(101 MHz, CDCl3) δ 169.2 (NHCO), 138.7 (ar.), 138.5 (ar.), 138.0 (ar.), 
137.3 (ar.), 135.7 (ar.), 128.7 (ar.), 128.5 (ar.), 128.4 (ar.), 128.3 (ar.), 
128.3 (ar.), 128.2 (ar.), 128.1 (ar.), 127.9 (ar.), 127.7 (ar.), 127.5 (ar.), 
127.0 (ar.), 81.1 (CH), 79.5 (CH), 77.8 (CH), 74.8 (CH2), 73.5 (CH2), 73.3 
(CH2), 72.6 (CH2), 68.8 (CH2), 25.8 (Me), 20.0 (Me), 18.8 (Me), 18.1 (Me); 
HRMS m/z: [M + H]+ Calcd for C46H53N2O5 713.3949; Found 713.3948. 
 
(2R,3R,4R)-N{4,5-dimethyl-2-[N1,N1-bis(3-methylbut-2-en-1-
yl)amino]phenyl}-2,3,4,5-tetrakis(benzyloxy)pentanamide, 2.2.38 
A THF solution (1.5 ml) of 2.2.35 (0.10 g, 0.16 mmol) 
was prepared and Cs2CO3 (0.318 g, 0.24 mmol, 1.5 
eq) added, followed by prenyl bromide (0.018 mL, 0.16 
mmol, 1 eq). The resulting solution was stirred at room 
temperature overnight, before extraction into EtOAc, 
washing of the organic layer with water, drying of the 
EtOAc layer over MgSO4, filtering evaporation and 
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purification by Telos silica column (PE:EtOAc to elute) to give a mixture of 
the mono and diprenylated products 2.2.39 (colourless oil, 0.015 g, 13%) 
2.2.38 (light yellow oil, 0.012 g, 10%); [α]23.6D 125 (c 1.41 in CHCl3); 
ṽmax/cm-1 2919, 1677, 1521, 1453, 1113, 731; 1H NMR (400 MHz, CDCl3) δ 
9.89 (s, 1H, ar.), 8.27 (s, 1H, ar.), 7.46 – 7.17 (m, 20H, ar.), 7.17 – 7.10 
(m, 3H, alkyl), 6.81 (s, 1H, alkyl), 5.04 – 4.89 (m, 2H, alkyl), 4.83 – 4.57 
(m, 6H, alkyl), 4.49 – 4.42 (m, 3H, alkyl), 4.23 (dd, J = 8.5, 1.9 Hz, 1H, 
alkyl), 4.09 (ddd, J = 8.4, 4.8, 2.2 Hz, 1H, alkyl), 3.74 (dd, J = 10.6, 2.2 Hz, 
1H, alkyl), 3.63 (dd, J = 10.6, 4.8 Hz, 1H, alkyl), 3.24 (ddd, J = 20.4, 14.2, 
6.7 Hz, 4H, alkyl), 2.19 (d, J = 10.3 Hz, 6H, Me), 1.50 (t, J = 24.3 Hz, 14H), 
1.43 (s, 6H, Me), 1.43 (s, 6H, Me), 1.24 (s, 1H); 13C NMR (101 MHz, 
CDCl3) δ 167.9 (NHCO), 138.7 (ar.), 138.7 (ar.), 138.3 (ar.), 138.0 (ar.), 
137.6 (ar.), 134.2 (ar.), 133.2 (ar.), 132.3 (ar.), 131.1 (ar.), 128.5 (ar.), 
128.4 (ar.), 128.3 (ar.), 128.2 (ar.), 128.1 (ar.), 128.0 (ar.), 127.9 (ar.), 
127.8 (ar.), 127.6 (ar.), 127.5 (ar.), 127.3 (ar.), 123.9 (ar.), 121.5 (ar.), 
120.1 (alkyl), 81.0 (alkyl), 79.8 (alkyl), 78.0 (alkyl), 73.8 (alkyl), 73.5 (alkyl), 
73.4 (alkyl), 72.6 (alkyl), 69.8 (alkyl), 51.7 (alkyl), 25.9 (Me), 19.8 (Me), 
19.7 (Me), 18.0 (Me); HRMS m/z: [M + H]+ Calcd for C51H61N2O5 
781.4575; Found 781.4563.  
 
(2R,3S,4S)-5-(2-amino-4,5-dimethylanilino) -2,3,4,5-
tetrakis(benzyloxy)pentane, 2.2.33 
A 1.0 M solution of LiAlH4 (3.10 mL, 2 eq) was added to 
a flame-dried flask under argon, and then cooled in an 
acetonitrile: dry ice cooling bath. A solution of 2.2.35 
(0.975 g, 1.51 mmol, 1 eq) in dry THF (20 mL) was 
added slowly dropwise. The flask was warmed to room 
temperature and then refluxed (70 °C) overnight. Water 
(30 mL) and Et2O (3 x 40 mL) were used to extract, followed by drying 
(MgSO4), filtration and concentration. Purification was carried out by silica 
column (0-40% EtOAc: PE) to yield 2.2.33 as an orange oil 0.841g (1.33 
mmol, 88%); [α]26.0D -11.2 (c 1.08 in CHCl3); ṽmax/cm-1 3031, 2863, 1520, 
1454, 1096, 736, 697; 1H NMR (400 MHz, CDCl3) δ 7.44 – 7.23 (m, 20H, 
ar.), 6.50 (s, 1H, ar.), 6.41 (s, 1H, ar.), 4.79 – 4.64 (m, 3H, alkyl), 4.64 – 
4.53 (m, 5H, alkyl), 4.08 – 3.96 (m, 2H, alkyl), 3.96 – 3.83 (m, 1H, alkyl), 
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3.83 – 3.54 (m, 3H, alkyl), 3.33 (d, J = 4.7 Hz, 2H, alkyl), 2.14 (s, 6H, Me); 
13C NMR (101 MHz, CDCl3) δ 138.5 (ar.), 138.5 (ar.), 138.4 (ar.), 138.3 
(ar.), 135.3 (ar.), 132.6 (ar.), 128.6 (ar.), 128.5 (ar.), 128.4 (ar.), 128.3 
(ar.), 128.2 (ar.), 128.1 (ar.), 128.1 (ar.), 128.0 (ar.), 127.9 (ar.), 127.8 
(ar.), 127.7 (ar.), 127.7 (ar.), 127.6 (ar.), 127.6 (ar.), 126.3 (ar.), 118.1 
(ar.), 114.8 (ar.), 78.7 (CH), 78.5 (CH), 77.8 (CH), 74.1 (CH2), 73.4 (CH2), 
72.5 (CH2), 71.8 (CH2), 69.9 (CH2), 65.4 (CH2), 61.4 (CH2), 60.4 (CH2), 
44.2 (CH2), 21.1 (Me), 19.2 (Me), 18.9 (Me), 14.3 (Me); HRMS m/z: [M + 
H]+ Calcd for C41H47N2O4 631.3530; Found 631.3519. 
 
6,7-dimethyl-1-((2S,3S,4R)-2,3,4,5-O-Benzylpentyl)-1,4-
dihydroquinoxaline-2,3-dione, 2.2.40 
Diethyl oxalate (20 mL) was added to 2.2.33 (0.303 g) 
and the resultant solution evaporated on a rotary 
evaporator at 55 °C for 25 hours at 20 mbar while 
protected from light (foil cover). The resulting brown oil 
was purified by silica column (0-100% EtOAc:PE) to give 
2.2.40 as a yellow-green oil (visible by 365 nm on TLC), 
(0.232 g, 0.339 mmol, 71%): [α]26.0D -97.7 (c 1.00 in CHCl3); ṽmax/cm-1 
3375, 3030, 2864, 1673, 1495, 1453, 1095; 1H NMR (400 MHz, CDCl3) δ 
11.65 (s, 1H, NH), 7.37 – 7.32 (m, 2H, ar.), 7.29 – 7.18 (m, 13H, ar), 7.15 
(s, 1H, ar.), 7.06 – 6.96 (m, 4H, ar.), 6.80 – 6.76 (m, 2H, ar.), 4.80 – 4.72 
(m, 3H, CH), 4.63 (t, J = 11.8 Hz, 2H, CH), 4.51 – 4.30 (m, 4H, CH), 4.24 
(m, 1H, CH), 4.15 (m, 1H, CH), 3.96 (dd, J = 7.6, 2.0 Hz, 1H, CH), 3.87 
(dt, J = 7.6, 3.7 Hz, 1H, CH), 3.69 (ddd, J = 14.7, 10.4, 3.7 Hz, 2H, CH), 
2.19 (s, 3H, Me), 2.04 (s, 3H, Me); 13C NMR (101 MHz, CDCl3) δ 155.7 
(CO), 155.6 (CO), 138.6 (ar.), 138.4 (ar.), 138.3 (ar.), 137.9 (ar.), 133.1, 
133.0 (ar.), 128.5 (ar.), 128.5 (ar.), 128.2 (ar.), 128.1 (ar.), 128.0 (ar.), 
127.9 (ar.), 127.9 (ar.), 127.8 (ar.), 127.7 (ar.), 127.6 (ar.), 125.6 (ar.), 
122.4 (ar.), 117.3 (ar.), 79.1 (CH), 78.0 (CH), 77.3 (CH), 74.0 (CH2), 73.6 
(CH2), 72.9 (CH2), 72.5 (CH2), 69.3 (CH2), 45.3 (CH2), 19.8 (Me), 19.00 
(Me); HRMS m/z: [M + H]+ Calcd for C43H45N2O6 685.3272; Found 
685.3267. 
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6,7-dimethyl-1-(3-methylbut-2-en-1-yl)-4-((2S,3S,4R)-2,3,4,5-tetra-O-
benzyl)-1,4-dihydroquinoxaline-2,3-dione, 2.2.41 
THF (0.5 mL) was used to dissolve 2.2.40 (0.040g, 
0.058 mmol), Cs2CO3 (0.028 g, 0.028 mmol) added, 
followed by prenyl bromide (0.087 mmol, 0.010 mL). The 
reaction was stirred overnight. Water (5 mL), then DCM 
(10 mL) were added, the organic layer separated and 
the aqueous layer re-extracted with DCM (10 mL). The 
volatiles were then evaporated to give 2.2.41 as a yellow 
orange oil (0.0409 g, 0054 mmol, 93%): [α]25.8D -54.6 (c 
1.26 in CHCl3); ṽmax/cm-1 3329, 2968, 2968, 1705, 1615, 1545, 1449, 1249, 
1033; 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.40 (m, 2H, ar.), 7.38 – 7.26 
(m, 18H, ar.), 7.16 – 7.04 (m, 4H, ar.), 6.89 (dd, J = 9.6, 2.6 Hz, 3H, ar.), 
5.18 (ddd, J = 6.4, 5.1, 1.3 Hz, 1H, CH prenyl), 4.88 – 4.74 (m, 5H, CH), 
4.68 (dd, J = 11.8, 7.2 Hz, 2H, CH), 4.60 – 4.53 (m, 3H, CH), 4.47 – 4.41 
(m, 2H, CH), 4.34 – 4.29 (m, 1H, CH), 4.26 – 4.20 (m, 1H, CH), 4.04 (dt, J 
= 9.4, 4.7 Hz, 1H, CH), 3.94 (ddd, J = 13.2, 8.3, 3.8 Hz, 1H, CH), 3.82 – 
3.69 (m, 3H, Me), 2.29 (s, 3H, Me), 2.12 (s, 3H, Me), 1.91 (s, 3H, Me), 
1.75 (d, J = 0.6 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 154.8 (CO), 154.0 
(CO), 138.6 (ar.), 138.5 (ar.), 138.4 (ar.), 138.0 (ar.), 137.2 (ar.), 132.3 
(ar.), 137.2 (ar.), 128.5 (ar.), 128.4 (ar.), 128.2 (ar.), 128.1 (ar.), 128.0 
(ar.), 127.9 (ar.),  127.9 (ar.), 127.8 (ar.), 127.7 (ar.), 127.4 (ar.), 127.4 
(ar.), 125.8 (ar.), 124.5 (ar.), 118.3 (ar.), 118.0 (ar.), 116.0 (ar.), 79.2 (CH), 
78.0 (CH), 77.7 (CH), 77.4 (CH), 74.0 (CH2), 73.6 (CH2), 72.9 (CH2), 72.5 
(CH2), 69.4 (CH2), 45.4 (CH2), 41.6 (CH2), 25.9 (Me), 19.8 (Me), 19.5 (Me), 
18.5 (Me). HRMS m/z: [M + H]+ Calcd for C48H53N2O6 753.3898; Found 
753.3890. 
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7,7,8,9-tetramethyl-1-((2S,3S,4R)-2,3,4,5-tetrahydroxypentyl)-6,7-
dihydro-1H,5Hpyrido[1,2,3-de]quinoxaline-2,3-dione, 
Hunanamycin A   
2.2.41 (0.080 g, 0.106 mmol) was dissolved in DCE (2 
mL) and AlCl3 (0.283 g, 2.12 mmol, 20 eq) added in 1 
portion. The reaction mixture was stirred for 48 hours, 
upon which the reaction was quenched with ice cold 
water. The DCE layer was separated and the aqueous 
layer extracted with EtOAc (5 x). The combined layers were dried 
(MgSO4), filtered and evaporated. Purification was carried out by silica 
column chromatography (0-20 % MeOH:DCM) to give a mixture of 
Hunanamycin A and 2.2.42  as a yellow-white solid. This was further 
purified into 1 (9%, 3.54 mgs, 0.009 mmol)  and 2 (6%, 2.47 mg, 0.006 
mmol) by preparative HPLC (MeOH(0-100):water:0.05%TFA): [α]23.5D 91.7 
(c 1.05 in CHCl3)42,58,29; ṽmax/cm-1 3358, 2935, 1670, 1405, 1204, 1134; 1H 
NMR (400 MHz, MeOD) δ 7.48 (s, 1H, ar.), 4.84 – 4.74 (m, 1H, CH2), 4.27 
(m, 2H, CH/CH2), 4.15 (dd, J = 12.0, 5.7 Hz, 2H, CH2), 3.85 – 3.72 (m, 3H, 
CH/CH2), 3.67 (dt, J = 10.9, 4.6 Hz, 1H, CH2), 2.46 (s, 3H, ar. Me), 2.34 (s, 
3H, ar. Me), 1.94 (t, J = 6.0 Hz, 2H, CH2), 1.56 (d, J = 1.4 Hz, 6H, Me); 13C 
NMR (101 MHz, MeOD) δ 156.4 (CO), 155.2 (CO), 136.0 (ar.), 134.2 (ar.), 
133.7 (ar.), 126.1 (ar.), 123.2 (ar.), 117.1 (ar.), 74.9 (CH), 74.3 (CH), 70.8 
(CH), 64.9 (CH2), 46.5 (CH2), 40.6 (CH2), 39.3 (CH2), 34.4 C(Me)2 , 29.2 
(Me), 28.8 (Me), 21.5 (ar. Me), 19.5 (ar. Me); MALDI-TOF: [M+Na]+ 
=414.70 (100%), 415.72 (40%); HRMS m/z: [M + H]+ Calcd for C20H29N2O6 
393.2020; Found 393.2020. 
 
Data conforms to literature data. 
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6,7-dimethyl-1-(3-methylbutyl)-4-((2S,3S,4R)-2,3,4,5-hydroxy)-1,4-
dihydroquinoxaline-2,3-dione, 2.2.42    
[α]23.5D 184 (c 0.669 in CHCl3); ṽmax/cm-1 3360, 2931, 
1674, 1207, 1140;  1H NMR (400 MHz, MeOD) δ 7.52 (s, 
1H, ar.), 7.19 (s, 1H, ar.), 4.74 (dd, J = 14.1, 9.7 Hz, 1H, 
alkyl), 4.33 – 4.20 (m, 3H, alkyl), 3.84 – 3.72 (m, 2H, 
alkyl), 3.72 – 3.63 (m, 1H, alkyl), 2.35 (s, 3H, Me), 2.34 
(s, 3H, Me), 1.77 (td, J = 13.2, 6.6 Hz, 1H, alkyl), 1.63 
(dd, J = 14.8, 7.8 Hz, 2H, alkyl), 1.05 (s, 3H, Me), 1.04 (s, 
3H, Me); MALDI-TOF: [M]+ = 394.90 (8%), [M+Na]+ = 
416.85 (100%), 417.85 (30%), [M+K]+ = 432.79 (90%), 433.81 (14%); [M + 
H]+ Calcd for C20H31N2O6 395.2177; Found 395.2176. 
 
4,5-Dimethyl-2-nitro-N-(α/β-D-ribopyranosyl)benzenamine, 2.3.2 
 
Synthesised according to literature procedure60 
 
To a solution of D-ribose (1.00 g) in dry ethanol (30 mL) under 
argon was added 3,4-dimethyl-2-nitrobenzeneamine (5.60 g) 
and recrystallised NH4Cl (0.64 g) and the resultant solution 
heated to reflux for 1.5 hours, cooled to room temperature, 
filtered and purified by silica column (CHCl3-CHCl3:MeOH 
(25:1) (60%,mixture of two isomers, only one isomer shown here); 1H 
NMR (400 MHz, CDCl3) δ 8.78 (m, 1H), 8.12 (m, J = 6.9 Hz, 0.4H), 7.84 
(s, 0.4H), 7.77 (s, 1H), 6.86 (s, 0.4H), 6.70 (s, 1H), 5.09-5.05 (m, 0.4H), 
4.86-4.79 (m, 1H), 4.36 –3.43 (m), 2.23 (d, J = 4.0 Hz, 52H), 2.15 (s, 18H), 
2.13 (s, 47H); LC-MS (ESI) 167, 201, 253, 321 [M + Na]+, 389 [M + NH4Cl 
+ K]+. Conforms to literature data.  
 
4,5-Dimethyl-2-nitro-N-(2’,3’,5’-tri-O-acetyl-α/β-D-
ribopyranosyl)benzenamine, 2.2.44 
 
Synthesised according to literature procedure60 
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To a solution of 2.3.2 (0.512 g, 2.08 mmol) in pyridine (8 mL) was added 
Ac2O (2.4 mL) dropwise. After overnight stirring at room temperature 
volatiles were evaporated and the residue purified by silica column (7:3 
PE:EtOAc) to give 2.2.44 as an orange oil (0.603 g, 1.42 mmol, 83 %); 1H 
NMR (400 MHz, CDCl3) δ 8.93 (d, J = 7.0 Hz, 1H), 7.98 (s, 1H), 6.90 (s, 
1H), 5.76-5.73 (m, 1H), 5.44-5.9 (m), 5.37-5.15 (m), 5.05 (qd, J =  5.2, 3.1 
Hz), 4.37 – 4.24 (m, 4H), 4.14 – 4.08 (m, 3H), 3.89 (t, J = 10.9 Hz, 1H), 
3.64 – 3.58 (m), 2.37 (s, 3H), 2.29 (s, 3H), 2.21 (s, 3H), 2.04 (s, 3H), 2.02 
(m, 3H); 13C NMR (101 MHz, CDCl3) δ 170.5, 169.7, 147.5, 141.6, 131.6, 
127.2, 115.9, 105.6, 71.78, 68.0, 66.2, 66.2, , 21.0, 20.8, 20.7, 18.8; 
MALDI-TOF 246 [M+Na]+ 
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Chapter Three 
 
3. Introduction to lariat peptides and synthesis towards 
teixobactin and analogues  
 
Peptides are molecules formed from amino acids linked by peptide bonds, 
ranging from two amino acid dipeptides (for example aspartame) to 
complex proteins made up of thousands of amino acid residues.90 
Peptides are usually defined as polypeptides between 2 and 50 amino 
acids.5,91 Many primary and secondary metabolites are peptides or 
molecules modified from peptides.  
Biosynthetically peptides are made by ribosomes according to the 
sequences coded by RNA, as required for the cell.91 It is not always 
practical to extract the necessary peptides from biological sources, or 
sometimes changes may need to be made to the peptide found in nature. 
Therefore, there are now several methods of chemical synthesis which 
may be carried out to make peptides. 
 
3.1 Synthesis of peptides 
 
The coupling of amino acids to form peptides was first reported in 190192, 
with N-protected amino acids used in synthesis by 1932.93 These 
reactions carried out in solution, rely on purification after each stage and 
can be very time-consuming to carry out. Despite these limitations solution 
state synthesis is still used to make many biologically and 
pharmaceutically relevant peptides.94 Figure 3.1.1 shows an outline of the 
process of solution phase coupling amino acids. 
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Figure 3.1.1: Solution phase synthesis of peptides. PG = protecting group. R1 /R2 = 
amino acid side chain. 
 
Due to the importance of peptides, much research has been carried out 
into efficient coupling agents and many reviews written on the subject.95,96 
It is important that the coupling agent does not decompose before the 
coupling has taken place and so coupling agents which allow faster 
coupling have been developed.95 Good coupling reagents are required to 
ensure both good yields and minimisation of racemisation.97 Other 
improvements to coupling agents include minimisation of side reactions, 
greater solubility and lower cost. Commonly used coupling agents today 
include CDI and EDC (carbodiimides), PyBop and PyBroP (phosphonium 
salts) and HATU and HBTU (guanidinium salts).96 The carbodiimides CDI 
and EDC (often used in combination with an N-hydroxy derivative such as 
HOBt to reduce racemisation and prevent intramolecular reaction) were 
introduced as more soluble carbodiimides than the original method using 
DCC.96 The advantages of using phosphonium or guanidinium salts show 
fast activation of the carboxyl groups. HATU is particularly useful for 
difficult sequences92 and does not react with amino groups.96   
 
Another technique (Figure 3.1.2), known as Solid Phase Peptide 
Synthesis (SPPS) first used by R. B. Merrifield in 1963 was used to 
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synthesise some of the peptides for this project.92,93,98  This technique 
uses a functional group attached to an insoluble solid support, which the 
first amino acid is reacted with. Subsequent amino acids are then added to 
the solid support via the previous amino acid. Each addition is carried out 
using protected amino acids that are deprotected once added to the 
peptide chain and then reacted with the next protected amino acid to form 
the peptide. The fully formed peptide can then be cleaved from the 
resin. During development of SPPS many different amine protecting 
groups were tested.   
 
 
Figure 3.1.2: Fmoc solid phase synthesis.  
The first synthesis reported using solid phase synthesis was carried out 
using a chloromethylated functional group on a polystyrene support. 
Carbobenzoxy protecting groups were used for N protection, and 
deprotected by HBr in AcOH. Coupling of the amino acids could then be 
carried out using N,N’dicylohexylcarbodiimide, with side products and 
unreacted materials removed easily by washing the resin with organic 
solvents and the final peptide released by NaOH. 
 
Improvements to the synthesis99 used t-butoxycarbonyl (Boc) as the N 
protecting group and HF to cleave the peptide from the resin. This 
synthesis using Boc protected amino acids and HF to cleave produced 
good yields. However, there are several disadvantages to this method. 
The main disadvantage is the use of HF to cleave the linkage to the solid 
support.  Some peptide sequences are not stable to HF92 and the use of 
HF itself is undesirable since it is very hazardous.100 Acid also removed 
the temporary protecting groups, although the linkage was stable to the 
moderate acids used for this deprotection.  
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A slightly altered method first reported in 1970101 used 9-
fluorenylmethoxycarbonyl (Fmoc) as an N protecting group. This allows 
"orthogonal" removal of the protecting group (with base) and cleavage of 
the peptide from the resin (with acid). Originally, ammonia was used as the 
base to deprotect. However, in this project and most 
current syntheses another mild base, piperidine in DMF is used to 
deprotect. Another advantage of Fmoc is that it also forms a UV active 
species which allows the possibility of residue attachment 
measurement by UV-Vis spectroscopy.   
 
Research has also been carried out on both the resins making up the 
beads and the linkers used to attach the functional groups, although these 
will not be mentioned here.  
 
The most commonly used resin in this project is substituted 
triphenylmethyl polystyrene resin, commonly known as 2-chlorotrityl 
chloride resin. First used in the 1980’s102 by Barlos it has many 
advantages. These include lower contamination by aldehyde formed than 
with benzyl alcohol resins, no possibility of the hydrolysed 2-chlorotrityl 
resin forming peptide bonds under the coupling conditions used, high 
loading resins and cleavage of the peptide under mildly acidic conditions.  
 
Fmoc amino acids can be attached to the resin using DIPEA as the base, 
with the reaction often complete in an hour. Any unreacted positions can 
be easily capped by using a mixture of MeOH and DIPEA. Peptide 
synthesis can then be carried out by using cycles of Fmoc removal 
(piperidine/DMF) followed by coupling. Several methods are used for 
coupling, but this project uses PyBOP/DIPEA, HATU/DIPEA, DIC/DIPEA 
or EDCI/HOBt/DIPEA as coupling reagents. Cleavage of the resin takes 
place under mildly acidic conditions a 1:1:8 mix of TFE:AcOH:DCM used 
in this project. 103 
 
Another, less common solid phase synthesis support is solid phase 
lanterns.104 Rather than the small beads which are the support of solid 
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phase resins, solid phase lanterns are bigger and may be picked up with 
tweezers rather than weighed like resins. The solid phase lanterns may be 
cut into sections if necessary to monitor or divide the products. Solid 
phase resins are useful for quickly making a large amount of similar 
peptides such as structure activity relationships for natural products which 
show interesting biological activity.   
 
3.2 Peptide drugs 
 
A share (2% of world wide drug sales)105 of the drugs made from or based 
on natural products is made up from drugs made from peptides.106 The 
first of these to be approved was insulin, a 51 amino acid hormone first 
available in 1923. By 2016 there were 234 peptides either approved or in 
clinical trials, with revenue from peptides drugs accounting for around 5% 
of worldwide pharmaceutical sales.106 
 
However, peptides are often seen as unattractive leads for new drugs107, 
with small molecules often favoured over peptides. Reasons for this 
include membrane impermeability, biological instability, inability to cross 
the blood-brain barrier, peptides rarely conforming to Lipinski’s rules, 
difficulty with oral formulation and the expense of synthesis. 
 
Despite these problems natural product based peptide drugs continue to 
be developed.2 Various methods can be used to make the natural product 
more attractive as a drug molecule.105 The first stage in the process is to 
identify which parts of the peptide are necessary, a process most often 
carried out by truncation and alanine scanning. Medicinal chemistry can 
then be used to enhance the peptide. Examples of methods include 
increasing hydrophobicity (N methylation of backbone108, N capping of the 
N terminal, substitution of amino acids), conjugation to another 
biomolecule (e.g. an antibody109), substitution of amino acids (for example 
with β amino acids or unnatural amino acids110) and cyclisation111. 
 
Cyclisation of a peptide has many advantages.112 It is more entropically 
favourable for cyclised peptides to bind to targets (since they show 
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structural preorganisation), they often have improved membrane 
permeability and are often more stable to degradation. These favourable 
characteristics are proven by the prevalence of cyclic peptides as 
bioactive natural products despite accounting for only 3% of known 
secondary metabolites.  
 
Teixobactin and telomycin belong to the class of drug candidates known 
as depsepeptides.19 These drugs are neither peptides (containing amino 
acids joined by purely peptide bonds) or polyesters (joined by ester 
linkages) but desepeptides with both ester and amide linkages. Many 
depsipeptides are also cyclic. This may provide some advantage for their 
activity since the macrocycle gives a good entropy for binding, but is also 
flexible enough that it can adapt its conformation when binding. The 
macrocycle can be formed with many different sized rings, as shown by 
the examples given in the next section.  
 
Depsipeptides are widely found in nature and have been isolated from 
many sources including sponges, algae, micro-organisms and fish.113 
They are promising candidates for new drugs since they are often 
biologically active (as shown by sections 3.2 and 3.3). Depsipeptides have 
been reported as potential anticancer, cardiovascular, antimalarial, 
immunosuppressant and anti-inflammatory drugs, as well as possible anti-
infectives including antibacterial, antiviral and antifungal drugs. Often a 
structure will show activity in more than one category, so has potential to 
be modified for use in several ways. Of the categories mentioned in 
section 3.3 two of the most common areas are antitumour compounds and 
antibiotics. The depsipeptides studied in this project shown antibiotic 
activity so several examples of useful depsipeptides are listed in the 
following subsection.   
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3.2.1 Daptomycin 
 
Daptomycin114 is a cyclic lipopeptide made up of 13 amino acids (Figure 
3.2.1) produced by Streptomyces roseosporus. It is a good candidate for a 
new antibiotic since it has good activity against many Gram positive 
bacteria including MRSA, VRSA and VREF, with an MIC of 4 µg ml-1 
against Staphylococcus aureus. The mechanism of action is different to 
other antibiotics, including vancomycin.  
 
 
 
Figure 3.2.1: The structure of daptomycin. 
 
Daptomycin inhibits lipotechoic acid synthesis and also inhibits 
peptidoglycan synthesis at concentrations above the MIC. Rather than 
entering the cell, daptomycin binds to the surface of the cell and destroys 
the lipoteichoic acid polymer (which only occurs on the cell surface) and 
disrupting the bacterial membrane potential causing cell death. Although it 
is also known that the mechanism is Ca2+ dependant a detailed mode of 
action is still not known.115,116 
    
Total synthesis of daptomycin and several analogues have been carried 
out most recently in 2018 using a complete Fmoc solid phase approach.117 
Daptomycin was approved for the treatment of skin infections by the FDA 
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in September 2003118 and the European Medicines Agency in January 
2006119. It is the first lipopeptide antibiotic approved by the FDA.118  
 
3.2.2 Ramoplanin 
 
Ramoplanin (Figure 3.2.2) is a more potent antibiotic than vancomycin 
(MICs of less than 1 µg ml-1 for most Gram-positive bacteria) and also 
targets peptidoglycan biosynthesis. The antibiotic is produced by 
Actinoplane ATCC33076120 and is active against many drug resistant 
bacteria including MRSA and VRSA.121 Syntheses of ramoplanin and 
analogues with good activity have been carried out.122,123 
 
 
  
Figure 3.2.2: The structure of ramoplanin. 
 
Cell wall biosynthesis relies on the synthesis of peptidoglycan. This is the 
cell process not occuring in eukaryotic cells, which is targeted by many 
depsipeptides. In particular studies have been carried out on ramoplanin 
to determine its mode of action.124  
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Figure 3.2.3 shows the first stage of polymerisation of the lipids to form 
peptidoglycan. The first lipid (Lipid I) is converted to Lipid II by the enzyme 
MurG. Lipid II is then translocated across the inner cell membrane where it 
is polymerised by the transglycosylases to form the cell wall. Without Lipid 
II the cell wall cannot be formed so the structure of the cell is weak.  
 
 
 
Figure 3.2.3: Cell wall biosynthesis, showing Lipid I and Lipid II. Taken from Ref123 
 
It was originally thought that binding to Lipid I was causing inhibition of this 
pathway.121 However, the inhibition of the catalysing enzyme MurG in this 
case is too weak to explain how biologically active ramoplanin is.125 
Therefore, more experiments were carried out which showed that the 
inhibition is caused by binding to Lipid II on the external surface of the cell. 
  
The data from the inhibition curves suggests that two molecules of 
ramoplanin are needed for every Lipid II molecule.126 Therefore a structure 
was suggested where the complex formed a dimer in solution, joined by 
hydrogen bonds. This forms a cleft which is the ideal size to give a good fit 
of Lipid II and enable tight binding. NMR experiments were carried out to 
determine if this model was accurate and proved the structure correct.126 
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Ramoplanin is currently in phase II and III trials for the treatment of 
Clostridium difficile infections.127,128 
 
3.2.3 Acyldepsipeptides 
 
Acyldepsipeptides (Figure 3.2.4) are cyclic depsipeptides. Enopeptin A the 
first reported acyldepsipeptide is formed from six amino acids, including 2 
non-proteinogenic amino acids. 
 
 
Figure 3.2.4: The structure of enopeptin, an acyldepsipeptide.  
 
Unlike the other examples of depsipeptides shown here, 
acyldepsipeptides target an enzyme. The casein lytic protease (Clp) 
complex usually degrades defective and misfolded proteins, as well as 
transcription factors and some other regulators. Enopeptins and 
acyldepsipeptides act on the catalytic core and eliminate the safeguards 
leading to uncontrolled proteolysis which leads to the death of the cell.  
 
A 2014 paper reported the total synthesis of six acyldepsipeptides isolated 
from Streptomyces hawaiiensis using solution phase synthesis.129 Most 
recently, a 2016 paper reported another 14 analogues showing potent 
activity against several Gram-positive and Gram-negative pathogens.130 
 
3.3 Lariat peptides 
  
The structure of both teixobactin and telomycin consists of a cyclic 
depsipeptide with an attached linear peptide chain (sometimes called a 
tail). These sorts of peptides are sometimes called lariat peptides or lasso 
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peptides. Many peptides of this type have been reported in the literature, 
with ring sizes varying from four to ten amino acid residues.  
Depsipeptides known as lariat peptides contain a macrocyclic 
depsipeptide ring made up of amino acid residues and a linear peptide 
chain comprising at least two amino acids. There are many examples of 
biologically active molecules that have a macrocyclic ring which is not 
made up completely of amino acid residues, or which have a linear tail 
made up of a single amino acid and other terminal groups. These types of 
macrocycles will not be covered here.  
 
The majority of the research in this thesis is about the synthesis of 
bioactive molecules. Therefore, the rest of this section will be about 
methods of synthesis of lariat peptides. Several relevant depsipeptides are 
reported in the literature with no synthesis yet complete. These are listed 
in the table 3.3.1, with the rest of the section expanding on reported 
methods of synthesis of lariat depsipeptides.  
 
Table 3.3.1: Bioactive lariat peptides with no completed total synthesis.  
Name of peptide Main activity 
Mirabamide131 Inhibits HIV-1 fusion 
Theopapuamide132 Cytotoxic against CEM-TART (HIV-
1) and HCT-116 cell (colorectal 
carcinoma) lines  
Neamphamide A133 HIV-inhibitory isolate 
Neamphamide B134 Potent anti-mycobacterial activity 
against Mycobacterium smegmatis 
Corticiamide A135 Not yet biologically tested 
Discodermins136 Wide range of activities including 
antimicrobial/anticancer 
Microspinosamide137  Exhibits anti-HIV activity 
 
A lariat peptide can be thought of as having two different parts; the 
macrocycle and the linear tail. There are several ways in which these two 
different parts may be joined in the synthesis of the final product. The first 
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method is to make the macrocycle and linear tail separately and then 
couple both together before global deprotection. Another is to make the 
entire peptide including tail before cyclisation and then cyclise to form the 
macrocycle. 
 
There is also variation in how the peptide bonds themselves are formed; 
either through convergent peptide synthesis or using solid phase 
synthesis. To form the macrocycle itself either macrolactonisation or 
macrolactamisation may be used. The higher reactivity of amines means 
that macrolactamisation is usually favoured over macrolactonisation. 
 
3.3.1 Convergent synthesis 
 
The oldest method of synthesis of lariat depsipeptides is convergent 
synthesis where solution phase methods are used to make each section of 
the depsipeptide and then couple them together using solution phase 
coupling. Lariat depsipeptides which have been made this way are 
didemnins, tamandarins, papuamide, largamides and coibamide A. 
 
3.3.1.1 Didemnins and Tamandarins 
 
The oldest example of a lariat peptide being made synthetically is for the 
didemnins, first isolated in 1981.138,139 The didemnins (Figure 3.3.1) 
showed a wide range of activities, with didemnin B139 in particular being 
tested in clinical trials as an anticancer, an immunosuppressant and an 
antiviral. However, toxicity led to the discontinuation of trials. Another 
analogue, dehydrodidemnin B140,139 has also been carried into clinical 
trials as an antitumour drug.  
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Figure 3.3.1: A) Structure of the didemnin core macrocycle, showing sites of 
macrolactamisation, B) macrolactamisation reagents 1141,142,2143,3144,140,4141,142  C) side 
chains of all natural didemnins. 139  
 
Several different methods have been reported for the synthesis of the six 
amino acid macrocycle common to all didemnins. Each method firstly 
makes the linear peptide followed by macrolactamisation at several 
different positions (shown in Figure 3.3.1). Although most couple the 
whole linear chain later, one method also adds the leucine residue before 
cyclisation. These methods have been used to make several members of 
the didmnin family.  
 
Tamandarins, first isolated in 2000139, are similar to the didemnins in both 
structure and activity. The synthesis of tamandarins has been reported 
only by convergent synthesis followed by macrolactamisation at the two 
positions shown in Figure 3.3.2 then addition of the side chain. The 
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majority of syntheses 145,146,147,148 cyclise the carboxyl of piperidine to the 
adjacent amino acid of the macrocycle.  
 
The two naturally occurring tamandarins are shown in Figure 3.3.2. 
However, due to the structural similarity of didemnins to tamandarins initial 
analogues149 firstly added the side chains of didemnins (shown in Figure 
3.3.1) to the macrocycles of both Tamandarin A and B. Other analogues 
include spirolactam β-turn mimetic side chain150 and substitution of the 
amino acids highlighted in Figure 3.3.2. While several analogues showed 
improved GI50 compared to natural tamandarins none have so far shown 
improved LD50.  
 
 
113 
 
 
Figure 3.3.2: Tamandarins A and B and modifications to the macrocycle. Analogues 
have also been made using the didemnin side chains from Figure 3.1.1 C).  
 
3.3.1.2 Papuamide 
 
Papuamides A-D have been found to protect cells from HIV infection151, 
while C-F have been found to be cytotoxic in a brine shrimp assay152. As 
for the didemnins the only currently published synthesis is a solution 
phase total synthesis for papuamide B153 (Figure 3.3.3). The non-
proteinogenic amino acids are first synthesised before the seven amino 
acids making up the macrocycle are coupled in solution using various 
protecting groups. Macrolactamisation is carried out in solution in the least 
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sterically hindered position, between the amine of alanine and the carboxyl 
of glycine. Solution phase peptide coupling was then used to couple the 
linear tail (in two fragments) to the macrocycle, giving papuamide B in 7% 
overall yield.  
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Figure 3.3.3: A) Naturally occurring papuamides and B) the synthesis of papuamide B; 
C) Synthesis of the macrocyclic section of papuamide B, i) a) TsOH, MeOH; b) Pd/C, H2; 
ii) EDC, HOAt, DIPEA iii) a) Dess-Martin oxidation; b) NaClO2, NaH2PO4; iv) DEPBT, 
DIPEA; v) a) [Pd(PPh3)4], PhNHMe; b) HATU, DIPEA; c) [Pd(PPh3)4], PhNHMe; d) Et2NH 
vi) a) HATU, DIPEA, DCM, r.t. b) CF3CO2H, DCM; D) i) CF3CO2H, DCM; ii) [Pd(Ph3)4], 
PhNHMe; iii) a) HATU, DIPEA; iv) a) NH3, MeOH; b) RuCl3.xH2O, NaIO4, MeCN, CCl4, 
H2O. and E) i) a) AD-mix-α, H2NSO2Me, tBuOH, H2O; b) TsOH, DMP, then Pd(OH)2/C, 
H2; c) Swern oxidation; ii) NaHMDS, THF, HMPA, -78⁰C to r.t. iii) a) (NH4)2Ce(NO3)6, 
borate buffer, MeCN, THF, 60⁰C; b) TBSCL, imidazole, DMF; c) aq. NaOH, MeOH; iv) a) 
BOP, DIPEA, MeCN; then [Pd(PPh3)4], PhNHMe. D) and E) shown the synthesis of the 
two side chain fragments of papuamide B. The coupling of these two fragments is shown 
in B).  
 
3.3.1.3 Largamides 
 
Another related group of depsipeptides is the largamides. A-H (Figure 
3.3.4) have been isolated154, with all apart from H classed as lariat 
peptides. Only D-G have been tested for biological activity with all found to 
inhibit chymotrypsin. 
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So far only a synthesis for B has been reported.155 This synthesis uses 
peptide couplings with various amine and carboxyl protecting groups, 
while also synthesising the unnatural amino acids. The synthesis was 
firstly attempted using a method of macrocycle synthesis followed by side 
chain coupling, similar to the synthesis of didemnins, tamandarins and 
papuamide. However, the macrocycle was unstable under all conditions 
used to attempt coupling of the side chain. Therefore, the side chain was 
added before cyclisation which then allowed macrolactamisation and the 
completion of the synthesis.  
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Figure 3.3.4: A) Largamide A-G and B) synthesis of largamide B.  
120 
 
3.3.2 Solid phase synthesis, solution phase cyclisation 
 
Although solution phase methods are still commonly used for peptide 
synthesis; shown by several recent syntheses detailed previously, solid 
phase synthesis is commonly used for small amounts of relatively simple 
peptides.  
 
3.3.2.1 Callipeltin 
 
Reported in 1996156, callipeltin A (Figure 3.3.5) is a cyclodepsipeptide 
isolated from the lithistid sponge Callipelta sp. collected off the East coast 
of New Caledonia. This peptide is the first of a class of callipeltins, 
currently ranging from A-Q.157,158,159,160 However, only calipeltin A features 
both the cyclodepsipeptide ring and the linear tail of a lariat peptide.  
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Figure 3.3.5: A) Callipeltin A, the only lariat depsipeptide of the callipeltins, with the 
macrocyclic ring common to callipeltin B highlighted and B) synthesis of callipeltins B and 
M. The linear precursor is made using Fmoc solid phase synthesis loading onto 2-trityl 
chloride resin, with the coupling reagents PyBop, HOBt and DIPEA used for the majority 
of the couplings and 20% piperidine/DMF used for Fmoc deprotection.   
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Currently there is no reported synthesis of callipeltin A. However, the 
related callipeltin B has the same macrocyclic core and a synthesis was 
published in Organic Letters in 2014161, following a structure activity study 
using only natural and N methylated amino acids in 2011162.  
 
Solid phase synthesis was first used to couple the seven amino acids.161 
Various macrolactonisation conditions, followed by deprotection then gave 
the final product of callipeltin B. As well as being the first synthesis 
mentioned which uses solid phase it is the first to use macrolactonisation 
rather than macrolactamisation. In part this is due to the synthetic paper 
also reporting the synthesis of callipeltin M, the uncyclized version of 
callipeltin B. However, the macrolactonisation position is the least sterically 
hindered in this macrocycle so it is also preferred for this reason. It was 
proposed that the synthesis of callipeltin B can be used as the basis for 
the synthesis of callipeltin A and analogues.  
 
3.3.2.2 Homophymine A 
 
A class of depsipeptides related to the callipeltins are the homophymines 
(Figure 3.3.6), depsipeptides extracted from the marine sponge 
Homophymia sp. The first member of the group to be isolated was 
Homophymine A163, reported in 2008. This was followed in 2009164 by nine 
more homophymines called B-E and A1-E1, differing in presence of 
glutamine or glutamic acid and the length and stereochemistry of the 
terminal alkyl chain on the linear peptide tail. Homophymine A was found 
to have anti-HIV activity, while B-E and A1-E1 showed potent 
antiproliferative activity against cancer cells.  
 
While synthetic studies have been carried out into sections of 
homophymine A165, no total synthesis has been completed for any of the 
homophymines. The synthesis of a macrocyclic section of homophymine 
B166 has however been completed. Solid phase synthesis was used to 
make the linear precursor to the macrocycle, with a simplified, truncated 
linear tail. The original route attempted solution phase macrolactonisation 
between the carboxyl of pipecolic acid and the hydroxyl of AHDH. 
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However, although the solid phase synthesis of the linear precursor 
proceeded smoothly the macrolactonisation could not be carried out under 
any conditions attempted. The macrocycle core was eventually made by 
macrolactamisation between the amine of pipecolic acid and the carboxyl 
of aspartic acid. This method will now be used to complete a total 
synthesis of homophymine B. 
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Figure 3.3.6: A) Extracted homophymines and B) Synthesised fragement of 
homophymine B. The linear precursor is made using Fmoc solid phase synthesis loading 
onto 2-trityl chloride resin, with the coupling reagents PyBop and HOBt used for the 
majority of the couplings and 20% piperidine/DMF used for Fmoc deprotection. 
Esterification was carried out on the resin DIPC, DMAP and DCM:DMF (9:1). 
Macrolactamisation was carried out at the position shown using PyBop, HOAt, DIPEA 
and DMF.    
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3.3.2.3 Stellatolide 
 
Stellatolides A-G (Figure 3.3.7) were isolated from the marine sponge 
Ecionemia acervus when extracts showed anti-tumour activity.167 
Structural assignment of purified compounds showed all except C were 
lariat depsipeptides. The same paper reports the solid phase synthesis of 
Stellatolide A as proof of structure.  
 
The initial attempt of the total synthesis took place entirely on the resin. 
Initial synthesis was attempted with a similar route to halicylindramide, with 
the first amino acid anchored to the resin by the side chain followed by 
coupling of amino acids making up the macrocycle, macrolactonisation 
and elongation of the linear tail. However, it was found that if the first 
amino acid of the linear tail was not added before cyclisation O->N 
acylation took place upon deprotection of the Fmoc. If the first amino acid 
was included steric hinderance made the cyclisation difficult. 
 
Therefore, the position of cyclisation was changed and the carboxyl of 
glycine instead anchored to the resin with Fmoc peptide coupling used to 
build the chain with esterification taking place in a similar way to the 
previous strategy. The macrocycle was then formed by 
macrolactamisation in solution phase after cleavage of the linear peptide 
from the resin, followed by deprotection to give stellatolide A.   
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Figure 3.3.7: A) Stellatolides A-G and B) synthesis of stellatolide A. The linear precursor 
is made using Fmoc solid phase synthesis loading onto 2-trityl chloride resin, with the 
coupling reagents HOBt and DIPCDI used for the majority of the couplings and 20% 
piperidine/DMF used for Fmoc deprotection. The section highlighted in green used HATU 
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and HOAt as a coupling reagent. Macrolactamisation was carried out at the position 
shown using HOAt, EDC, DCM, DMF at 0 °C for 5 h. 
 
3.3.2.4 Kahalalide  
 
The kahalalides (Figure 3.3.8) are a class of depsipeptides with fatty acid 
chains which were isolated from the marine mollusks Elysia rufescens, 
Elysia ornate and Elysia grandifolia and the algae Bryopsis pennata. 
There are many members of the group ranging from A-X with several 
subdivisions within some letters.168 Many of these depsipeptides are 
acyclic and many have no biological activity. The members of the group 
which are classed as lariat peptides are F (and IsoKahalalide F and 5-
OHKahalalide), R1 and R2 and S1 and S2.  
 
Kahalalide F and IsoKahalalide F were isolated in 1993168, with its 
analogues R1 and S1 isolated in 2006 and R2 and S2 in 2007. The main 
biological activity of Kahalalides is as anti tumour compounds. Testing has 
shown that Kahalalide F, IsoKahalalide F and Kahalalide R1 are active as 
anti cancer agents.  
 
Several strategies have been reported for the synthesis of Kahalalide F. In 
total six different strategies have been reported by solid phase synthesis, 
with cyclisation taking place in solution phase. Of these, four make the 
linear precursor to the macrocycle by SPPS and two make the entire 
sequence by SPPS before cyclisation. Both lactamisation and 
lactonisation have been used for synthesis with shorter times achieved 
using lactamisation so this method is preferred. Over 100 analogues have 
been prepared by using this method and have allowed a detailed SAR to 
be discovered, leading to several synthetic analogues with better activity 
than Kahalalide F itself. The synthesis and biology of kahalalides has been 
recently reviewed in more detail.168  
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Figure 3.3.8: Kahalalides classed as lariat depsipeptides. Further synthetic details can 
be found in ref168.  
3.3.2.5 Polydiscamides 
 
The first polydiscamide (Figure 3.3.9) to be isolated, polydiscamide A169, 
was extracted from the marine sponge Discodermia sp. and first reported 
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in 1991. The other members of the family polydiscamides B-D were not 
reported until 2007170, isolated from the sponge Ircinia sp. Polydiscamide 
A was reported to inhibit the proliferation of lung cancer cells, while B-D 
are potent human sensory neuron-specific G protein couple receptor 
(SNSR) agonists.  
 
The total synthesis of B, C and D has been carried out171. Solid phase 
synthesis was used to make the both the linear precursor to the 
macrocycle (plus one amino acid of the linear tail) and separately, the 
three different linear tails of B, C and D. After cleavage from the resin, 
macrolactamisation was carried out and native chemical ligation (Figure 
3.3.9) rather than peptide coupling used to couple the linear tail to the 
macrocycle.  
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Figure 3.3.9: A) Polydiscamides A-D and B) the synthesis of polydiscamides B-D. The 
linear precursor is made using Fmoc solid phase synthesis loading onto 2-trityl chloride 
resin, with the coupling reagents PyBop and N-Methylmorpholine used for the majority of 
the couplings and 10% piperidine/DMF used for Fmoc deprotection. DIC and DMAP in 
DMF were used for the on resin esterification.  
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3.3.3 Complete solid phase synthesis 
 
The following syntheses were carried out completely by solid phase. 
 
 
3.3.3.1 Halicylindramide 
 
Another lariat peptide which has been successfully synthesised is 
halicylindramide A.172 Halicylindramide A-C (Figure 3.3.10) are a series of 
a lasso depsipeptides which have been shown to have anti fungal activity 
and are cytotoxic to leukaemia cells.  
 
The synthesis of halicylindramide has been carried out completely on the 
resin.173 N-Fmoc, OAllyl aspartic acid was attached to the resin by the side 
chain and subsequent peptide couplings until the Alloc-Sar-OH was added 
by ester coupling. To prevent O->N acyl shift the first amino acid of the 
linear tail coupled before cyclisation. Removal of the Alloc and allyl groups 
allowed on resin macrolactamisation and peptide coupling was then used 
to complete the linear peptide tail. Deprotection of the protecting groups 
and cleavage from the resin gave the product in 1.5% overall yield. This 
method was also used to make several analogues. Results suggest that 
replacing the ester bond with an amide174 could possibly form a more 
stable secondary structure, although no biological testing has yet been 
carried out.   
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Figure 3.3.10: A) Halicylindramides A-C and B) Solid phase synthesis of halicylindramide 
A. The resin used was rink amide resin. The majority of couplings used PyBop and HOBt 
or HOAt for peptide couplings and DIC, DMAP, MC and DMF for esterification. 20% 
piperidine in DMF was used for Fmoc deprotection.  
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3.3.3.2 Pipecolidepsins 
 
Pipecolidepsins A and B (Figure 3.3.11) were isolated from the 
Madagascan Sponge Homophymia lamellose , reported in the journal of 
natural products in 2014.175 Extracts containing these molecules were 
found to show cytotoxicity against several cancer cell lines. Structural 
assignments of pipecolidepsins A and B were made through NMR, LCMS 
and degradation studies, with the proposed structure of pipecolidepsin A 
proved through a solid phase total synthesis176 separately published in 
nature communications, with macrolactamisation taking place on the resin. 
In contrast to the synthesis of halicylindramide the entire sequence is 
coupled before macrolactamisation is carried out. 
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Figure 3.3.11: A) Pipecolidepsins A-B and B) solid phase synthesis of pipecolidepsin A. 
The synthesis used low functionalized aminomethyl resin and various coupling reagents 
for peptide couplings. Fmoc deprotection was carried out using 20% piperidine/DMF. 
Cyclisation was carried out on the resin.  
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3.3.4 Other examples 
 
3.3.4.1 Daptomycin 
 
One of the depsipeptide antibiotics mentioned in section 3.2.1, daptomycin 
can also be classed as a lariat peptide. Initially most of the syntheses of 
daptomycin were carried out by fermentation and genetic engineering.177 
However, a total synthesis was reported in 2013.178 The first synthesis 
attempted several solid phase routes before succeeding in making a linear 
precursor of the complete sequence and then using chemoselective serine 
ligation to complete the solution phase cyclisation. An alternative route 
published in 2015116 again uses solid phase synthesis and constructs the 
entire sequence before cyclisation but instead uses coupling reagents to 
carry out macrolactamisation before cleaving the peptide from the resin. 
For both methods the position of cyclisation is between serine and glycine 
(Figure 3.3.12).  
 
Figure 3.3.12 : Daptomycin, with site of macrolactamisation indicated.  
 
3.3.4.2 Coibamide A 
 
For the majority of lariat depsipeptides only one method of synthesis is 
generally used for the majority of the syntheses. For Coibamide A, 
however there has been a synthesis published for each method listed 
above.  
 
136 
 
Coibamide A was extracted from the cyanobacterium Leptolyngbya in 
2008.179 Purification of one fraction showing a range of biological activities, 
most notably anticancer activity against lung tumour cells provided the 
highly methylated lasso cyclodepsipeptide Coibamide A (Figure 3.3.13). 
Further biological180 studies on the purified compound showed promising 
anticancer activity through a novel mechanism. As is commonly seen for 
cyclic peptides, the linearised peptide showed no activity. Further 
studies181 on xenograft mouse models of glioblastoma showed that 
coibamide A stopped the growth of subcutaneous tumours for 28 days at a 
concentration of 0.3 mg/kg. However, treatment also caused weight loss, 
with the authors suggesting that coibamide A would be useful only after 
medicinal chemical investigations. 
 
The first synthesis182 (published in 2014) formed the ester bond and 
peptide coupling to make the linear depsipeptide which was cyclised by 
macrolactamisation, followed by coupling of the linear tail to form 
Coibamide A.  
 
Following the first synthesis of Coibamide A using solution phase 
methods, a Fmoc solid phase synthesis studies183 with methylations also 
taking place on the resin was attempted. After formation of the complete 
11 amino acid sequence on the resin, macrolactonisation was carried out 
in solution phase. However, only the [D-MeAla11]-epimer was made using 
this method. Biological testing showed although less effective than the 
natural product the product retained nano-molar activity. A further solid 
phase synthesis was carried out in 2015184 using aryl hydrazide resin and 
methylated Fmoc amino acids, with cyclisation carried out by 
macrolactamisation. During the synthesis the stereochemistry of two 
amino acids (Figure 3.3.13) were revised following differences in the 1H 
NMR. 
 
 A further synthesis using 2-chlorotrityl chloride resin allowed synthesis, 
including macrolactamisation, to be carried out completely on the resin.185 
The same group later reported Azacoibamide A and O-Desmethyl 
Azacoibamide A186, analogues replaced ester linkages with amide bonds, 
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giving low micromolar activity against cancer cell lines, in comparison to 
the nanomolar activity given by the natural product and epimers.   
 
 
Figure 3.3.13: Coiabamide A and methods of cyclisation.  
3.4 Lariat peptides in this project 
 
The two final lariat peptides are teixobactin and telomycin. More detailed 
review of teixobactin and telomycin are given in the relevant sections.  
 
3.5 Teixobactin  
 
3.5.1 The isolation of teixobactin 
 
The iChip187 is a new technique for culturing bacteria. It allows the amount 
of bacteria which can potentially be cultured in a laboratory setting to 
drastically increase from around 1% to near 50%. This technique was 
used with a previously uncultured bacteria Eleftheria terrae (a new genus 
thought to be related to Aquabacteria). A biologically active isolated 
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fraction188 showed a molecular mass of 1,242 daltons, a mass which did 
not match any previously known metabolite. Further purification and 
assignments based on NMR showed that it was a cyclodepsipeptide 
containing both a linear peptide tail and a macrocycle with an ester 
linkage. A few other unusual features included N-methylated 
phenylalanine, the non-proteinogenic amino acid enduracidinine and 4 D- 
amino acids (Figure 3.5.1). Researchers named this compound 
teixobactin. 
 
3.5.2 Properties of teixobactin 
 
Teixobactin188 has been shown to be exceptionally active against Gram-
postitive bacteria, with an MIC of less than 1 µg mL-1 against Mycobacteria 
tuberculosis, 5 ng mL-1 against Clostridia difficule and 20 ng mL-1 against 
Bacillus antharis. Additionally, no toxicity against mammalian cells was 
observed and attempts to produce mutant strains of resistant bacteria 
were unsuccessful. 
 
Teixobactin has been shown to inhibit cell wall biosynthesis by forming a 
dimer which traps Lipid II, an essential intermediate in cell wall 
biosynthesis. The mechanism has been shown to be similar to that of 
ramoplanin. 
 
 
Figure 3.5.1: The structure of teixobactin, with unusual features highlighted. 
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3.5.3 Synthetic efforts 
 
Naturally, there was much interest in the synthesis of teixobactin. Solid 
phase peptide synthesis (SPPS) is a good method of synthesising small 
amounts of peptides quickly. Therefore, the first four papers reporting 
either total synthesis of teixobactin or synthesis of analogues used SPPS.  
One of the main considerations for synthesis was the position of 
macrocyclisation of the macrocycle. While methods of synthesis and total 
syntheses using both lactonisation and lactamisation exist, the favoured 
method for early syntheses was lactamisation.  
 
Since enduradacidine is a rare amino acid which currently needs to be 
made by time-consuming multistage synthesis, early syntheses substituted 
enduradacidine with a more common proteinogenic amino acid, most 
commonly arginine. Other papers were also written on new methods of 
synthesis of enduradacine. This review will focus firstly on total synthesis, 
followed by analogue synthesis. A recent review has covered 
enduracididine synthesis so this will not be covered.189   
 
3.5.4. Total synthesis 
 
3.5.4.2 Payne synthesis 
 
The first total synthesis of teixobactin was reported by the Payne group in 
May 2016.190 The paper firstly reports a new method of synthesising 
enduracididine before elaborating the synthesis of the natural product. 2-
Chloro trityl chloride resin (to allow the release of the carboxyl of D-Thr) 
and Fmoc SPPS are used. For this synthesis (Figure 3.5.2) D-Thr is added 
to the resin, with cleavage of the peptide followed by solution phase 
cyclisation between Thr and the N terminus of Ala. 
 
 
3.5.4.2 Li Synthesis 
 
A further total synthesis, published in August 2016 was carried out by the 
Li group.191 This synthesis uses a mix of solid and solution phase 
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techniques (Figure 3.5.3) to complete the synthesis. As has been 
commonly used in early syntheses, cyclisation took place through 
lactamisation in solution phase. Esterification took place in solution phase 
followed by attachment of the carboxyl of Ile to trityl chloride resin. This 
synthesis attaches the Ser at position 7 before addition of the final two 
amino acids contained within the ring. Cleavage and cyclisation are then 
carried out. The cyclisation itself is carried out using standard reagents, 
although the concentration is an order of magnitude lower than other 
reported cyclisations. 
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Figure 3.5.2: Key steps of the Payne synthesis. 
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Figure 3.5.3: Key steps of the Li synthesis. 
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3.5.5. Analogue Synthesis 
 
3.5.5.1 Albericio Synthesis 
 
The first synthesis of an analogue of teixobactin (and the first synthetic 
paper about teixobactin) was reported in December 2015.192 Albericio et 
al. reasoned that since enduradicine is a cyclised derivative of arginine it 
should be possible to substitute the more complex, non-commercially 
available L-enduracidine with the proteinogenic, cheap and readily 
available arginine. The synthesis reported is detailed in Figure 3.5.4. The 
two main considerations for position of cyclisation were minimum steric 
hindrance and minimum racemization during cyclisation. Therefore, 
cyclisation was carried out between Ala and Arg.  
 
Trityl chloride resin was chosen to allow release of the carboxylic acid of 
Ala. HATU was used to build the peptide chain, with esterification taking 
place between D-Thr and L-Ile followed by peptide bonding of N-Alloc 
protected L-Arg(Pbf). This allowed orthogonal deprotection of Alloc once 
the rest of the tail had been assembled. Macrolactamisation took place 
upon deprotection of Alloc and cleavage of the peptide from the resin.   
 
The Albericio group expanded on their results in a paper published July 
2016.193 Using the same strategy previously employed to synthesise their 
original analogue they report two more analogues– substitution of all D- 
amino acids in the linear chain with L amino acids and substitution of the 
terminal N-Me with N-Ac. For both of these analogues all antibacterial 
activity was lost.  
 
3.5.5.2 Taylor and Singh Synthesis 
 
Similarly to Albericio et al, Taylor and Singh considered routes to 
teixobactin analogues using SPPS.194 Their early synthetic efforts focused 
on carrying out a synthesis involving a final esterification step. However, 
this was found to fail at the macrolactonisation step so a different method 
using macrolactamisation between Ala and Arg (similar to Albericio) was 
instead used. Similarly to the first synthesis, 2-chloro trityl chloride resin 
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was also used. The route is shown in Figure 3.5.4, and is compared to the 
synthesis of the same analogue carried out by the Albericio group.  
 
3.5.5.3 Reddy Synthesis 
 
The first departure from both SPPS and macrolamization was published in 
2016 by the Reddy group.195 This paper published a route using solution 
phase Boc chemistry to synthesis large amounts of both a model analogue 
and the macrocycle of teixobactin (Figure 3.5.5). Macrolactonisation was 
carried out under various conditions, with the most efficient found to be 
Shiina cyclisation templated by Dy(OTf)3. Although presenting a useful 
cyclisation, the linear tail has not been coupled by this method, proving 
only the synthesis of the macrocyclic core. No biological activities have 
been reported. 
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Figure 3.5.4: Comparison of Taylor-Singh (left, blue) and Albericio (right, pink) 
analogue synthesis routes. 
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Figure 3.5.5: Reddy solution phase synthesis 
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3.5.6. Structure-Activity Relationship 
 
In addition to synthetic efforts, a paper studying the structure-activity 
relationship of teixobactin was also published.196 Similarly to previous 
syntheses Arg was used as a substitute for End, with the justificiation that 
several papers had already been published with biological activity of the 
Arg analogues so the activity was already known and comparisons made 
of analogues relating to this structure would be justified. The synthesis 
employed (Figure 3.5.6) for all analogues was similar to previous results 
as it used trityl choride SPPS with Arg linked to the resin and solution 
phase cyclisation. 
 
The results of SAR (Table 3.5.1) found that while the stereochemistry 
within the macrocycle was important, the enantiomer of the arginine 
analogue also showed good activity. Changing the identity of amino acid 
10 gave unexpected results. It did not depend on the guanidine functional 
group as expected – lysine was found to be more active than arginine, 
with the lysine analogue 2-4 times more active than the arginine analogue, 
showing MICs comparable to those of vancomycin. A linear analogue 
containing Arg at position 10 showed no antibacterial activity. 
Investigations into the linear chain showed that while the complete 
removal of amino acids 1-5 has a very negative effect on the activity of the 
analogue, replacement by dodecanoyl retained good activity. 
 
This paper was closely followed by several other SAR and analogue 
studies197,198 including a lysine199 and alanine199 scan, replacement of 
amino acid 10 by several other amino acids200 and many substitutions of 
the linear tail of teixobactin. Following the publication of several analogue 
papers two reviews197,198 were published detailing the analogues made 
and the effect of substitution at each position.  
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Figure 3.5.6: Key steps of analogue synthesis method used by Novick et al.  
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Table 3.5.1: Activity of teixobactin analogues.  
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3.6 Synthetic studies towards teixobactin analogues discussion 
 
3.6.1 Design of analogues 
 
The main aim of this project is to synthesise analogues of teixobactin 
rather than the natural product itself. Therefore, research into teixobactin 
started by simplifying the natural product itself to create simpler, cheaper 
to make and more drug like molecules.  
 
The first simplification made was to replace non-proteinogenic 
enduracididine with proteinogenic arginine. As can be seen in Figure 3.5.1 
enduracididine has only one bond difference from arginine. At the time this 
research was started this replacement was theorised to allow some activity 
to be maintained and provide a simple method of testing the effectiveness 
of analogues. Since this time several papers have been published 
confirming this, but also showing that, surprisingly, lysine is a better 
substitute to maintain activity.191 However, substituting arginine also gives 
good activity and so is used for all analogues made in this project.  
 
The second modification is to simplify the linear tail section. The 
depsipeptide ring is usually more sensitive to modification than the linear 
tail and a paper investigating the pharmacophore of teixobactin found that 
activity was lost with most modifications to the ring.196 
 
3.6.2 Synthesis of truncated analogues  
 
The first simplication made to the linear tail in this project is to truncate it. 
By shortening it the length of tail which is necessary for activity can be 
discovered. To maintain the charge of the peptide the termial amine is 
protected by acetyl.  
 
Section 3.1 describes SPPS and how it is a quick method of making 
relatively small amounts of peptides with less than 30 aminos.106 For the 
truncated analogues in this section, a small amount of each peptide is 
needed so solid phase is used.  
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The retrosynthesis is shown in Figure 3.6.1. Trityl chloride resin was 
chosen as a suitable resin as it allows cleavage of the resin to give a 
terminal carboxyl group. Additionally, unlike many other resins cleavage 
takes place under mildly acidic conditions so side chain protecting groups 
will still be present after cleavage, which is necessary to prevent side 
reactions during the cyclisation.  
 
 
Figure 3.6.1: Retrosynthetic analysis of the initial series of analogues made. 
Cyclisation was planned to take place in solution phase via 
macrolactonisation. Therefore, Fmoc-Ile-OH was added to the resin and 
truncated peptide chains built from this amino acid. Using PyBop as the 
coupling agent, the amino acids were added sequentially, and the end 
terminal then capped with an acetyl group201 (Figure 3.6.2). As well as 
preventing side reactions, this also ensured the N terminal was a 
secondary amine, as for the natural product.  
 
The first peptide made was a tetrapeptide precursor to the macrocycle, 
3.2.2 (Figure 3.6.2). It was proved to not be necessary to protect the 
hydroxyl of threonine during acetylation as the higher reactivity of the 
amine prevented significant side reactions. 
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Figure 3.6.2: Synthesis of acetylated tetrapeptide precursor, 3.2.2. Tetrapeptide 3.2.1 
was synthesized using a general procedure for solid phase synthesis, detailed in section 
3.11. 
 
Macrolactonisation using the conditions shown in Figure 3.2.3 showed a 
m/z in the MALDI spectrum matching the expected mass of 3.2.2. 
Formation of a new HPLC peak was also seen. Therefore, the conditions 
were judged to have been successful and several more cyclisations 
carried out using the same conditions (Table 3.6.1). For all peptides, it was 
not necessary to protect the hydroxyl of the threonine for SPPS, with linear 
peptides made in good purity without hydroxyl protection. Table 3.6.1 
below shows the analogues synthesised and the yields achieved. 
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Table 3.6.1: Peptides synthesized and yields achieved. 
 
 
Linear precursor 
peptide, R = 
 
Yield 
(%) 
 
Depsipeptide, R = 
 
 
Yield 
(%) 
 
        
 
52 
 
 
 
1 
 
 
 
41 
 
 
7 
155 
 
 
 
13 
 
 
 
 
1 
 
 
44 
 
 
0 
 
 
 
 
 
 
Crude 
 
 
 
 
 
Crude 
 
 
The solid phase synthesis of the linear precursors 3.2.2, 3.2.3, 3.2.4 and 
3.2.5 (shown in Table 3.6.1, column 1) proceeded smoothly, giving the 
peptides in the yield shown. However, despite several attempts, it was not 
possible to make the complete 11 amino acid sequence using this method. 
Macrolactonisation using the conditions in Figure 3.6.3 was carried out on 
3.2.2, 3.2.3, 3.2.4 and 3.2.5. HPLC and MALDI were then used to analysis 
the reaction mixture. The HPLC traces in Figure 3.6.3 show that as R 
(Figure 3.6.3) increases in length, the conversion into cyclized product 
decreased. Purification by prep HPLC yielded the depsipeptides listed in 
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Table 3.6.1, column 2. Although a low yielding reaction, 3.2.2, 3.2.3, 3.2.4 
provided a small amount of each macrocycle. However, 3.2.5 showed no 
trace of cyclisation when the same conditions were used. 
 
 
 
 
 
 
 
 
 
Figure 3.6.3: Sections of the HPLC traces showing formation of a macrocycle and side 
products, as shown by Table 3.6.1.  
 
To complete the synthesis of the analogues deprotection was then carried 
out using 95% TFA, as shown in the general procedure in the 
experimental. For the deprotection of 3.2.7 and 3.2.8 this gave the 
required product. However, for 3.2.9, no mass which could be matched to 
the product was seen. Therefore, it appears that the product has 
decomposed or been lost under the conditions used for global 
deprotection (general procedure in experimental).  
 
While this research in this section (3.6.2) was carried out the paper 
“Elucidation of the Pharmacophore of teixobactin”196 was published. 
Although using a different method of synthesis, with macrolactamisation 
rather than macrolactonisation used, many of the ideas were similar to this 
research. Interestingly, while the truncated analogues196 showed little 
activity, an analogue replacing amino acids 1-5 with an alkyl chain (Figure 
3.6.4) showed remarkably high activity. This detail was used to design a 
new series of analogues detailed in Section 3.6.3.  
 
Cyclised 
product 3.2.6 
Starting material 
3.2.2/side products 
Cyclised 
product 3.2.7 
Starting material 
3.2.3/side products 
Cyclised 
product 3.2.8 
Starting material 
3.2.4/side products 
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Figure 3.6.4: Nowick analogue “lipobactin”.  
 
3.6.3 Solid phase synthesis of N-Alloc protected macrocycle 
 
As shown by the review of lariat peptides in section 3.3, there are several 
methods of making lariat peptides but the most common has remained 
synthesis of the macrocycle, then addition of the linear peptide tail. 
Therefore, this method will be used for the synthesis of the rest of the 
teixobactin analogues. Another advantage of this method is that small 
amounts of many analogues can be made from a common macrocycle.  
For this synthetic route the linear chain will be coupled to macrocycle 
3.2.27 by peptide coupling (Figure 3.6.5), so a free amine on the threonine 
residue is required. Acetyl is not the optimum group to be used for 
orthogonal removal. In contrast, the Alloc protecting group can be 
removed orthogonally to acidic protecting groups. Removal is usually 
carried out by catalytic amounts of Pd(PPh3)4 without affecting the other 
protecting groups. Therefore, Alloc was chosen for the temporary 
protection of the N terminus of threonine.  
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Figure 3.6.5 Retrosynthesis of second series of analogues. 
 
Alloc may be added to the N terminus of threonine in two ways. The first 
uses a similar method as for the addition of acetyl, with addition carried 
out on the resin to the amine of threonine. For the synthesis of the 
truncated analogues on-resin acetylation was advantageous since many 
different acetylated terminal amino acids were needed. However, for the 
synthesis of the analogues in Section 3.2.3 only Alloc-D-Thr-OH will be 
needed. Therefore, it is more practical to make the Alloc-Thr-OH by 
solution phase and then couple to the resin. Both methods furnished the 
macrocycle in acceptable purity. However, with the better purity achieved 
using premade 3.2.16. This method was used to make several hundred 
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milligrams of 3.2.22, which was used directly for macrolactonisation. This 
macrolactonisation was ultimately successful (further detailed in section 
3.6.5) and so larger quantities of 3.2.22 were required for analogue 
synthesis. Therefore, efforts were directed into a solution phase synthesis 
of the 3.2.22.  
 
3.6.4 Solution phase synthesis of macrocycle 
 
3.6.4.1 Method 1 
 
Although solid phase could be used to make 3.2.22 quickly, solution phase 
is still useful for making large amounts of peptide. Therefore, after showing 
it was possible to make macrocycle 3.2.26 from this linear precursor, 
synthesis was started on a solution phase route.  
 
Initially, the solution phase synthesis used a similar route to the solid 
phase synthesis (Figure 3.6.6). Since it was not necessary to protect the 
hydroxyl group of threonine for the solid phase synthesis, the solution 
phase synthesis was initially started using 3.2.15 (with no hydroxyl 
protection). The carbonyl of isoleucine was protected by methoxide 
(Figure 3.6.6), since it is commercially available and can usually be 
removed easily and orthogonally to alloc.  
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161 
 
 
Figure 3.6.6: Initial strategy for solution phase synthesis. 
Although the synthesis can be carried out by either route a or b (Figure 
3.6.6), the highest yields for 3.2.16 were achieved with route b). For route 
B) the methoxide of 3.2.17 also needs to be deprotected. The standard 
deprotection with LiOH removed the alloc group as well as the methoxide. 
Deprotection using NaOH also removed the alloc group. Deprotection of 
3.2.17 was eventually carried out successfully using K2CO3 to give 3.2.18 
in 72% yield.   
 
However, using the same conditions as for 3.2.18 to attempt to deprotect 
3.2.16 was not successful. Deprotection also failed when using LiOH and 
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Ba(OH)2. Mass spectrometry however, showed an m/z of 738 which did 
not correspond with the Alloc group being removed.  
 
3.6.4.2 Method 2 
 
Therefore, the carboxyl protecting group of isoleucine was changed to a 
trichloroethyl ester (TCE). Synthesis of 3.2.19 proceeded smoothly with 
the conditions shown in Figure 3.6.6 with all data consistent with the 
proposed structure. The synthesis was attempted using Fmoc solution 
phase synthesis rather than Boc synthesis, which is not optimal. The initial 
coupling to Fmoc-Arg(Pbf)-OH showed the expected mass in mass 
spectrum and a peak in carbon-13 NMR which could be assigned to the 
TCE group. However, there were several extra peaks in the carbon-13 
NMR which could not be assigned to anything and neither carbon-13 or 
mass spectrometry can be used to quantify the purity of a compound. 
Many 1H NMR peaks overlapped making this less useful for unambiguous 
characterisation. Therefore, since the purified product showed some 
positive results the synthesis to couple to 3.2.18 was carried out. 
However, for this stage neither mass spectrometry or carbon-13 NMR 
could find a trace of the required mass.   
 
3.6.4.3 Method 3 
 
Since synthesis seemed to be complicated by the presence of the 
unprotected hydroxyl groups, the free hydroxyl was protected, with TBS 
chosen as the protecting group. Since 3.2.16 had already been 
synthesised the first attempt at making 3.2.14 was carried out by 
endeavouring to add TBS-Cl to 3.2.16. Only 3.2.16 was recovered from 
this reaction and so a route to make 3.2.20 from 3.2.15 was devised. 
 
The initial approach to the synthesis of 3.2.21 was, as for 3.2.16 to firstly 
make two dipeptides and then couple these to give a tetrapeptide. The 
synthesis shown in Figure 3.6.6 B) was used with 3.2.20 rather than 
3.2.15 and gave a 58% yield of coupling using either MeCN or DCM as the 
solvent.  
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Methoxide deprotection could be carried out using LiOH as shown in 
Figure 3.2.7. However, using K2CO3 in the same method as for 3.2.18 led 
to the TBS protecting group partially decomposing. 
 
Couplings to give 3.2.21 from dimers succeeded in giving product in a 
58% yield. However, the alternative route using 3.2.14, to make 3.2.21 
initially gave a yield of 61% so was instead used. Due to the superiority of 
the second route the synthesis of 3.2.14 was optimised by changing the 
coupling agent to HATU. This increased the yield to 89%, further 
encouraging the use of this route. Although the coupling itself proceeded, 
well purification was more difficult due to the co-elution of one of the side 
products of HATU with 3.2.21. The difficulties in purification did not 
improve upon changing the solvent system of the silica column, so in an 
attempt to simplify the purification the coupling agent was changed from 
HATU to PyBop. Although purification was easier when using PyBop, the 
yield also decreased.  
 
 The final steps of the synthesis to provide 3.2.22 were carried out in the 
order of deprotection of the methoxide, followed by deprotection of the 
TBS.  Deprotection of the methoxide could be carried out by LiOH. This 
deprotection was, however, shown to be slow with the reaction not going 
to completion even after 6 days reaction. 
 
Although methoxide deprotections using peptides are often ran at 0oC to 
prevent isomerisation, due to the slowness of this reaction it was ran at 
room temperature. After 48 hours reaction, a reasonable yield of 50% was 
achieved which could then be carried forward to the next stage. 
Additionally, 22% of starting material was also recovered. In contrast, 
running the reaction for 6 days gave a yield of 63%, with only 7% of 
starting material recovered. Since purification of 3.2.21 proved 
challenging, running the methoxide deprotection without fully removing the 
side product was additionally tested. This carried out deprotection in 42% 
yield. However, the amount of starting material 3.2.21 recovered was 
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higher at 12%. Additionally, around double the decomposition product was 
isolated from the reaction containing impurities (8.12 mgs compared to 4.2 
mgs).  
 
The solvent system used was 3:3:1 THF:MeOH:water. Reactions carried 
out in methanol led to complete decomposition of the starting material. As 
for 3.3.1 K2CO3 caused some of the TBS group to be removed.  
A yield of 53% was achieved for the removal of the TBS group to give 
3.2.22. However, starting material was still present after 3 days of reaction. 
Similar literature reactions noted that the speed of the reaction may be 
increased by addition of molecular sieves to both the reaction mixture and 
the reagent bottle of TBAF solution. However, for the synthesis of 3.2.22 
this did not increase the rate of reaction significantly.  
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Figure 3.6.7: Successful solution phase synthesis of 3.2.22.  
Comparison of the data from 3.2.22 from both solid and solution phase 
methods were very similar. The 1H NMRs shown below (Figure 3.6.8) 
demonstrate the similarity. As shown by Figure 3.6.8 and Table 3.6.2 one 
major difference is seen in the 4.45-4.25 region. This may indicate that 
isomerisation has taken place and the diastereomer isolated. Since 
purification is carried out after each stage of solution phase synthesis but 
the crude cleavage product is used in macrolactonisation it is not 
surprising the purity of 3.2.22 obtained by solution phase synthesis shows 
a higher purity by HPLC.  
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 Figure 3.6.8: Comparison of the NMRs of the solid and solution phase 1H NMRs. 
Table 3.6.2: A comparison of the 1H signals of 3.2.22 obtained by solid and solution 
phase. 
Solid phase synthesis Solution phase 
(proposed to be 
other 
diastereoisomer) 
Solution phase (proposed 
to be expected 
diastereoisomer) 
5.93 (1H) 5.93 (1H) 5.92 (1H) 
5.35-5.28 (1H) 5.35-5.28 (1H) 5.34-5.27 (1H) 
5.21-5.17 (1H) 5.21-5.17 (1H) 5.20-5.15 (1H) 
4.61-4.50 (2H) 4.62-4.49 (2H) 4.60-4.48 (2H) 
4.44-4.30 (3H) 4.42-4.35 (2H) 
4.30-4.26 (1H) 
4.44-4.34 (2H) 
4.34-4.28 (1H) 
4.17-4.09 (1H) 4.17-4.10 (1H) 4.17-4.09 (1H) 
4.07-4.01 (1H) 4.06-4.03 (1H) 4.06-4.01 (1H) 
3.27-3.13 (4H) 3.29-3.14 (4H) 3.29-3.10 (4H) 
3.01 (2H) 3.01 (2H) 3.00 (2H) 
2.58 (3H) 2.58 (3H) 2.57 (3H) 
2.52 (3H) 2.52 (3H) 2.51 (3H) 
2.09 (3H) 2.09 (3H) 2.08 (3H) 
1.96-1.80 (2H) 1.96-1.82 (2H) 1.95-1.79 (2H) 
1.76-1.48 (5H) 1.74-1.49 (5H) 1.76-1.48 (5H) 
1.47 (6H) 1.47 (6H) 1.46 (6H) 
1.42-1.35 (4H) 1.44-1.38 (4H) 1.43-1.35 (4H) 
1.24-1.18 (4H) 1.25-1.17 (4H) 1.23-1.19 (4H) 
0.99-0.88 (9H) 1.06-1.01 (2H) 
0.96-0.90 (7H) 
1.03-0.98 (2H) 
0.96-0.89 (7H) 
Solid 
phase  
Solution 
phase  
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3.6.4.4 Future work 
 
Although method 3 was successful, the protecting groups may not be 
optimal. Using TMSE and TBS protecting groups which could both be 
removed using TBAF may be one option. Another may be to use TCE but 
carry out the couplings as shown in Figure 3.6.9. (TCE with Boc 
tetrapeptide).  
 
Figure 3.6.9: Another possible synthesis for the tetrapeptide. 
3.7 Macrolactonisation 
 
With 3.2.22 in hand attempts were made to carry out macrolactonisation to 
give 3.2.26. The retention time of 3.2.22 on HPLC was known as a 
reference for monitoring. The literature reports202 several methods for 
macrolactonisation (several of which are mentioned in Section 3.1). Shiina 
cyclisation is one of the favoured methods since it allows cyclisation to be 
carried out under relatively mild conditions. Figure 3.7.1 shows the 
lactonisation carried out, with Table 3.7.1 showing conditions varied and 
results.   
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Figure 3.7.1: Conditions used for cyclisation and Alloc removal.  
Table 3.7.1: Conditions tested for cyclisation of 3.2.22. All entries used 2.5 eq MNBA, 5 
eq DMAPO and 225 mL DCM and used 0.20 g of 3.2.22 unless otherwise noted. (* 3 eq 
DMAPO instead of 5 eq; **113 mL DCM rather than 225 mL DCM, ***5 eq DMAP rather 
than DMAPO, ****113 mL toluene rather than 225 mL DCM and 0.10 g of 3.2.22. 
 Conditions varied Crude 
yield 
(product/g) 
Crude 
yield 
(starting 
material/g) 
HPLC 
purity of 
3.2.26 
(product/%) 
HPLC 
purity of 
3.2.22 
(starting 
material/%) 
1 r.t., 4 days. 0.135 0.107 64 55 
2 50 oC, 4 days. 0.100 0.061 49 49 
3 50 oC, 4 days, 5 
eq, Dy(OTf)3 , 1 
eq, DIPEA, 3 eq 
DMAPO* 
0.062 0.075 - - 
4 30 oC, overnight. 0.030 0.126 86 95 
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Initially, the reaction was carried out at room temperature and monitored 
by HPLC (entry 1, Table 3.7.1). After 118 hours the reaction was stopped 
when the HPLC trace showed no further change. The reaction mixture 
was evaporated and then purified by silica column. HPLC and MALDI 
confirmed formation of the product. However, several side products with 
retention times between the starting material and product were seen and 
some co-eluted from the column with 3.2.26 (Figure 3.7.2).  
 
 
Figure 3.7.2 HPLC analysis of the macrolactonisation. A) starting material (3.2.22) and 
side products B) cyclised 3.2.26. 
 
5 113 mL DCM**, 
r.t., 4 days. 
0.042 0.054 - - 
6 50 oC, 2 days, 5 
eq DMAP*** 
0.057 0.132 - - 
7 113 mL 
toluene****, r.t., 3 
days. 
- - - - 
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Since conversion of 3.2.22 into 3.2.26 was low, the temperature of the 
next reaction (entry 2, Table 3.7.1) was increased from room temperature 
to 50oC. This led to increased conversion into product (as seen in Figure 
3.7.3), although the formation of side products also increased. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.3 HPLC comparison of entries 1 and 2 of Table 3.7.1. 1) was carried out at 
30⁰C and shows a large amount of the starting linear peptide (3.2.22) as indicated by the 
diagram. A small amount of macrocycle 3.2.26 is also seen, along with several 
unidentified side products. 2) was carried out at 50⁰C. In comparison to 1) it shows a 
small amount of starting linear peptide (3.2.22) and unidentified side products and a 
larger amount of macrocycle 3.2.26. HPLC traces showing purification of this reaction are 
shown in Figure 3.7.1. 
 
The next improvement which was proposed for the cyclisation was the use 
of heavy metals as templating agents.202 However, while preparing for this 
reaction a paper195 was published which also used similar conditions with 
a different linear precursor peptide. The reaction using 3.2.22 was, 
however carried out to giving similar results as entries 1 and 2. As shown 
by entry 4, work up and purification after overnight reaction gave a 
significantly reduced yield. Unfortunately, due to equipment malfunction it 
was not possible to analysis entries 5 and 6 using a similar method, 
although the crude yields are listed in Table 3.7.1. An attempt to use 
toluene as the solvent rather than DCM failed, with no product formation 
observed (entry 7). This was probably due to the low solubility of  3.2.22 in 
toluene at 30 oC.   
 
1) 2) 
Starting material 3.2.22 
Cyclised product 3.2.26 
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Peptide 3.2.22 was synthesised in 95% purity by solution phase and used 
in the same cyclisation conditions as initially used for 3.2.22 made by solid 
phase (entries 1 and 4 respectively). As for peptide derived from solid 
phase conversion into 3.2.26 was low. However, the superior purity of 
3.2.22 showed almost no side product formation. Therefore, purification by 
silica column gave purer product with an accurate yield.  
 
When analysed by HPLC, although 3.2.26 has been successfully made, it 
has not been made in 95% purity. Several attempts to fully purify by C-18 
silica column did not remove all contaminating side products. Therefore, 
the most favourable course of action was determined to be to continue 
onto removal of the alloc protecting group, leading to a decrease in HPLC 
retention time and aiding purification.  
 
Alloc deprotection using the conditions shown in Figure 3.2.12 led to 
complete disappearance of the starting material 3.2.26 after 1 hour. 
Purification was then carried by silica column to give 3.2.27. On small 
scales this was sufficient to remove the all catalyst. However, for larger 
scales additional purification with activated carbon was needed. The minor 
impurities remaining from cyclisation were removed using the column for 
all scales tested.  
 
3.8 Synthesis of linear chain 
 
The other section of a lariat peptide, the linear tail, was also made. As 
small amounts of many different peptides are needed, solid phase 
synthesis is a good method to use. Therefore, the linear tail was made 
completely by solid phase.  
 
3.8.1 Complete solid phase synthesis of teixobactin tail 
 
Initially a synthesis was attempted to make the linear tail using only 
commercially available amino acids and with all synthesis taking place on 
the solid phase resin (Figure 3.8.1; B)). The seven amino acids were 
coupled using the standard solid phase coupling procedures. Methyl was 
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then added to phenylalanine before cleavage from the resin. A well known 
method108 has been developed to allow on resin methylation. The 
orthogonal protecting group O-NBS protects the terminal amine, leaving 
only one NH position available for methylation. After methylation, the O-
NBS can then be selectively removed to allow further couplings to take 
place. However, since the terminal N needs protection to avoid side 
reactions during the coupling to the macrocycle the O-NBS protecting 
group was not removed.  
 
 
 
 
Figure 3.8.1: Two possible linear chains for use in synthesis of seco-teixobactin.  
Although this route has the advantage of the ease of solid phase 
synthesis, with no purification needed until the end, the purification was 
difficult. The HPLC trace (Figure 3.8.2) was very impure and although 
purification was possible by preparative HPLC, the standard HPLC 
method could not be used and a new method needed to be written. The 
solubility of the peptide was also very poor meaning that only small 
amounts could be loaded onto the column and so purification was tedious.  
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Another disadvantage to this method occurs during global deprotection, 
where deprotection must be carried out in a two-step process. 
 
 
Figure 3.8.2: Crude HPLC traces of A) and B) from Figure 3.2.13, showing the better 
purity of the crude of 3.2.32 compared to 3.2.30. 
 
3.8.2 Resin synthesis with premade BocMe-D-Phe-OH 
Therefore another method for linear tail synthesis was used. As previously 
the first six amino acids of the linear tail were coupled to the resin. The 
seventh amino acid was 3.2.31 which was made (Figure 3.8.3) and 
purified in solution. Although requiring this amino acid to be made this 
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method proved cleaner and had better solubility than the previous attempt 
(Figure 3.8.2). This coupling was clean enough to allow purification by 
flash column chromatography using Combiflash.  
 
 
Figure 3.8.3: Synthesis of N-Boc-N-Me-D-Phe-OH. 
3.8.3 Synthesis using solid phase lanterns 
All synthesis so far has using solid phase resin, the more common 
medium to use as a solid support. Another method (used by the Doi group 
Tohoku University, Sendai, Japan) is to use solid phase lanterns104 (Figure 
3.8.4). The couplings themselves use the same coupling reagents with the 
same mechanism, but with a different support. As seen in Figure 3.8.4 the 
lanterns are larger (around 1.5 cm in length and 0.5 cm in diameter) and 
can be picked up and moved by tweezers. Rather than weighing an 
amount of lanterns, the loading on each lantern is known and this is used 
for calculation. Another difference is that rather than calculating 
equivalents of coupling reagent, a solution of known concentration is made 
up and the coupling ran overnight.  
 
 
Figure 3.8.4: Solid phase resin (left) and solid phase lanterns (right). 
Another advantage of lanterns is that they allow the amino acid in the 
coupling solution to be added to more than one peptide at the same time. 
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This has been shown effectively in the “split and pool” here method used 
by the Doi group to make a large amount of related macrocycles.203 The 
Doi group are also working on the synthesis of teixobactin. However, 
unlike the Ganesan group method of using a tetrapeptide as the linear 
precursor for macrolactonisation, the Doi group use a pentapeptide, 
incorporating the first serine of the linear chain before cyclisation. 
Therefore, the two peptides (Figure 3.8.5) that are necessary for the linear 
chain in each macrocyclisation method are made using the “split and pool” 
method, with monitoring by LCMS. The HPLC of 3.2.29 showed a 
significant side product. However, this may be due to transportation from 
Japan rather than the synthesis itself.   
 
 
 
Figure 3.8.5: The two linear peptides made by lantern synthesis.  
 
3.8.4 Synthesis of linear chain analogues 
 
Following the successful synthesis of the linear tail of teixobactin as found 
in the natural product, attention was turned to possible analogues.  
The Nowick et al.196 reported an active analogue with an alkyl chain 
(Figure 3.6.4). Since this retained activity an idea to replace the linear tail 
with simpler amino acids rather than the alkyl chain was used. Therefore, 
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the first two amino acids of the chain (serine and isoleucine) were 
maintained and the other five amino acids replaced by glycine. Two more 
analogues were then synthesised using alanine with one using all L amino 
acids and the other using amino acids of the correct stereochemistry. 
Table 3.8.1 shows the linear chains which were made and the changes 
effected. Solid phase synthesis gave the required peptides in good purity, 
with further purification carried out by either silica column via Combiflash 
or by reverse phase (C18) silica, also using combiflash.  
 
Table 3.8.1: Analogues of the linear tail of teixobactin. 
1 
 
2 
 
3 
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4 
 
5* 
 
6* 
 
7* 
 
8* 
 
9ƚ 
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10 ƚ 
 
11 ƚ 
 
12 ƚ 
 
13 ƚ 
 
 
Coupling of the linear chains to macrocycle 3.2.27 could then be carried 
out. Initially, to test the reactivity of the free amine of 3.2.27 Boc-Ser(tBu)-
OH was coupled, using HATU and DIPEA as commonly used for solution 
phase couplings while making the macrocycle. This coupling proceeded 
smoothly, with the resulting product purified by silica column using EtOAc 
and MeOH to elute and yielding 57% of 3.3.1 as a white powder.  
 
However, an attempt to use similar conditions to couple 3.2.34 to 3.2.27 
were not successful. The lower solubility in common organic solvents of 
3.2.34 led to a dilute reaction solution and although a small amount of the 
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required mass could be detected by mass spectrometry, the HPLC trace 
showed a very messy and incomplete synthesis even after several days 
reaction.  
 
Improvements were then made by using DMF to achieve a higher 
concentration for couplings and DEPBT, a powerful coupling agent known 
to suppress isomerization was used in the place of HATU. These 
conditions were then used to attempt to make the 4 analogues shown in 
Table 3.8.2. The crude reaction mixtures were analyzed by LC-MS. No 
masses could be assigned to any products of the reaction. However, large 
amounts of starting materials were observed.  
 
Due to time constraints no further research on teixobactin could be carried 
out.  
 
 
Table 3.8.2: Attempts at coupling to make analogues. 
1 
 
2 
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3 
 
4 
 
5 
 
 
3.9 Conclusions and future work 
 
In conclusion, several truncated analogues of teixobactin have been 
synthesised. A synthesis of the macrocycle 3.2.27 with a free amine has 
been produced and its reactivity proved by the coupling to Boc-Ser(tBu)-
OH. A series of linear chain peptides has been made which could be used 
to further test the structure activity relationship. However, all coupling 
conditions attempted so far have failed so alternative methods are needed 
to make the analogues in this series.  
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Future work should initially focus on synthetic methods using the existing 
macrocycle and linear chain. However, it may be necessary to redesign 
several stages of the synthetic route in order to make a larger number of 
analogues. 
Synthesis of analogues should be followed by biological testing to improve 
the understanding of the structure activity relationship of teixobactin.  
 
3.10 Enduracididine synthesis 
The unnatural amino acid enduracididine a part of the macrocycle of 
teioxbactin. However, unlike each of the other amino acids in teixobactin, 
enduracididine is not commercially available. Therefore it must be made 
by chemical synthesis. Despite enduracididine having only one bond 
difference compared to arginine, the most convenient amino acid to start 
from is aspartic acid (Figure 3.10.1). 
 
Figure 3.10.1: Retrosynthesis of enduracididine.  
 
Before the discovery teixobactin there were few methods for the synthesis 
of enduracididine since it is a relatively rare amino. However, since 2014 a 
review has been written detailing the uses of enduracididine and the 
current syntheses available.189   
 
Synthesis of enduracididine starts with protection of the amine and acid 
group while leaving the side chain carboxylic acid group free for reaction. 
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This molecule is well known in the literature with several variations on the 
synthesis used to make the product. The process used was based 
on204,205 and gave the product in overall highest yield (Figure 3.10.2). 
   
 
Figure 3.10.2: First stages of synthesis of enduracididine.  
The next step to reduce the side chain from a carboxylic acid to an 
aldehyde proved to be more challenging than previous steps. Initially 1M 
BH3.THF added dropwise at 0oC and stirred at room temperature for 24 
hours showed incomplete reaction with the product showing additionally 
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removal of one of the tert-butyl groups as well as reduction of the 
carboxylic acid to hydroxyl.  
 
Therefore alternative methodology was attempted. Following a similar 
example,206 3.2.52 was used with DIBAL to attempt to reduce directly to 
the aldehyde. Although this method successfully provided the aldehyde 
the isolated yield was only 12%, with another 5% of the alcohol isolated. 
The column also provided 31% of starting material. Due to the low yield 
and conversion and complete reduction to alcohol this route was not 
continued.   
 
A different literature method204 (Figure 3.10.2) uses an efficient method to 
reduce to the alcohol before using DMPI to oxidise back to the aldehyde. 
The initial step to reduce to the alcohol proceeded well. Despite initial 
problems with excess acetic acid removing the Boc group, the DMPI 
oxidation eventually proceeded to give the aldehyde in near quantitive 
yield.  
 
The stereospecificity of next step was crucial to the synthesis. Figure 
3.10.3 shows the two possible products. Using the S,S cobalt catalyst is 
predicted to give primarily product a) and using the R,R catalyst is 
predicted to give primarily product b). Fortunately, the two products had 
different NMRs and TLC Rf.  
 
Since the natural product requires a) this was attempted first on a 70 mg 
scale. This gave almost completely a) product (with a yield of 62%) with 
only traces of b). For the same reaction on this scale with a S,S catalyst to 
give b), TLC showed only a faint trace of a) which was insufficient to be 
isolated by column. However, the yield was lower at around 45% (30 mg).  
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Figure 3.10.3: The two possible products from the nitroaldol reaction. 
Repeating this reaction on a 1.0 g scale gave a 60% yield with the S,S 
catalyst and around 75% with R,R, with each giving only trace amounts of 
the non-desired isomer.   
 
With the completion of this reaction, obtaining products which were pure 
by NMR and TLC, the next stage of the reaction, reduction of the nitro 
group to the amine was carried out (Figure 3.10.4). However, despite this 
step working with a different synthesis of enduracididine within the group 
the reaction initially failed using these products, giving only starting 
material. However, reaction material isolated from the reductions then 
proceeded without issues. Examination of the starting material compared 
to the product after reaction showed that the initial starting material was an 
off-white colour showing slight contamination of the product by catalyst. 
The trace catalyst (an inadequate amount to be shown by NMR), is 
thought to be poisoning the Pd/C. The activated carbon part of the catalyst 
was removing the cobalt catalyst from the previous step.  
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Figure 3.10.4: Synthesis of enduracididine using stereoselective nitroaldol (Henry 
reaction).  
Therefore, another attempt to remove catalyst from the product was 
attempted using QuandraSil MTU resin. However, this did not successfully 
remove all colour from the compound.  
 
The next steps (Figure 3.10.4) to give protected enduracididine 3.2.58 
then proceeded smoothly.  
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Due to this part of the project being carried out in Tohoku University, no 
further results were obtained, in part due to time constraints and in part 
due to the facilities not being available at UEA to continue the project (in 
particular a -80 oC freezer available for 3 days of -78 oC stirring).   
 
3.10.1 Future work using enduracididine 
 
Future work on teixobactin will firstly require biological testing of the 
analogues made so far. Testing will reveal the most potent analogues and 
direct further synthesis of other analogues. The linear chains of the most 
promising analogues can then be coupled to a macrocycle incorporate 
enduracididine.  
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3.11 Experimental for teixobactin 
 
All chemicals and solvents were purchased from Sigma-Aldrich, Fisher 
Scientific, Fluorochem, TCI, Merck or ATGC Bioproducts and were used 
without purification unless otherwise stated. Anhydrous solvents (with the 
exception of THF) were purchased from Sigma-Aldrich in Sure Seal 
bottles. Dry THF was either purchased from Sigma-Aldrich or dried over 
sodium, using benzophenone as an indicator.  
All air and moisture sensitive reactions were carried out under an argon 
atmosphere. TLC monitoring was carried out using Merck TLC Silica Gel 
60 F254 aluminium backed plates. Plates were visualised using 254 and 
365 nm UV light and stained with ninhydrin, bromocresol or KMnO4 as 
appropriate. Flash column chromatography was carried out using either 
Davisil LC60A 40-60 micron silica gel, or using a Teledyne ISCO 
Combiflash Rf 150 with prepacked 4g, 12g, 20g and 40g Telos columns 
and repacked 100g Biotage columns. Brine is a saturated solution of 
sodium chloride in water. Solvents removed under reduced pressure were 
removed using Buchi rotary evaporators (various models). 
  
Melting points were carried out using a Stuart Melting point SMP10. 
Optical rotation was carried out using an ADP440 polarimeter. Optical 
rotations were carried out using either chloroform, methanol or ethanol. 
Infrared spectra were measured using a Perkin Elmer FTIR Spectrum 
Two. Absorptions are given in wave numbers (cm-1). 1H and 13C NMR 
were recorded on Bruker Ultrashield 400 Plus (400 MHz for 1H and 100 for 
13C). Splitting patterns are reported as s=singlet, d=doublet, t=triplet, 
q=quartet and m=multiplet. Chemical shifts are given in pm and coupling 
constants in Hertz.  
 
Low resolution mass spectra were measured by MALDI Kratos Analytical 
Axima-CRF using either α-Cyano-4-hydroxycinnamic acid or 2,5-
Dihydroxybenzoic acid as a matrix or a Shimadzu 2010 EV. High 
resolution and all low resolution mass spectra measured by other 
techniques were carried out by the national mass spectrometry service at 
Swansea University.  
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Analytical high pressure liquid chromatography was carried out using 
Agilent Technologies 1200 Series, with a Eclipse YDB-C18 column (4.6 x 
150 mm, 5µm particle size). Preparative HPLC was carried out using an 
Agilent Technologies 1260 Infinity, with a Zorbax Agilent Flo XDB-C18 
column (21.2 x 150 mm, 5µm particle size). Unless otherwise stated, 
solvents used were HPLC methanol and high purity water with 0.5% TFA.  
Solid phase synthesis was carried out in glass peptide synthesis columns 
with fritted glass filters. The resin used was purchased from either Matrix 
Innovation or Novabiochem. Shaking was carried out using a Stuart Flask 
Shaker SF1.   
 
 
Alloc-D-Thr-OH, 3.2.15 
Experimental procedure 1: 1.6 g of D-Thr-OH and 
8.46 g of NaCO3 was dissolved in 280 mL of 2:1 
THF:H2O and cooled to 0 °C and 6.3 mL of allyl 
chloroformate added slowly. The solution was stirred 
for 3 days at rt, before the addition of another 3.15 mL (0.5 eq) of allyl 
chloroformate and another day of stirring at rt. 6 N HCl was then added 
until the solution was at pH 2 and extracted into ether (3 x). After 
evaporation of volatiles, a yellowish oil was obtained (8.26 g, 81%); 
Experimental procedure 2: To a solution of D-Thr (2.00 g, 16.8 mmol), 
NaHCO3 (2.72 g, 33.6 mmol), THF (10.0 mL) and water (10.0 mL) was 
added Alloc-Cl (2.14 mL, 20.2 mmol) slowly. After overnight stirring the 
reaction was quenched with 2N HCl (20 mL) and extracted into EtOAc (3 x 
25 mL). The combined organic extracts were washed with brine, dried 
over MgSO4, filtered and evaporated. The residue was purified by flash 
column chromatography (DCM:MeOH) to give Alloc-D-Thr-OH as a 
yellowish oil (2.50 g, 12.28 mmol, 73%); [α]24.8D 9.43 (c 1.03 in methanol); 
ṽmax/cm-1 3082, 3060 3025, 3002, 2924, 2850, 2361, 2338, 1601, 1493, 
1451; 1H NMR (400 MHz, CDCl3) δ 5.98 – 5.83 (m, 1H, CH2=CHCH2O), 
5.37 – 5.18 (m, 1H, CH2=CHCH2O), 4.99 (s, 1H, CH2=CHCH2O), 4.59 (d, 
J = 4.7 Hz, 1H, CH2=CHCH2O), 4.35 (ddd, J = 23.1, 21.3, 10.3 Hz, 1H, 
NCHCOO), 3.48 (s, 1H, CH3CHOH), 1.30 – 1.21 (m, 3H, Me); 13C NMR 
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(101 MHz, CDCl3) δ 174.3 (COOH), 157.2 (NCHCOO), 132.6 
(CH2=CHCH2O), 118.1 (CH2=CHCH2O), 68.0 (CH3CHOH), 66.3 
(CH2=CHCH2O), 59.2 (NCH), 19.5 (CH3). 
 
Fmoc-Arg(Pbf)-Ile-OMe, 3.2.13 
Fmoc-Arg(Pbf)-OH (3.601 g, 5.55 mmol) 
and HN-Ile-OMe.HCl (1.038 g, 5.71 mmol) 
were stirred in dry DCM (40 mL) with EDCI 
(1.304 g, 1.2 eq), HOBt (0.8924g, 1.2 eq) 
and DIPEA (1.1 mL,1.2 eq) at room temperature for 3.5 hours until TLC 
showed completion of the reaction. Volatiles were then evaporated and 
purification carried out by silica column chromatography (0-5% 
MeOH:DCM) to give 3.2.13 as a white solid (4.02g, 5.18 mmol, 94%); 
[α]22.4D  -56.4 (c 1.01 in MeOH); ṽmax/cm-1 3314, 2966, 1726, 1620, 1660, 
1543, 1450, 1244, 1090, 740, 661; 1H NMR (400 MHz, MeOD) δ 7.80 (d, J 
= 7.5 Hz, 2H), 7.66 (t, J = 6.8 Hz, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.34 – 7.27 
(m, 2H), 4.42 – 4.34 (m, 3H), 4.26-4.15 (m, 2H), 3.70 (s, 3H), 3.19 (s, 2H), 
2.98 (s, 2H), 2.60 (s, 3H), 2.53 (s, 3H), 2.08 (s, 3H), 1.94-1.84 (m, 1H), 
1.80 – 1.71 (m, 1H), 1.68 – 1.47 (m, 4H), 1.45 (s, 6H), 1.32 – 1.18 (m, 1H), 
0.91 (m, 6H); 13C NMR (101 MHz, CDCl3) δ 172.6, 162.8, 158.9, 156.5, 
143.9, 143.8, 141.3, 141.3, 138.5, 132.9, 132.4, 127.8, 127.2, 125.3, 
124.7, 120.0, 117.6, 86.5, 67.3, 57.1, 54.3, 52.2, 47.1, 43.3, 37.2, 31.6, 
28.7, 25.3, 19.4, 18.1, 15.6, 12.6, 11.5; HRMS m/z: [M + H]+ Calcd for C41 
H54 N5 O8 S1 776.3688; Found 776.3682.  
 
Fmoc-Ala-Arg(Pbf)-Ile-OMe, 3.2.14 
Dipeptide 3.2.13 (2.002 g, 2.57 mmol) was 
dissolved in MeCN (75 mL) and NHEt2 (15 
mL) and stirred at room temperature until 
disappearance of starting material by TLC. 
The volatiles of the resulting crude mixture 
were evaporated and DCM (x4) used to 
remove all of the NHEt2 by azeotrope and the orange oil coupled to Fmoc-
Ala-OH (0.800 g, 2.57 mmol) using HATU (1.47 g, 3.86 mmol) and DIPEA 
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(1.34 mL, 7.72 mmol) in 4:1 DCM:MeCN (50 mL) to give 3.1.14 as a white 
powder (1.913 g, 2.30 mmol, 89%): [α]26.0D -23.3 (c 1.59 in CHCl3); 
ṽmax/cm-1 3321, 2977, 2940, 1651, 1548, 1251, 1107, 839; 1H NMR (400 
MHz, MeOD) δ 7.80 (dd, J = 7.6, 0.6 Hz, 2H, Fmoc ar.), 7.67 (t, J = 7.5 Hz, 
2H, Fmoc ar.), 7.43 – 7.26 (m, 4H, Fmoc ar.), 4.45 (dd, J = 8.0, 5.6 Hz, 
1H, H-2), 4.36 (dd, J = 8.6, 6.8 Hz, 3H, H-31, 17, 7), 4.25 – 4.09 (m, 2H, 
H-30), 3.80 – 3.67 (m, 4H, H-60, 57), 3.26 – 3.12 (m, 3H, H-57, 20), 2.96 
(s, 2H), 2.84 (d, J = 3.5 Hz, 2H), 2.55 (d, J = 27.7 Hz, 6H, Pbf-Me), 2.05 
(d, J = 15.1 Hz, 3H, Pbf-Me), 1.97 – 1.77 (m, 2H, H-18/19), 1.75 – 1.51 (m, 
3H, H-12, 18/19), 1.50 – 1.31 (m, 19H, H-58,59, 16, 14), 0.91 (t, J = 7.8 
Hz, 6H, H-13,15);13C NMR (101 MHz, MeOD) δ 175.6, 174.0, 173.4, 
159.8, 145.3, 145.2, 142.5, 139.4, 134.4, 133.5, 128.8, 128.2, 126.2, 
126.0, 120.9, 118.4, 87.6, 68.0, 58.3, 55.8, 53.9, 52.5, 52.0, 43.9, 43.8, 
38.9, 38.3, 30.4, 28.7, 26.3, 19.6, 18.7, 18.4, 18.1, 17.2, 16.0, 13.2, 12.5, 
11.7; MALDI-TOF 652 = [M-Fmoc]+ 846 = [M]+.  
 
Alloc-D-Thr-Ala-OMe, 3.2.17 
Under argon, 3.2.15 (2.002 g) and H-Ala-OMe 
(1.371 g), EDCI (2.262 g), HOBt (1.593 g) and 
DIPEA (2.06 mL) were stirred overnight in dry 
MeCN. Volatiles were evaporated and the 
crude purified on a 45 g Telos column using MeOH:DCM to elute, giving 
3.2.17 as a white powder (2.61 g, 7.81 mmol, 82%): [α]24.4D -27.3 (c 1.03 in 
MeOH); ṽmax/cm-1 3338, 1737, 1651, 1015; 1H NMR (400 MHz, MeOD) δ 
6.01 – 5.89 (m,1H), 5.33 (d, J = 17.2 Hz, 1H), 5.23 – 5.17 (m, 1H), 4.61 – 
4.54 (m, 2H), 4.44 (q, J = 7.3 Hz, 1H), 4.10 (s, 1H), 3.72 (s, 3H), 1.40 (d, J 
= 7.3 Hz, 3H), 1.19 (d, J = 6.0 Hz, 3H); 13C NMR (101 MHz, MeOD) δ 
174.3, 172.9, 158.4, 134.2, 117.8, 68.7, 66.8, 61.7, 52.8, 49.6, 20.0, 17.4; 
HRMS m/z: [M + H]+ Calcd for C12 H21 N2 O6 289.1394; Found 289.1390.  
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Alloc-D-Thr-Ala-OH, 3.2.18 
To a solution of 3.1.17 (0.350 g, 1.23 mmol) in 
MeOH (7 ml) was added K2CO3 (0.2 M, 7 ml). 
The resulting solution was stirred for 5.5 hours 
until TLC showed completion. KHSO4 (5% 
aqueous solution) was then added dropwise until the solution was acidified 
to pH 3. The resulting solution was then evaporated to dryness and 
purification carried out by column chromatography using a 12 g silica 
cartridge, with a gradient of 0 – 10% MeOH in DCM to yield a colourless 
oil, (0.240 g, 0.875 mmol, 72%); [α]23.3D 36.6 (c 1.12 in MeOH); ṽmax/cm-1 
3301, 2937, 1710, 1646, 1392, 1358, 1226, 746; 1H NMR (400 MHz, 
MeOD) δ 6.02-5.89 (m, 1H), 5.35 (d, J = 17.2 Hz, 1H), 5.23-5.17 (m, 2H), 
4.66 – 4.55 (m, 1H), 4.49 – 4.39 (m, 2H), 4.19 – 4.06 (m, 2H), 1.43 (d, J = 
7.3 Hz, 3H), 1.20 (d, J = 6.2 Hz, 3H); 13C NMR (101 MHz, MeOD) δ 174.5, 
173.9, 171.5, 157.1, 132.8, 128.2, 127.0, 125.9, 117.2, 116.3, 110.1, 67.3, 
65.5, 60.4, 19.4, 18.5, 16.3; HRMS m/z: [M - H]- Calcd for C11 H17 N2 O6 
273.1092; Found 273.1091. 
 
Alloc-D-Thr-Ala-Arg(Pbf)-Ile-OMe, 3.2.16 
To a solution of 3.2.13 (0.424g, 0.547 
mmol) in MeCN (5 ml) was added 
NHEt2 (0.25 ml). The solution was 
stirred for 6.5 hours until consumption 
of 3.2.13 upon which volatiles were 
evaporated and DCM used to 
azeotrope once. The crude was then added to 3.2.18 (0.150 g, 0.547 
mmol) and HATU (0.212 g, 0.821 mmol, 1.5 eq) and dissolved in dry DCM 
and DIPEA (0.29 mL, 3 eq) added. After overnight stirring volatiles were 
evaporated and  the crude purified using a 12 g Telos column and DCM: 
MeOH to elute to provide 3.2.16 as an off-white powder (0.239 g, 0.295 
mmol, 54%); [α]18.9D -13.0 (c 0.769 in MeOH); ṽmax/cm-1 3312, 2970, 1646, 
1537, 1235, 844; 1H NMR (400 MHz, MeOD) δ 5.95-5.88 (m, 1 H), 5.30 
(dd, J =  17.1 1.27, 1H), 5.17 (dd, J = 10. 1.89,1H), 4.60-4.48 (m, 2H), 
4.49-4.54 (m, 1H), 4.42-4.30 (m, 1H), 4.14-4.06 (m, 1H), 4.04-3.99 (m, 
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1H), 3.69 (s, 3H), 3.66-3.56 (m, 1H), 3.25-3.14 (m,),3.00 (s, 2H), 2.57 (s, 
3H), 2.51 (s, 3H) 2.08 (s, 3H),1.94-1.79 (m, 2H), 1.74-1.50 (m, 3H) 1.50-
1.44 (m, 7H), 1.34-1.40 (m, 5H), 1.20 (d, J = 6.47 ,3H), 0.93-0.90 (m, 6H); 
13C NMR (101 MHz, MeOD) δ 174.9, 173.6, 173.3, 168.5, 159.9, 149.5, 
139.4, 134.4, 134.2, 133.5, 126.0, 118.4, 117.8, 87.7, 68.5, 66.9, 64.1, 
62.4, 58.4, 55.8, 52.4, 50.8, 44.0, 38.2, 30.0, 28.7, 26.4, 20.0, 19.6, 18.4, 
17.5, 16.0, 13.2, 12.5, 11.7; HRMS m/z: [M + H]+ Calcd for C37 H60 N7 O11 
S1 810.4066; Found 810.4058.  
 
Fmoc-Ile-OTCE, 3.2.15 
To a dry flask was added Fmoc-Ile-OH (1.00 g, 
2.83 mmol) and a minimum amount (20 mL) of 
dry DCM to dissolve Fmoc-Ile-OH was added via 
syringe. The flask was then cooled to 0 °C and 
trichloroethanol (0.33 mL, 3.40 mmol), DMAP (0.173 g, 1.42 mmol) and 
DCC (0.702g, 3.40 mmol) added and the reaction stirred at room 
temperature overnight. After filtration to remove urea, the solution was 
concentrated and the crude purified via silica column using PE:EtOAc to 
elute, giving 3.2.15 as a yellow oil (1.07 g, 78%): [α]26.0D 8.15 (c 1.23 in 
MeOH); ṽmax/cm-1 3330, 2965, 1757, 1713, 1041, 719; 1H NMR (400 MHz, 
CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H), 7.60 (d, J = 7.2 Hz, 2H), 7.40 (t, J = 7.4 
Hz, 2H), 7.31 (t, J = 7.4 Hz, 2H), 4.92 (d, J = 11.9 Hz, 1H), 4.66 (d, J = 
11.9 Hz, 1H), 4.55 – 4.47 (m, 1H), 4.43 (d, J = 6.8 Hz, 2H), 4.23 (t, J = 6.8 
Hz, 1H), 4.17 – 4.07 (m, 2H), 2.04 (s, 3H), 1.26 (t, J = 7.1 Hz, 3H), 1.01 (d, 
J = 6.5 Hz, 3H), 0.95 (t, J = 7.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 
170.7, 156.3, 144.0, 143.8, 141.5, 127.9, 127.2, 125.2, 120.2, 120.1, 94.6, 
74.6, 67.3, 58.6, 47.3, 37.9, 25.0, 21.2, 15.8, 14.3, 11.7; HRMS m/z: [M + 
H]+ Calcd for C23 H25 Cl3 N1 O4 484.0844; Found 484.0840. 
 
Alloc-D-Thr(OTBS)-OH, 3.2.20 
To 3.2.15 (8.698 g, 42.8 mmol) dissolved in dry DMF (50 
mL) and DIPEA (23.4 mL, 134 mmol) was added TBSCl 
(12.6 g, 83.9 mmol) in several portions. After stirring 
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overnight at room temperature, the mixture was acidified to pH 3 with 2N 
HCl and extracted into EtOAc (3 x 25 mL) then washed with brine (2 x). 
The organic layer was dried (MgSO4), filtered and evaporated and the 
residue purified by 20 g Telos silica column (0-5% MeOH:DCM). Tubes 
containing 3.2.15 were combined and evaporated, with toluene used to 
remove residual DMF and TBSOH via azeotrope, giving a white solid 
(8.314 g, 26.2 mmol, 61%); ṽmax/cm-1 3402, 3088, 2931, 2957, 2859, 1754, 
1736, 1685, 1525, 1070, 835, 774; 1H NMR (400 MHz, CDCl3) δ 9.10 (s, 
br, 1H), 5.99-5.88 (m, 1H), 5.45 (d, J = 9.1 Hz, 1H), 5.32 (dd, J = 17.2, 1.4 
Hz, 1H), 5.22 (dd, J = 10.4, 1.1 Hz, 1H), 4.59 (dt, J = 5.7, 1.4 Hz, 2H), 4.47 
(qd, J = 6.3, 2.1 Hz, 1H), 4.28 (dd, J = 9.1, 2.1 Hz, 1H), 1.20 (d, J = 6.3 
Hz, 3H), 0.85 (s, 9H), 0.06 (s, 3H), 0.03 (s, 3H); 13C NMR (101 MHz, 
CDCl3) δ 175.4, 156.7, 132.7, 118.1, 68.7, 66.2, 59.6, 25.8, 18.0, -4.4, -
5.1; m/z (ESI)+ 342 = [M+Na+H]+, 364 = [M+2Na]+, 705.  
 
 
Alloc-D-Thr-Ala-OMe, 3.3.1 
 3.2.20 (0.500 g, 1.58 mmol) and H-Ala-OMe 
(0.225 g, 1.58 mmol) were stirred overnight 
under argon with EDCI (0.364 g, 1.89 mmol, 1.2 eq), HOBt (0.262 g, 1.89 
mmol, 1.2 eq) and DIPEA (0.33 mL, 1.2 eq) in dry MeCN (5 mL). Upon 
completion the reaction mixture was washed with 1 N NaHCO3 (2 x 5 mL) 
1 N HCl (2 x 5 mL) and brine (2 x 5 mL). The organic layer was dried and 
evaporated to give a yield of 0.369 g (0.369 g, 0.917 mmol, 58%); White 
powder; [α]26.0D -42.6 (c 7.11 in MeOH); ṽmax/cm-1 3290, 2930, 2857, 1713, 
1753, 1651, 1538, 1239, 1133, 833; 1H NMR (400 MHz, MeOD) δ 6.37 (d, 
J = 8.7 Hz, 1H), 5.86 (ddd, J = 22.7, 10.8, 5.5 Hz, 1H, CH2=CHCH2O), 
5.24 (dd, J = 17.2, 1.3 Hz, 1H, CH2=CHCH2O), 5.11 (ddd, J = 10.5, 2.8, 
1.4 Hz, 1H, CH2=CHCH2O), 4.53 – 4.42 (m, 2H, CH2=CHCH2O), 4.38 – 
4.30 (m, 1H, CH), 4.23 – 4.14 (m, 1H, CH), 4.07 – 4.00 (m, 1H, CH), 3.62 
(s, 3H, OMe), 1.29 (d, J = 7.2 Hz, 3H, Me-Ala), 1.08 (d, J = 6.2 Hz, 3H, 
Me-Thr), 0.81 – 0.76 (m, 9H, (CH3)3C), 0.02 – -0.07 (m, 6H, Si-Me); 13C 
NMR (101 MHz, MeOD) δ 174.3 (COOMe), 172.0 (CHC=ONH), 158.3 
(OC=ONH), 134.2 (CH2=CHCH2O), 117.9 (CH2=CHCH2O), 70.3 (CH), 
194 
 
66.9 (CH), 61.6 (CH), 52.8 (COOCH3), 49.5 (CH2=CHCH2O), 26.3 
((CH3)3C), 20.6 (Me-Thr), 18.8 ((CH3)3C), 17.9 (Me-Ala), -4.4 (Me-Si), -4.9 
(Me-Si); HRMS m/z: [M - H]+ Calcd for C18 H35 N2 O6 Si 403.2259; Found 
403.2254. 
 
Alloc-D-Thr-Ala-OMe, 3.3.2 
Dipeptide 3.3.1 (0.166 g, was dissolved in 
3:3:1 mixture of MeOH:THF:water (4.8 mL). 
LiOH (0.01 g, 1.4 eq) was added and the 
reaction monitored until completion. After removal of volatiles, the residue 
was acidified with 2N HCl, extracted with EtOAc (3 x 20 mL), dried 
(MgSO4) and concentrated to give 3.3.2 as a colourless oil; (0.131 g, 
0.337 mmol, 82%): [α]26.0D 29.7 (c 0.539 in MeOH); 1H NMR (400 MHz, 
MeOD) δ 5.86 (ddd, J = 22.6, 10.7, 5.5 Hz, 1H), 5.23 (d, J = 17.2 Hz, 1H), 
5.11 (ddd, J = 10.5, 2.8, 1.4 Hz, 1H), 4.54 – 4.42 (m, 2H), 4.37 – 4.26 (m, 
1H), 4.20 (dd, J = 6.1, 3.4 Hz, 1H), 4.05 (dd, J = 8.7, 3.4 Hz, 1H), 1.31 (d, 
J = 7.2 Hz, 3H), 1.13 – 1.02 (m, 3H), 0.82 – 0.73 (m, 9H), 0.03 – -0.06 (m, 
6H); 13C NMR (101 MHz, CDCl3) δ 172.6, 172.2, 147.1, 113.0, 111.1, 
81.8, 55.6, 49.5, 43.6, 38.6, 28.6, 25.7, 25.2, 19.3, 18.6, 17.9, 17.3, 15.5, 
12.5, 11.5; HRMS m/z: [M - H]- Calcd for C17 H31 N2 O6 Si 387.1957; 
Found 387.1954. 
 
Alloc-D-Thr(OTBS)-Ala-Arg(Pbf)-Ile-OMe, 3.2.21 
A solution of 3.2.14 (1.504 g, 
1.80 mmol) in MeCN (52 mL) 
and diethylamine (10.5 mL) 
was stirred for 3 hours until 
disappearance of 3.2.14 by 
TLC. Volatiles were evaporated 
and DCM (3 x) used to azeotrope the remainder of diethylamine. The 
crude was then coupled to 3.2.20 (0.57 g, 1.80 mmol), HATU (1.03 g, 2.70 
mmol) and DIPEA (0.94 mL, 5.40 mmol) in DCM (30 mL) and MeCN (15 
mL). After evaporation of solvent the crude was purified by silica column 
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(MeOH:DCM) to give 3.2.21 as an orange oil (1.0115 g, 1.09 mmol, 61%): 
[α]26.0D 6.62 (c 1.06 in MeOH); ṽmax/cm-1 3303, 2964, 2931, 2860, 1740, 
1635, 1544, 1455, 1251, 1091, 832, 778, 661; 1H NMR (400 MHz, MeOD) 
δ 5.92 (ddt, J = 17.2, 10.8, 5.5 Hz, 1H), 5.31 (dd, J = 17.2, 1.4 Hz, 1H), 
5.18 (ddd, J = 10.5, 2.8, 1.4 Hz, 1H), 4.59 – 4.50 (m, 2H), 4.40-4.33 (m, 
3H), 4.26 (dd, J = 6.2, 3.7 Hz, 1H), 4.11 – 4.08 (m, 1H), 3.69 (s, 3H), 3.17 
(t, J = 6.5 Hz, 2H), 3.00 (s, 2H), 2.57 (s, 3H), 2.51 (s, 3H), 2.08 (s, 3H), 
1.94 – 1.77 (m, 2H), 1.73 – 1.51 (m, 3H), 1.45 (s, 6H), 1.35 (d, J = 7.1 Hz, 
3H), 1.30-1.27 (m, 1H), 1.24 (t, J = 7.1 Hz, 1H), 1.18 (d, J = 6.2 Hz, 3H), 
0.93 – 0.86 (m, 15H), 0.08 (d, J = 9.9 Hz, 6H); 13C NMR (101 MHz, MeOD) 
δ 174.5, 174.0, 173.4, 172.2, 159.9, 158.3, 158.1, 139.4, 134.4, 134.1, 
133.5, 126.0, 118.4, 117.9, 87.6, 70.2, 67.0, 61.9, 58.3, 54.1, 52.5, 50.4, 
44.0, 38.3, 30.1, 28.7, 26.3, 20.7, 19.6, 18.8, 18.4, 18.4, 16.0, 12.5, 11.8, -
4.4, -4.8; HRMS m/z: [M + H]+ Calcd for C43 H74 N7 O11 S1 Si1 924.4931; 
Found 924.4930.  
 
Alloc-D-Thr-Ala-Arg(Pbf)-Ile, 3.2.22 
 
General procedure for solid 
phase  
 
Or 
 
To a solution of 3.3.3 (0.250 g, 0.275 mmol) in AcOH (0.113 mL) and THF 
(3.7 mL) was added a solution of TBAF (1M, 1.37 mL). The reaction was 
monitored by TLC until completion (3.5 hours), diluted with EtOAc, washed 
with a 5% KHSO4 solution, sat. NaHCO3 solution and brine. The combined 
organic extracts were dried (MgSO4), evaporated and purified by silica 
column (20 g Telos column, 0-20% MeOH:DCM) to give 3.2.22 as a 
colourless oil (0.098 g, 0.123 mmol, 45%): ṽmax/cm-1 3318, 2969, 2932, 
1712, 1645, 1544, 1244, 1091, 660; 1H NMR (400 MHz, MeOD) δ 5.93 
(ddt, J = 17.2, 10.6, 5.4 Hz, 1H), 5.36 – 5.28 (m, 1H), 5.19 (ddd, J = 10.6, 
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2.8, 1.4 Hz, 1H), 4.63 – 4.48 (m, 2H), 4.38 (q, J = 7.2 Hz, 2H), 4.28 (d, J = 
5.3 Hz, 1H), 4.14 (dd, J = 6.4, 4.1 Hz, 1H), 4.04 (d, J = 4.1 Hz, 1H), 3.29 – 
3.13 (m, 4H), 3.01 (s, 2H), 2.58 (s, 3H), 2.52 (s, 3H), 2.09 (s, 3H), 1.95 – 
1.81 (m, 2H), 1.73 – 1.49 (m, 5H), 1.47 (s, 6H), 1.41 (d, J = 7.3 Hz, 4H), 
1.22 (d, J = 6.3 Hz, 4H), 1.04 (t, J = 7.4 Hz, 2H), 0.97-0.86 (m, 7H); 13C 
NMR (101 MHz, MeOD) δ 174.9, 173.8, 173.6, 159.8, 158.5, 158.1, 139.4, 
134.3, 134.1, 133.5, 126.0, 118.4, 117.9, 87.7, 68.5, 66.9, 62.4, 59.5, 
58.5, 50.8, 44.0, 41.5, 38.4, 30.0, 28.7, 26.2, 24.8, 20.7, 20.0, 19.6, 18.4, 
17.6, 16.1, 13.9, 12.5, 11.9; HRMS m/z: [M - H]- Calcd for C36 H56 O11 N7 
S1 794.3764; Found 794.3745; HRMS m/z: [M + H]+ Calcd for C36 H58 N7 
O11 S1 796.3910; Found 796.3904. 
 
(3S, 6S, 9S, 12R)-6-[5-(2,3-dihydro-2,2,4,5,7-pentamethyl-6-
benzofuran-6-sulfonyl)carbamimidamidopentyl]-3-((S)-3-methyl-
pentyryl)-9-methyl-12-(2-propen-1-yloxy)carbonylamino)-1-oxa-4,7,10-
triazacyclotridecane-2,5,8,11-tetraone, 3.2.26 
 
To a three-necked flask equipped with 
a dropping funnel and reflux 
condenser was added MNBA (0.22 g, 
0.63 mmol), DMAPO (0.17 g, 1.3 
mmol) and 30 mL DCM (dried over 
MgSO4). A solution of 3.2.22 (0.20 g, 
0.25 mmol) in DCM (195 mL, dried over MgSO4) was added dropwise to 
the stirred flask over several hours. Upon completion of the addition the 
reaction was left to stir at 50 °C for 4 days. Volatiles were evaporated and 
the crude separated by silica column (20g Telos column, 0-40% 
MeOH:DCM) to give a mixture of 3.2.22 and 3.2.26; White powder; 
ṽmax/cm-1 3323, 2977, 2932, 1726, 1661, 1532, 1239, 1091, 661; 1H NMR 
(400 MHz, MeOD) δ 6.01 (ddd, J = 22.7, 10.8, 5.5 Hz, 1H), 5.45 (dd, J = 
6.4, 2.8 Hz, 1H), 5.38 (dd, J = 17.2, 1.5 Hz, 1H), 5.25 (ddd, J = 10.5, 2.8, 
1.3 Hz, 1H), 4.74-4.65 (m, 1H), 4.63 – 4.48 (m, 3H), 4.45 – 4.35 (m, 1H), 
4.28-4.18 (m, 1H), 3.26-3.14 (m, 2H), 3.01 (s, 2H), 2.58 (s, 3H), 2.52 (s, 
3H), 2.46 (s, 3H), 2.09 (s, 3H), 1.99 (dd, J = 14.7, 7.6 Hz, 2H), 1.64 – 1.48 
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(m, 2H), 1.48 (d, J = 9.5 Hz, 7H), 1.44 – 1.34 (m, 5H), 1.32 – 1.24 (m, 4H), 
0.94 (t, J = 7.4 Hz, 3H), 0.88 (d, J = 6.8 Hz, 3H); 13C NMR (101 MHz, 
MeOD) δ 175.9, 172.6, 172.4, 171.5, 159.9, 158.8, 147.3, 139.4, 138.2, 
137.1, 134.3, 134.2, 133.5, 130.7, 126.0, 122.7, 118.4, 118.0, 87.7, 73.8, 
67.2, 59.1, 56.7, 56.6, 53.3, 44.0, 41.6, 37.1, 28.8, 28.7, 27.6, 19.5, 19.2, 
18.4, 16.7, 16.2, 15.0, 12.5, 12.1; MALDI-TOF: [M +Na]+= 800,  [M + K]+ = 
817; HRMS m/z: [M + H]+ Calcd for C36 H56 N7 O10 S1 778.3804; Found 
778.3800. 
 
(3S, 6S, 9S, 12R)-6-[5-(2,3-dihydro-2,2,4,5,7-pentamethyl-6-
benzofuran-6-sulfonyl)carbamimidamidopentyl]-3-((S)-3-methyl-
pentyryl)-9-methyl-12-amino-1-oxa-4,7,10-triazacyclotridecane-
2,5,8,11-tetraone, 3.2.27 
To [Pd(PPh3)4] (0.1 eq) under argon was added THF, then phenylsilane (2 
eq). The resulting solution was added to 3.2.26 
(under argon) and stirred for 1 hour at room 
temperature. The solvent was then evaporated and 
purification carried out by silica column 
(DCM:MeOH) to give Ct-2-41 as a brown oil; 1H 
NMR (400 MHz, MeOD) δ 5.44 – 5.32 (m, 1H), 
4.58 (s, 1H), 4.50 – 4.40 (m, 1H), 4.36-4.16 (m, 
2H), 3.63-3.54 (m, 1H), 3.39 (d, J = 2.5 Hz, 1H), 3.27 – 3.08 (m, 3H), 3.00 
(s, 2H), 2.57 (s, 3H), 2.51 (s, 3H), 2.08 (s, 3H), 2.01 – 1.90 (m, 1H), 1.89 – 
1.78 (m, 1H), 1.69 – 1.54 (m, 4H), 1.53 – 1.25 (m, 18H), 1.22 – 1.09 (m, 
2H), 0.97 – 0.84 (m, 7H); HRMS m/z: [M + H]+ Calcd for C32 H52 N7 O8 S1 
694.3593; Found 694.3590. 
 
NMeBoc-Phe-OH 
To the N-Boc glycine (9.31 mmol) stirred at 0oC in anhydrous THF 
(40 mL) and MeI (74.5 mmol, 4.64 mL) was added NaH (60% 
dispersion in oil) (28.9 mmol, 1.15 g) gradually and the 
resulting mixture stirred at room temperature for 24 hrs. 
EtOAc (10 mL) and water (5 mL) were then added and the solution 
concentrated. The residue was dissolved in water (30 mL) and extracted 
twice with ether (2 x 30 mL) before acidification of the aqueous layer with 
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5% citric acid which was then extracted with EtOAc (4 x 20 mL). The 
combined organic extracts were washed with brine, dried over MgSO4 , 
filtered and evaporated. The residue was purified by column 
chromatography, eluting with petroleum ether. Colourless oil, (2.005 g, 
7.18 mmol, 77%); νmax/cm-1 2976 (CH), (COOH), 1694 (NC=O), (C-O); 1H 
NMR (400 MHz, CDCl3) δ 7.29 (t, J = 7.3 Hz, 5H), 7.25 – 7.16 (m, 6H), 
4.81 (dd, J = 10.9, 5.0 Hz, 1H), 4.62 (dd, J = 10.8, 4.2 Hz, 1H), 3.37 – 3.26 
(m, 2H), 3.19 – 2.97 (m, 2H), 2.72 (d, J = 29.1 Hz, 6H), 1.37 (d, J = 23.8 
Hz, 18H). 
 
General procedures 
 
Solid phase synthesis (1) 
200 mg of 1.3 mmol g-1 trityl chloride resin is swollen in dry DCM (1/2 – 1 
hour) and washed (5 x dry DCM). The first amino acid (2 eq) is then 
dissolved in dry DCM (2 ml), DIPEA added (5 eq) and this solution added 
to the resin in a dry glass peptide column under argon. This is shaken 
overnight, followed by washing with DCM (x 2) and capping with 
DCM:MeOH:DIPEA (17:2:1) (2 x 5ml x 10 minutes). The resin is then 
washed with DCM (x 5).  
 
Subsequent couplings are carried out by deprotection (3 x 2ml 20% 
piperidine in DMF x 3 minutes), washing (5 x DMF, 5 x DCM, 5 x MeOH, 5 
x DMF), 2 x coupling (0.75 eq Fmoc protected amino acid, 0.75 eq PyBop, 
1.5 eq DIPEA), washing (5 x DMF, 5 x DCM, 5 x MeOH, 5 x DMF).   
 
Cleavage is carried out by washing with DCM followed by shaking for 1 
hour with 2 ml of Acetic acid:TFE:DCM (1:1:8), draining into a 100ml rbf, 
washing with another 2ml of Acetic acid:TFE:DCM (1:1:8), adding this to 
the rbf, adding 60 ml hexane and then evaporation of solvent.  
This procedure has been used to give the linear peptides which are used 
in the cyclisation without purification.  
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Additional step for acetylation 
To the Fmoc deprotected resin was added a 1:8:8 mixture of acetic 
anhydride:pyridine:DCM comprising of 1.2 eq of acetic anhydride. 
Additional DCM was added until the resin mixed freely with the solution 
and shaking carried out for 7.5 minutes. The resin was washed (5 x DMF, 
5 x DCM, 5 x MeOH, 5 x DMF) and the Kaiser test carried out. After a 
negative test the resin was cleaved as for the general procedure.  
 
Cyclisation of truncated analogues 
To 2-Methyl-6-nitrobenzoic anhydride (MNBA) (1.2 eq) and N,N-4-
Dimethylaminopyridine (DMAP) (2.4 eq) dissolved DCM in an oven dried 
three neck flask was slowly added a solution of linear precursor peptide 
in DCM:MeCN. The resulting solution was stirred for 60 hours at room 
temperature, followed by evaporation of solvent and purification by 
preparative HPLC.  
 
Global deprotection of acid sensitive protecting groups 
A 95:2.5:2.5 TFA:TIPS:H2O solution was added to the peptide. The 
solution was stirred for 1 hour, or until completion by TLC. Ice cold ether 
was added to precipitate and solvent carefully removed by pipette and 
further drying carried out by rotary evaporator, using MeCN to azeotrope 
and HPLC to purify if necessary.  
 
General procedure for solid phase synthesis (2) 
 
The preloaded resin (0.20 g) was placed into a glass peptide synthesiser 
fitted with a fritted glass filter. 5 mL of DCM was added and the resin 
agitated for 30 minutes using the shaker. The DCM was drained and the 
Fmoc deprotected using 3 x 3mL 20% piperidine in DMF for 3 minutes 
each time. The resin was then washed 5 x for 5 minutes with DMF. A 
solution containing Fmoc amino acid (1.5 eq, 0.225 mmol), PyBop (1.5 eq, 
0.225 mmol) and DIPEA (3 eq, 0.45 mmol) in 3 mL DMF was then added 
to the resin and shaken overnight. The resin was then washed 5 x for 5 
minutes with DMF. Fmoc deprotection and addition of amino acids was 
repeated until completion of the sequence. The resin was then washed 
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with DCM and a 8:1:1 mixture of DCM:TFE:AcOH (2 mL) added and the 
resin shaken for 30 minutes-1 hour. The solution was drained into hexane 
(60 mL) and the resin washed with another 2 mL of cleavage solution. 
After evaporation the resulting peptide was analysed by MALDI and HPLC 
and purification carried out if necessary.  
 
On-resin N-methylation108  
 
After deprotection of the Fmoc of the terminal amino acid the resin was 
washed with NMP and a solution of O-NBS-Cl (4 eq) and collidine (10 eq) 
in NMP added and shaken for 15 minutes before washing 5x with NMP. 
DBU (3 eq) in NMP was shaken with the resin for 3 minutes, followed by 
the addition of DMS (10 eq) for 2 minutes then drainage of solution. 
Addition of DBU and DMS was repeated and the resin washed 1 x 5 
minutes with NMP. If removal of O-NBS protecting group was required 
mercaptoethanol (10 eq) and DBU (5 eq) in NMP was added to the resin 
and shaken for 5 minutes, drained and this step repeated. Washings with 
NMP and DMF were carried out and the next amino acid coupled 
immediately using the standard procedure.  
 
Deprotection of Alloc 
 
To one flask was added [Pd(PPh3)4] (0.1 eq) and under argon THF and 
phenylsilane (2 eq) added. This solution was added to the peptide in a 
separate flask under argon. The reaction was stirred for 1 hour at room 
temperature, volatiles evaporated and purification by silica column carried 
out.  
 
Peptides 3.2.2-3.2.5 were made by general procedure for solid phase 
synthesis (1). All were used without further purification. 
 
3.2.2. White powder (0.242 g, 0.341 mmol, 52%); MS: C35H55N7O10S m/z 
calc. for [M+H] += 776.36 , found: 775.93; HPLC: 81%. 
 
3.2.3. White powder (41%); MS: C41H68N8O12S m/z calc. for [M+Na] += 
919.46 , found: 919.58; HPLC: 100%. 
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3.2.4. White powder (0.0409 g, 0.034 mmol, 13%); MS: C47H79N9O13S m/z 
calc. for [M+H] += 1032.54 , found: 1032.94 [M+K] + = 1048.52 Found: 
1049.93; HPLC: 90%. 
 
3.2.5. White powder (0.130 g, 0.115 mmol, 44%); MS: C53H90N10O14S m/z 
calc. for [M+Na] += 1145.63, found: 1146.12 [M+K] + = 1161.60  Found: 
1163.22; HPLC: 91%. 
 
Peptides 3.2.6-3.2.9 were made by general procedure for cyclisation of 
truncated analogues. Purification was carried out by reverse phase HPLC.  
 
3.2.6. Colourless oil (1.85 mg, 1%); MS: C34H53N7O9 m/z calc. for [M] += 
735.36, found: 735.81; HPLC: 94%. 
 
3.2.7. Colourless oil (0.54 mg, 7%); MS: C41H66N8O11 m/z calc. for 
[M+Na+H] += 903.08, found: 903.57; HPLC:  
 
3.2.8. Colourless oil (0.1 mg, 1%); MS: C47H77N9O12 m/z calc. for 
[M+Na+H] += 1014.53, found: 1014.53; HPLC: 64%  
 
Peptides 3.2.10-3.2.11 were made by general procedure for global 
deprotection.  
 
3.2.10. White solid (impure, needs additional purification); MS: C23H40N7O7 
m/z calc. for [M+Na]+= 526.30, found: 526.32; HPLC: N/A. 
 
3.2.11. Orange oil (impure, needs additional purification); MS: C24H42N8O8 
m/z calc. for [M+Na] += 593.30, found: 594.5018; HPLC: 34%. 
 
Peptides 3.2.33-3.2.45 were made by general procedure for solid phase 
synthesis (2). With the exception of peptides marked with * all were purified 
by silica column using DCM:MeOH:AcOH. All peptides marked with * were 
purified by C18 silica using MeOH:H2O 
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3.2.33*. Off-white crystals crystal (0.110 g, 0.063 mmol, 42%); MS: 
C71H102N8O13 m/z calc. for [M+Na] + = 1185.48, found: 1184.23; [M+K] + = 
1201.48, found: 1200.19; HPLC: 25%. 
  
3.2.34. Off-white crystals (0.274 g, 0.215 mmol, 29%); MS: C71H102N8O13 
m/z calc. for [M+NH4] + = 1292.79, found: 1292.7904; HPLC: 79%. 
 
3.2.35. White powder (0.056 g, 0.090 mmol, 60%); MS: C29H51N7O11 m/z 
calc. for [M+Na] + = 696.35, found: 696.16; [M+K] + = 712.33, found: 
712.16; HPLC: 72%. 
 
3.2.36. White powder (0.110 g, 0.063 mmol, 42%); MS: C58H76N8O12 m/z 
calc. for [M+Na] + = 1099.55, found: 1100.78; [M+K] + =1115.52, found: 
1117.78; HPLC: 69%. 
 
3.2.41. White crystal (0.110 g, 0.063 mmol, 42%); MS: C65H91N7O12 m/z 
calc. for [M+Na] + = 1185.48, found: 1184.23; [M+K] + = 1201.48, found: 
1200.19; HPLC: 98%. 
 
3.2.42. White powder (0.122 g, 0.080 mmol, 53%); = MS: C89H113N9O14 m/z 
calc. for [M+Na] + = 1555.93, found: 1555.29; [M+K] + = 1571.93, found: 
1571.20; HPLC: 96%. 
 
3.2.43. White powder (0.115 g, 0.090 mmol, 60%); MS: C71H102N8O13 m/z 
calc. for [M+Na] + = 1298.64, Found: 1297.99; [M+K] + = 1314.64, Found: 
1313.05 (8-10); HPLC: 91%. 
 
3.2.44. White precipitate (0.129 g, 0.107 mmol, 72%); MS: C67H94N8O12 m/z 
calc. for [M+K] + = 1242.53, Found: 1242.37; HPLC: 83%. 
 
3.2.45. White crystals (0.101 g, 0.082 mmol, 55%); MS: C68H96N8O13 m/z 
calc. for [M+H] + = 1233.56, Found: 1233.86; HPLC: 85%. 
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3.2.38. White powder (81.4 mg, 49%); MS: C61H82N8O12 m/z calculated for 
[M+Na]+ = 1142.37, found 1142.43, [M+K]+ = 1158.37, found 1158.42; 
HPLC: 92%. 
 
3.2.37*. White precipitate (18.9 mg, 17%); MS: C34H61N7O11 m/z calculated 
for [M+Na]+ = 766.9, found 766.25, [M+K]+ = 782.9, found 782.2; HPLC: 
62% 
 
3.2.29*. White precipitate (); MS: C34H61N7O11 m/z calculated for [M+Na]+ = 
766.9, found 766.25, [M+K]+ = 782.9, found 782.2; HPLC: 75% 
 
3.2.40. White powder (130 mg, 73%); MS: C67H94N8O12 m/z calculated for 
[M+Na]+ : 1212.51 (found 1211.86); HPLC: 85% 
 
 
The following synthesis was carried out in the laboratory of Professor Doi 
in Tohoku University, Japan.  
 
General procedure for solid phase synthesis using lanterns.  
 
First amino acid addition 
 
The lanterns were swollen for 5 minutes in 3 mL dry DCM, before addition 
to a solution of 9:1 DCM:AcCl. The solution was shaken for 4 hours, 
drained and the lanterns added to a 0.1M solution of amino acid and 0.2 M 
DIPEA  solution in DCM. After overnight shaking the lanterns were 
washed with 5x DCM x 5 minutes. The loading was then measured by 
cleavage of 1 resin with a 30% solution of HFIP in DCM.  
 
 
 
 
Amino acid coupling 
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The Fmoc was deprotected with a 20% piperidine in DMF solution for 1 
hour (shaking). The lanterns were then washed with DMF (5 x 5 minutes). 
A coupling solution of 0.1 M Fmoc amino acid, 0.1 M DIC and 0.15M HOBt 
in DMF and shaken overnight. The solution was drained, washed with 
DMF ( 5 x 5 minutes) and DCM (3 x 5 minutes). The reaction was 
monitored by LC-MS.  
 
Cleavage 
 
The lanterns were cleaved with 30% HFIP in DCM. 
 
3.3.3 
L-Aspartic acid (10.025g, 75.1 mmol) was dissolved in 
MeOH (250 mL) and TMSCl (17.9 g, 20.9 mL) added at 
0oC. The resulting solution was stirred for 30 minutes and 
then concentrated to approximately half the volume. Diethyl 
ether was added to precipitate and the resulting white solid filtered and 
dried under vacuum and used without further purification in the next 
reaction, white powder (9.55 g, 64.5 mmol, 86%); 1H NMR (400 MHz, 
CD3OD) δ 4.16 (dd, J = 6.9, 4.5 Hz, 1H), 3.66 (s, 3H), 2.94 (d, J = 4.5 Hz, 
1H), 2.91 (d, J = 6.9 Hz, 1H) 
 
3.3.4 
A solution was made of 3.3.3 in 1:1 dioxane:water (200 
mL). Na2CO3 (15.9 g, 150 mmol) and Boc2O (24.6 g, 113 
mmol) added at 0oC and the solution stirred at rt 
overnight. The reaction was the acidified to pH 4, 
concentrated, extracted with 3 x 100 mL EtOAc, washed with brine, dried 
(MgSO4), filtered and evaporated. The resulting white solid was used 
without purification in the next stage of the reaction white powder (20.7 g, 
83.7 mmol, 56%); 1H NMR (400 MHz, CDCl3) δ 5.64 (d, J = 8.5 Hz, 1H), 
3.63 (s, 3H), 2.93 (d, J = 4.4 Hz, 1H), 2.81 (d, J = 4.8 Hz, 1H), 1.37 (s, 9H) 
 
3.2.52 
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Compound 3.3.4 (18.6 mmol) was dissolved in dry DCM and 
trichloroacetimidate (26.9 mL, 150 mmol, 2 eq) was 
added. After overnight stirring at room temperature the 
solution was quenched with 1M HCl (75 mL) and 
extracted with DCM (75 mL), washed with saturated 
NaHCO3 and brine, then dried (MgSO4), filtered and 
evaporated. Further purification was carried out by silica column (15:1 
Hexane:EtOAc) to give a yellow oil (16.52 g, 74%); 1H NMR (400 MHz, 
CDCl3) δ 5.44 (d, J = 8.0 Hz, 1H), 4.48-4.42 (m, 1H), 3.69 (s, 3H), 2.95 
(dd, 16.6 Hz, 4.4 Hz, 1H), 2.76 (dd, 16.6, 4.9 Hz, 1H), 1.45 (s, 18H) 
 
 3.2.55 
1M aqueous LiOH (48.4 mL) was added to a solution of 
3.2.52 (7.328 g, 24.2 mmol) in THF (48 mL) at 0 °C. The 
reaction was monitored by TLC, quenched with 10% 
aqueous citric acid, concentrated, then extracted with 
EtOAc, washed with brine, dried (MgSO4), filtered and concentrated. 
Further purification was carried out by silica column (1:1 hexane:EtOAc) to 
give a white solid (6.414 g, 92%) 
1H NMR (400 MHz, CD3OD) δ 4.25 (t, J = 6.0 Hz, 1H), 2.64 (d, J = 1.8 Hz, 
1H), 2.63 (d, J = 2.3 Hz, 1H), 1.36 (s, 9H), 1.35 (s, 9H); 13C NMR (100 
MHz, CD3OD) δ 172.7, 170.6, 156.3, 81.6, 79.3, 50.9, 36.0, 27.3, 26.8. 
 
3.2.53 
A solution of 3.2.52 in toluene was cooled to -78oC. 
DIBAL (1.1 eq) was added dropwise and the solution 
stirred for 5 minutes before quenching with acetone (0.5 
mL) and water (0.5 mL). Approximately 1g of NaHCO3 
was added before warming to room temperature and filtered through celite 
with a pad of NaHCO3 with EtOAc washing. After concentration of the 
solution purification was carried out with silica column (2:1 Hexane:EtOAc) 
to give a mixture of products (0.054 g, 12% 3.2.53); 1H NMR (400 MHz, 
CDCl3) δ 9.74 (s, 1H), 5.46-5.33 (m, H), 4.49-4.46 (m, 1H), 3.71-3.69 (m, 
1H), 3.07-2.91 (m, 2H), 1.45 (s, 9H), 1.44 (s, 9H). 
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3.2.54 
A solution of 3.2.52 in THF was cooled to -10oC and 
triethylamine and ethyl chloroformate added dropwise. 
After stirring at -10 oC for 30 minutes the mixture was 
filtered and slowly added to NaBH4 in water at 0oC. After stirring at room 
temperature and monitoring the solution was acidified with 1M HCl. The 
aqueous phase was then extracted with EtOAc and the combined organic 
extracts washed with saturated NaHCO3 and brine, dried (MgSO4), filtered 
and evaporated and used without purification in the next stage.   
 
3.2.53 
NaHCO3 (10 eq) was added to a solution of 3.2.54 
(0.0744 g, 0.27 mmol) in DCM, followed by DMPI (0.172 
g, 0.41 mmol) as a 0.3M DCM solution. After stirring for 
1 hour a 1M sodium thiosulfate was added, followed by 
5 minutes of stirring, the extraction of the product with DCM, drying and 
evaporation of volatiles. Purification was carried out by column (8:2 
Hexane:EtOAc) to give 3.2.53 in quantative yield. NMR as previous 
 
3.2.56/3.2.59 
To a DCM (84 mL) solution of 3.2.53 (1.0 g, 3.66 
mmol) was added the relevant Co catalyst (10 mol%) 
and nitromethane (7.9 mL). The mixture was cooled to 
-78oC and DIPEA added and stirred for 3 days at -
78oC. After warming to room temperature and quenching with saturated 
aqueous NH4Cl the crude product was extracted with DCM, washed with 
brine, dried, filtered and evaporated. Purification was carried out by silica 
column (Et2O:DCM) to give an off white solid (0.725 g, 60%): 1H NMR 
(400 MHz, CDCl3) δ 5.42-5.30 (m, 1H), 4.58-4.52 (m, 1H), 4.48-4.46 (m, 
2H), 4.28-4.26 (m, 1H), 2.10-2.07 (m, 1H), 1.93-1.86 (m, 1H), 1.45 (s, 9H), 
1.43 (s, 9H);  
 
3.2.57 
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To a solution of 3.2.56 (0.200 g, 0.598 mmol) in MeOH (2 
mL) was added ammonium formate (0.377 g, 5.98 mmol) 
and 10% Pd/C and the solution stirred at -10 °C for 4 hours 
before filtration through celite. After concentration the 
residue was dissolved in EtOAc and basified with saturated NaHCO3. The 
EtOAc was separated and the aqueous layer extracted twice. The 
combined layers were washed with brine, dried and filtered. The volatiles 
were evaporated and the residue used without purification. This stage was 
repeated twice.  
 
The residue from the previous reaction was dissolved in dioxane and 
water and triethylamine and Goodman’s reagent added. The solution was 
stirred at room temperature overnight before quenching with saturated 
ammounium chloride. The aqueous layer was then separated and 
extracted with EtOAc. The combined EtOAc layers were washed with 
brine, dried with MgSO4 and filtered. After evaporation of the volatiles the 
residue was purified by silica column (toluene:EtOAc 8:1) to give 3.2.57 as 
a white powder (0.029 g, 0.071 mmol, 12%); 1H NMR (400 MHz, CDCl3) δ 
11.7 (s, 1H), 8.69 (t J = 5.2 Hz, 1H), 7.36-7.27 (m, 10H), 5.40 (s, 1H), 5.18 
(s, 2H), 5.10 (s, 2H), 4.53 (s, 1H), 4.26-4.16 (m, 1H), 4.00-3.89 (m, 1H), 
3.68-3.57 (m, 1H), 3.45-3.34 (m, 1H), 2.01-1.91 (m, 1H), 1.86-1.76 (m, 
1H), 1.43 (s, 18H).  
 
Compound 3.2.57 (0.186 g) was dissolved in DCM (8 
mL) and triethylamine (2 eq) and MsCl (0.027 g) 
added. After stirring for 2 hours at room temperature 
the reaction was quenched with 1M HCl. The aqueous 
layer was separated and extracted with EtOAc. The 
combined EtOAc were washed with brine, dried (MgSO4), filtered and 
evaporated. The crude residue was then dissolved in DCM and DBU (2 
eq) added, then stirred for 4 hours, quenched with 1M HCl. The aqueous 
was separated and extracted with EtOAc and the combined organic layers 
washed with brine, dried (MgSO4), filtered and evaporated. The residue 
was purified by silica column (toluene:EtOAc 5:1) to give 3.2.61 (0.123 g); 
1H NMR (400 MHz, CDCl3) δ 8.63 (s, 1H), 7.46-7.30 (m, 10H), 5.28 (s, 
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2H), 5.11 (m, 3H), 4.63-4.47 (m, 1H), 4.18-4.06 (m, 1H), 3.83-3.68 (m, 
1H), 3.65-3.52 (m, 1H), 2.33-2.21 (m, 1H), 1.96-1.82 (m, 1H), 1.43 (s, 
18H);  
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Chapter Four 
4. Synthetic studies towards telomycin analogues 
 
4.1 Introduction to Chapter Four 
 
Telomycin (Figure 4.1.1 B)) is part of a family of cyclic depsipeptides made 
up from the amino acids serine, allo-threonine, threonine, alanine, glycine, 
dehydrotryptophan, β-methyltryptophan, 3-hydroxyproline and 3-
hydroxyleucine and often aspartic acid. So far, four members of the family 
have been identified; neotelomycin207 (consisting of the two cyclic 
depsipeptides A-128-OP and A-128-P), LL-A-0341B208,209 (also called LL-
A-0341β1) and telomycin210.  
 
Figure 4.1.1: A) The telomycin structure originally reported, B) corrected structure and 
the related depsipeptides C) A-128-P and D) A-128-OP. 
 
4.1.1 Extraction of telomycin 
 
The extraction of the depsipeptide antibiotic telomycin was first reported 
by Miesk. et al. in 1958210. It was reported as a colourless solid extracted 
from a culture broth of unidentified Streptomyces and identified as an 
active antibiotic against Gram-positive bacteria, with an MIC of 8 µg mL-1 
against Staphylococcus aureus. However, it showed little activity against 
Gram-negative bacteria. A further paper published in 2013211 separately 
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reported that a different bacteria, Micromonospora schwarzwaldensis sp. 
nov. also produced telomycin. 
 
4.1.2 Structure of telomycin 
 
A proposed structure of telomycin was published in a 1963 
communication212, with a more detailed paper following in 1968.210 Using a 
variety of degradation studies the structure was determined to be made up 
of 11 amino acids, including three new amino acids erythro-β-
hydroxyleucine, cis-3-hydroxyproline and trans-3-hydroxypropline. The 
initially proposed structure is shown in Figure 4.1.1, with all amino acids in 
the L stereochemistry.  
Two papers using 1H NMR to confirm the identity of the amino acids in 
telomycin were later published. The first paper, published in 1973213, used 
220 MHz 1H NMR to assign the signals of the spectrum, further confirming 
the identity of the amino acids making up telomycin. A second paper, also 
published in 1973214, focused on the conformation of telomycin in solution 
and made several suggestions for possible conformations.  
 
4.1.3 Studies into other members of the telomycin family, leading to 
structural reassignment 
 
Between 1970 and 1975 a series of papers about the structure of the 
related antibacterial depsipeptides A-128-P and A-128-OP were 
published207,215,124,216,217,218. These related structures were found to be two 
components of the natural product neotelomycin and were both reported 
as showing biological activity against S. aureus of 10 g mL-1. Both A-128-
P and A-128-OP (Figure 4.1.1 C) and D)) were found to consist of L-
threonine, L-alanine, glycine, L-cis-3-hydroxyproline, L-hydroxyleucine, L-
β-methyltryptophan and dehydrotryptophan. Like telomycin, A-128-OP 
also contains L-trans-3-hydroxyproline. However, in A-128-P this is 
replaced by L-proline. Unlike telomycin both A-128-P and A-128-OP also 
contain 3 D-amino acids; D-aspartic acid, D-serine and D-allo-threonine. 
These three amino acids make up the linear tail of the macrocycle with 
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cyclisation taking place between L-threonine and L-cis-hydroproline, giving 
a smaller macrocyclic ring size than telomycin.   
 
The assumption so far was that the primary structure of each member of 
the telomycin family was the same sequence as published in 1968 for 
telomycin. However, Silaev, Katrukha et al proposed a modification of the 
structure of A-128-OP in 1976. By using NBS219 to cleave the peptide at 
the tryptophan residues it was discovered that a dipeptide made of L-cis-
hydroxyproline and L-hydroxyleucine was obtained. This proved that L-
hydroxyleucine must be coupled to the C-terminal L-cis-hydroxyproline 
and β-methyltryptophan, giving the revised structure shown in Figure 
4.1.1.  
 
The same method was used for a related peptide, initially called A-128-
Hyp220. Alkaline cleavage of the lactone ring followed by treatment with 
NBS gave identical peptides for both A-128-Hyp and telomycin, leading to 
the reassignment of telomycin as the structure shown in Figure 4.1.1 B).  
The next paper dealing with the structure of telomycin was not published 
until 2015221. This paper published the data for biosynthesis of telomycin 
and confirmed the revised structure of telomycin. This paper confirmed the 
synthesis of telomycin by a nonribosomal peptide synthetase. Additionally, 
further details of the coupling of the peptide followed by cyclisation and 
modification by enzymes of the proteinogenic amino acids to give 
telomycin were given.   
 
4.1.4 Unnatural analogues of the telomycin family 
 
The structures of A-128-P and A-128-OP were first modified in 1973215,222. 
Several moieties were added to the N terminus including acyl, benzoyl and 
succinyl. All modifications of this type showed a drop in activity, sometimes 
only showing 1% of the biological activity of the parent compound.  
In contrast to these findings, the more lipophilic analogues (Figure 4.1.2 2-
5)221 of telomycin made by semi-synthesis in 2015 have been shown to 
have increased activity. During an investigation into the biosynthesis of 
telomycin several intermediates from biosynthesis were collected. The 
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only active intermediate differed from telomycin only by one less 
hydroxylation of a proline. However, deactivation of the tem25 gene 
cluster led to an intermediate (Figure 4.1.2, 2) acylated at the N-terminus 
of telomycin by 6-methylheptanoic acid (Figure 4.1.2 2) which showed 
better activity than telomycin. The semisynthetic derivatives with more 
lipophilic acyl groups were made using this pathway. The most active of 
these was the n-dodecanoyl derivative (Figure 4.1.2 5).  
 
  
 
Figure 4.1.2: 2) A biosynthesis intermediate with better activity than telomycin, and 3-5) 
semisynthetic derivatives based on 2. 
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4.1.5 Other Analogues of telomycin 
 
The final member of this family is LL-A-0341β1. First isolated in 1966 with 
the correct structure (Figure 4.1.3) reported in a 1993 paper208, this 
peptide is the most dissimilar member of the group with a truncated tail 
consisting of only serine and L-proline. Despite the shortened linear 
peptide tail LL-A-0341β1 still shows good antibacterial activity.  
 
Another natural analogue was proposed in 2015223. Isolated from 
Streptomyces ambofaciens F3, the only difference between telomycin and 
ambobactin appears to be the stereochemistry of the novel amino acid 3-
methyltryptophan. In ambobactin,3-methyltryptophan has a D-
configuration compared to the L-configuration of telomycin. However, 
further studies are needed before confirmation of ambobactin as a new 
member of this family.   
 
 
Figure 4.1.3: LL-A0341-B1. 
 
4.1.6 Mode of action of telomycin 
 
Despite its discovery in 1958 and subsequent investigations in 1968 and 
1973, the mode of action of telomycin was not reported until 2016209. As 
part of a study into antibiotics showing specific activity on previously 
unknown targets, telomycin was chosen as an example of a class of new 
antibiotics. 
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A previous study on the mode of action of LL-A0341β1 208  (Figure 4.1.4) 
concluded that the cytoplasmic membrane was the area targeted by the 
macrocycle, also accounting for the inactivity of the telomycin family in 
Gram-negative bacteria. However, the study did not identify a specific 
target for LL-A0341β1 and therefore the telomycin family.  
The report in 2016 carried out a series of experiments revealing three 
things. Telomycin resistant bacteria have mutations in the genes encoding 
cardiolipin, telomycin is more active when more cardiolipin is produced by 
the bacteria and an opaque solution is formed when telomycin is added to 
a solution of cardiolipin.  
 
Cardiolipin is a diphosphalidylglycerol lipid found in the inner mitochondrial 
membrane and in bacterial membranes. This finding is in agreement with 
the previous paper on the mode of action of LL-A0341β1208.  
The mode of action also explains the activity of the semi-synthetic 
derivatives of telomycin shown in Figure 4.1.2. The increased 
hydrophobicity probably improves the activity by increasing the binding to 
the hydrophobic membrane, the site of cardiolipin.  
 
4.1.7 Potential for research into telomycin 
 
As has been proven by the synthesis of semi-synthetic analogues with 
greater activity than telomycin224 itself and by the discovery of the novel 
mode of action of telomycin209, telomycin and related compounds are good 
candidates for medicinal chemistry research into the next generation of 
antibiotics.  
 
Research into telomycin was firstly carried out by Takahiro Noro at the 
University of East Anglia, August-November 2016 (unpublished work, 
marked with * here).  All synthetic work from 4.2.3 onwards was carried out 
by Verity Buckingham while under my supervision at the University of East 
Anglia, October 2017-March 2018 (unpublished work). 
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4.2 Research into telomycin 
 
For the purposes of the research carried out, the most recently reported 
sequence of amino acids reported is used (Figure 4.1.1 B) rather than A)). 
 
As shown previously, many of the amino acids in telomycin are non-
proteinogenic. Therefore, to make a cheaper analogue and test structure 
activity relationship all non-proteinogenic amino acids are replaced by a 
proteinogenic amino acid.  
 
The first strategy for making analogues is shown in Figure 4.2.1, with all 
replaced amino acids highlighted. 3-Hydroxyproline is replaced with NMe 
threonine, both modified tryptophans replaced by proteinogenic tryptophan 
and hydroxyleucine with threonine.  
 
 
Figure 4.2.6: Replacement of non-proteinogenic amino acids by proteinogenic amino 
acids.  
 
The retrosynthetic analysis of the telomycin analogue is shown below in 
Figure 4.2.2. As for teixobactin in the previous chapter the first 
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disconnection is to separate the linear chain from the macrocycle and 
synthesise both separately. However, unlike teixobactin the synthesis of 
the linear tail is uncomplicated since it consists of only two amino acids 
with the remaining nine amino acids making up the macrocycle. As 
mentioned previously, the preferred method for small amounts of peptides 
is solid phase synthesis. Therefore, this method will be used to make the 
linear precursor to the macrocycle. As for teixobactin, trityl chloride resin is 
used for the synthesis since this allows cleavage of the resin under mildly 
acidic conditions to give a carboxylic acid group but leaves the side chain 
protecting groups intact.225 As for the synthesis of teixobactin, an acid 
group and protected side chain are important for the next stage of 
macrocyclisation. However, for the telomycin analogue macrolactamisation 
rather than macrolactonisation is used to carry out cyclisation. The 
position of cyclisation is chosen as the amide bond between glycine and 
alanine, the two least sterically hindered amino acids.  
217 
 
 
Figure 4.2.2: Reterosynthetic analysis of initial target of telomycin analogue. 
 
4.2.1 Initial attempts at synthesis of the analogue 
 
The majority of the amino acids used here are commercially available 
Fmoc amino acids with acid labile protecting groups.  
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One of the amino acids to be made is Alloc-Thr-OH. The amine is 
protected with the orthogonal Alloc protecting group to allow ester bond 
formation to the free hydroxyl, as also used in the synthesis of the 
macrocycle of teixobactin. The carboxyl and hydroxyl are left free for on-
resin coupling. The same method as used in Chapter 3 to make Alloc-D-
Thr-OH could be used here.  
 
The N-methylated threonine is not commercially available. Initial 
unpublished attempts at synthesis within the group* focused on solution 
phase synthesis of the N-methylated threonine, followed by solid phase 
coupling. However, this was found to be time-consuming and inefficient 
with several steps needed to add the methyl. The hydroxyl protecting 
group also needed to be changed to a benzyl group, complicating the final 
global deprotection. Attempts at synthesis using the products in solid 
phase synthesis of the macrocycle were unsuccessful. Since monitoring 
by mass spectrometry was not possible at the time it was not clear when 
the synthesis failed.  
 
An alternative method226 of N-methylation, briefly explored in the linear 
chain synthesis of teixobactin, is to carry out methylation on resin.  
 
4.2.2 Attempted synthesis of first analogue 
 
Therefore, on-resin synthesis was started with the addition of Fmoc-Ala-
OH to trityl chloride resin and coupling (and on-resin methylation) carried 
out until the fifth amino acid (Figure 4.2.2) to give resin bound 4.10. 
Cleavage of a small amount of resin was carried out and the resultant 
peptide analysed by HPLC and MALDI (Figure 4.2.3). This showed 
although not pure, a mass corresponding to methylation and addition of 
the next amino acid had taken place.  
 
However, the coupling of the next amino acid was less successful. The 
first attempt at coupling used Fmoc-Trp-OH for the sixth amino acid. This 
coupling was unsuccessful so was repeated instead using Fmoc-Trp(Boc)-
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OH. This was also unsuccessful. Doubling the amount of coupling agents 
also did not have a significant effect on the success of the coupling.   
 
 
 
Figure 4.2.3: The first five amino acids of 4.9, with MALDI showing [M+H]+ = 983, 
[M+Na]+ = 1004 and [M+K]+ = 1020.  
 
4.2.3 New strategies 
 
Since it was proven that the first five amino acids (Figure 4.2.3) could be 
added to the resin, a 1g batch**2of resin bound pentapeptide was 
prepared. This was then split into 5 equal portions to investigate conditions 
for the coupling of the sixth amino acid in the sequence.  
 
Since all previous couplings using coupling agents had failed, the acid 
chloride of Fmoc-Trp(Boc)-OH was prepared. Although not reported to be 
used for Fmoc-Trp(Boc)-OH, the general synthesis of Fmoc acid chlorides 
is well known227 and proceeded smoothly and in good yield to give Fmoc-
Trp(Boc)-Cl, 4.12 (Figure 4.2.4). Several attempts of couplings using 4.12 
were then carried out.  
 
                                                          
* Synthesis in this paragraph carried out by Takahiro Noro at the University of East Anglia, 
August-November 2016 (unpublished work).   
 
** Synthesis in this section carried out by Verity Buckingham under my supervision at the 
University of East Anglia, October 2017-March 2018 (unpublished work). 
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Figure 4.2.4: Synthesis of Fmoc-Trp(Boc)-Cl. 
 
To test the conditions the resin bound peptide shown in Figure 4.2.3 was 
divided into several portions. For the first conditions Fmoc deprotection 
was carried out on 1/5 of the resin bound peptide and couplings using 2 
eq. of Fmoc-Trp(Boc)-Cl and 5 eq of collidine ran for 1 hour. The Kaiser 
test was negative so the same conditions were used to attempt to add 
another Fmoc-Trp(Boc)-Cl. However, after using the same conditions 4 
times the Kaiser test was still turning blue. Cleavage of the resin and 
MALDI of the product confirmed that the reaction was unsuccessful.  
 
A second attempt to make the linear precursor of the telomycin analogue 
again used cycles of 2 eq. of 4.12 and 5 eq of collidine for 1 hour until a 
negative Kaiser test was given. After deprotection of Fmoc the second 
coupling used a different method of 4 eq. each of HOBt and DIPEA with 4 
eq of Fmoc-Trp(Boc)-Cl. MALDI showed a mass corresponding to the 
relevant peptide so synthesis of the peptide was continued to make the 
rest of the linear precursor. NMR showed a small amount of peptide had 
formed. However, purification by preparative HPLC showed none of the 
major peaks collected were the expected product. 
 
Increasing the number of equivalents to 10 and decreasing the volume 
were also unsuccessful. Therefore, to test if the problem was the amino 
acid added or the peptide chain already formed, phenylalanine was used 
instead of tryptophan. The results for this were much the same with MALDI 
showing a mass which could be assigned to the completed by-product, but 
with no product isolated by preparative HPLC. Therefore, this method was 
judged to have failed. 
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4.2.4 Different analogue tests 
 
Since it proved difficult to carry out couplings more than one amino acid 
after methylation, an analogue with no methylations was attempted (Figure 
4.2.5). Synthesis of these 4.13a and 4.13b proceeded smoothly, with the 
structures shown in Figure 4.2.6. Macrolactamisation of the crude peptide 
4.13 to give 4.14, followed by removal of the alloc protecting group to give 
4.15 was then carried out as shown in Figure 4.2.6. MALDI showed 
formation of 4.14a and 4.15a but not 4.14b and 4.15b. Upon purification, 
4.15 was coupled to the side chain 4.16 (Figure 4.2.7). 
 
 
Figure 4.2.7: The rational for the synthesis of 4.18.   
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Figure 4.2.6: Macrolactamisation and deprotection. 
 
4.2.5 Synthesis of side chain 
 
Synthesis of protected asparagine, 3.2.52 was previously carried out in the 
synthesis of enduracididine. With the exception of the addition of tert-butyl 
(different procedure listed in 4.2), all other steps are carried out in an 
identical way to the synthesis carried out in the Doi group (chapter 3.2.6). 
SPPS is then used to couple to Ser(tBu) to 3.2.52 to give 4.16. Trityl 
chloride resin preloaded with Ser(tBu) (also previously used for teioxbactin 
side chain synthesis, chapter 3.2.5) was used.  
 
Coupling and then global deprotection was then carried out as shown 
below in Figure 4.2.7 to give 4.18.   
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Figure 4.2.7: Coupling of side chain and deprotection.  
 
4.2.6 Overview to Chapter Four 
 
In summary, synthesis of peptide 4.9 was unsuccessful using both solid 
phase N-methylation and addition of N-methylated threonine to the resin. It 
was therefore not possible to make macrocycle 4.8 and analogue 4.7. 
However, synthesis of 4.13a using SPPS proceeded smoothly with MALDI 
(Appendix 3) showing formation, although HPLC showed two major peaks. 
The two products could not be separated by silica column so were used in 
a macrolactamisation to give 4.14a without further purification. Synthesis 
to give 4.18a was successfully carried out and purification attempted. 
However, although purification by HPLC was attempted the small 
quantities complicated the detection by the HPLC. Therefore, 4.18a 
overlapped with coupling agents from the synthesis of 4.17a and a pure 
yield could not be recorded. Since this method of making 4.18a has been 
proven to be successful further synthesis on larger scale could be carried 
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out and purification after the synthesis of 4.17a used to eliminate this 
problem.  
 
SPPS of 4.13b also gave two major products by HPLC (appendix) with 
MALDI showing the expected mass. However, MALDIs of 4.14b, 4.17b 
and 4.18b do not show an m/z within one mass unit of the expected 
product.   
 
4.2.7 Future work 
 
Future work should start by repeating the synthesis of 4.18a and modifying 
the synthesis to allow 4.18b to be made. This will allow further 
characterisation and purification of the final products. Using the same 
method an analogue with both 3-hydroxyprolines replaced with proline 
should also be made. Biological testing with these three products will then 
give the start of a structure-activity relationship.  
 
Since the synthesis of 4.7 has not been successful with the conditions 
attempted so far, alternative methods should be tested for methylation. If 
possible, monitoring should be carried out by LC-MS. This will allow 
quantification of the amount of product formed compared to side products 
and will allow the reason for failure to be identified more easily.  
The first amino acid to be added to the resin after methylation in each 
attempt is threonine. However, threonine is a substitute for hydroxy-
leucine (Figures 4.2.1 and 4.2.5). Therefore, another attempt should try 
using leucine to see if the synthesis proceeds more smoothly, followed by 
synthesis of hydroxyleucine and use of this in solid phase synthesis.  
If synthesis is still unsuccessful, then difficult couplings should be carried 
out in solution and added to the rest of the resin-bound peptide at a site 
that is known to couple well.  
 
Another useful part to this work could be to carry out a total synthesis of 
telomycin. If solid phase synthesis is still not possible difficult parts of the 
macrocycle could be made through solution phase synthesis (Figure 4.2.8) 
before coupling to the resin. Synthesis of modified tryptophan was started 
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while solid phase synthesis was being attempted and could be used in a 
total synthesis.   
 
Figure 4.2.8: Possible start of a total synthesis. 
 
The overall aim of any future work should be to build upon the synthesis of 
4.18a to provide a structure-activity relationship and to carry out a total 
synthesis of telomycin.  
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4.3 Experimental for Chapter 4 
 
(3S)-4-tert-butoxy-3-[(tert-butoxycarbonyl)amino]-4-oxobutanoic acid, 
4.2204,205 
 
General procedure (Chapter 3 experimental), Yellow 
solid, 16% over 4 steps: [α]23.5D -30.9 (c 0.91 in MeOH); 
ṽmax/cm-1 3425, 2981, 2933, 1738, 1746, 1696, 1502, 
1156; 1H NMR (400 MHz, CD3OD) δ 4.25 (t, J = 6.0 Hz, 
1H), 2.64 (d, J = 1.8 Hz, 1H), 2.63 (d, J = 2.3 Hz, 1H), 1.36 (s, 9H), 1.35 
(s, 9H) ppm. 13C NMR (100 MHz, CD3OD) δ 172.7, 170.6, 156.3, 81.6, 
79.3, 50.9, 36.0, 27.3, 26.8 ppm.  
 
(2S)-2-{[(3S)-3-[(tert-butoxycarbonyl)amino]-4-tert-butoxy-4-
oxobutanoyl]amino}-3-tert-butoxypropanoic acid, 4.16 
 
General procedure for solid phase synthesis (Chapter 3 experimental), 
colourless glass (0.052 g, 16%): [α]23.5 D 46.5 (c 
0.43 in MeOH); ṽmax/cm-1 3347 (br.), 2978, 2939, 
2833, 1697, 1659, 1368, 1154, 1023; 1H NMR 
(400 MHz, CDCl3) δ 6.46 (d, J = 7.5 Hz, 1H), 5.65 
(d, J = 7.7 Hz, 1H), 4.63 (ddd, J = 7.1, 5.6, 3.9 Hz, 1H), 3.89 (dd, J = 8.9, 
3.9 Hz, 1H), 3.51 (dd, J = 9.0, 5.7 Hz, 1H), 1.45 (s, J = 9.0 Hz, 9H), 1.44 
(s, 9H), 1.20 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 176.0, 173.0, 170.5, 
170.2, 163.3, 155.9, 127.9, 125.9, 82.1, 79.8, 73.8, 61.7, 52.9, 51.0, 49.8, 
38.0, 30.7, 29.8, 29.8, 28.4, 28.0, 27.4, 17.7; LRMS (MALDI-TOF): m/z 
471 ([M + K]+, 100%), 456 ([M + Na]+, 20%). 
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Fmoc-Trp(Boc)-Cl, 4.12 
 
Procedure as for ref101 
 
A solution of Fmoc-Trp(Boc)-OH (5.0 g, 9.5 mmol) in 
DCM (25 mL) was treated with SOCl2 (6.93 mL, 95 
mmol, 10 eq) and DMF (0.074 mL, 0.95 mmol, 0.1 eq). 
Stirring at room temperature with TLC monitoring 
showed complete conversion from starting material. 
Evaporation of volatiles followed by precipitation of 
product in hexane (10 mL) gave Fmoc-Trp(Boc)-Cl as a fine, off white 
powder (4.44 g, 86%): [α]23.6 D -3.0 (c 0.68 in MeOH); ṽmax/cm-1 3305, 
1749, 1690, 1453, 1368, 835, 740 (s); 1H NMR (400 MHz, CDCl3) δ 8.11 
(m, 1H), 7.67 (d, J = 7.6 Hz, 2H), 7.52 – 7.39 (m, 4H), 7.31 (m, 3H), 7.24 – 
7.16 (m, 3H), 5.42 (m, 1H), 4.89 (m, 1H), 4.40 – 4.25 (m, 2H), 4.11 (m, 
1H), 3.40 – 3.21 (m, 2H), 1.57 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 
174.5, 155.7, 155.5, 143.6, 141.4, 127.9, 127.2, 125.1, 125.1, 125.1, 
124.8, 124.8, 123.1, 120.1, 118.7, 115.7, 113.5, 84.2, 67.6, 63.0, 47.1, 
31.0, 28.3; LRMS (MALDI-TOF): m/z 533 ([M-Cl-Na]+, 100%), 568 
([M+Na]+, 10%), 596 (47%). 
 
N-[(tert-butoxy)carbonyl]-Indole-3-carboxyaldehyde, 4.22 
To a DCM (50 mL) solution of indole-3-carboxyaldehyde (5.0 
g, 34.5 mmol) was added DMAP (2.10 g, 17.3 mmol), DIPEA 
(9.0 mL, 51.7 mmol) and Boc2O (11.3 g, 51.7 mmol). The 
resulting reaction mixture was stirred for 2 hours, then washed with 1M 
HCl (2 x 100 mL), sat. NaHCO3 (2 x 100 mL) and brine (80 mL). The 
organic layer was dried (MgSO4) and concentrated to give 4.22 as a white 
solid (6.89 g, 82%): [α]23.5 D -59.3 (c 1.98 in MeOH); ṽmax/cm-1 2990, 2814, 
1741, 1676, 1357, 1241, 1133, 760; 1H NMR (400 MHz, CDCl3) δ 10.10 (s, 
1H), 8.31 – 8.26 (m, 1H), 8.23 (s, 1H), 8.15 (d, J = 7.9 Hz, 1H), 7.44 – 7.34 
(m, 2H), 1.71 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 185.8, 148.8, 136.5, 
136.0, 126.1, 126.1, 124.6, 122.2, 121.6, 115.2, 85.7, 28.1. 
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Methyl (2E)-2-[(tert-butoxycarbonyl)amino]-3-(1-[(tert-
butoxycarbonyl)amino]-1H-indol-3-yl)prop-2-enoate, 4.19 
 To a solution of phosphonoglycine in methyl tri-
methyl ester (1.60 g, 5.38 mmol) in DCM (15 mL) 
was added DBU (0.74 mL, 4.95 mmol). After 20 
minutes a solution of 4.22 (1.10 g, 4.49 mmol) in 
DCM (10 mL) was added dropwise. After stirring for 
3 hours at room temperature the reaction mixture 
was washed with 5% citric acid (2 x 20 mL) and brine (80 mL). The organic 
phase was dried (MgSO4), filtered and concentrated and the residue 
purified by silica column (PE:EtOAc) to give 6 as a white solid (1.13 g, 
60%): [α]23.5 D 31.1 (c 0.87 in MeOH); ṽmax/cm-1 3387, 2982, 1743, 1727, 
1715, 1231, 1087, 772, 762, 754; %). 1H NMR (400 MHz, CDCl3) δ 8.15 
(d, J = 8.2 Hz, 1H), 7.94 (s, 1H), 7.71 (d, J = 7.6 Hz, 1H), 7.59 (s, 1H), 
7.32 (dtd, J = 24.3, 7.4, 1.1 Hz, 2H), 3.88 (s, 3H), 1.68 (s, 9H), 1.45 (s, 
9H); 13C NMR (101 MHz, CDCl3) δ 166.0, 149.4, 135.0, 129.7, 127.5, 
125.2, 123.3, 122.5, 119.2, 115.5, 114.5, 84.6, 81.1, 52.7, 28.4, 28.3; 
LRMS (MALDI-TOF): m/z 455 ([M + K]+, 78%).  
 
Peptides 4.13a and 4.13b 
Solid phase synthesis (General procedure C) was used to make 4.13a and 
4.13b, which were used without purification in cyclisation.  
 
Cyclodepsipeptides 4.14a and 4.14b and 4.15a and 4.15b 
To a stirred solution of 4.14 in DCM (2 mM) was added HATU (1.2 eq) and 
DIPEA (10 eq). After overnight stirring at room temperature the volatiles 
were evaporated under vacuum, the residue analysed by MALDI and 
HPLC and used without purification in the general procedure for alloc 
deprotection. Purification was carried out by flash column chromatography 
(DCM:MeOH) to give 4.15a as a yellow solid (0.178 g, 89%) and 4.15b as 
a yellow solid (0.092 g, 38%).  
 
Telomycin analogues 4.18a and 4.18b 
To a solution of 4.15 in DMF was added DEPBT (2.5 eq), DIPEA (10 eq) 
and 4.16 (1.5 eq). After overnight stirring at room temperature the solution 
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was concentrated, analysed by HPLC and MALDI, then used without 
purification in the general procedure for acid labile protecting group 
removal to give 4.18a and 4.18b. 
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Overall conclusion 
 
The overall aim of this project was to carry out research into a new 
generation of antibiotics based on the three selected natural products. 
 
For hunanamycin, a promising start has been made, with a new route 
discovered which can be easily adapted for analogue synthesis. 
 
For teixobactin, promising initial results into the macrocycle have been 
achieved. However, further work is required to produce viable analogues.  
 
Several problems were encountered with the research into telomycin. 
However, these problems may relate to the many amino acids substituted 
in the analogues compared to the natural product. Therefore, a further 
structure activity relationship could reveal analogues which are easier to 
make, in addition to increased biological activity.  
 
In conclusion, the overall aim has been met, with significant research 
carried out into natural product based antibiotic candidates.  
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Abbreviations 
Ac = Acetyl 
Alloc-Cl = Allyl chloroformate 
Bn = Benzyl 
Boc = tert-Butyloxycarbonyl 
tBu = tert-butyl 
Bz = Benzoyl 
oC = Degrees centigrade 
Cbz = carboxybenzyl 
cm-1 = Wave numbers 
DBU = 1,8-diazobicyclo[5.4.0]undec-7-ene 
DCC = N,N-dicyclohexylcarbodiimide 
DIBAL = Diisobutylaluminium hydride 
DIC = Diisopropyl carbodiimide 
DIPEA = N,N-Diisopropylethylamine 
DCM = Dichloromethane 
DMAP = N,N-4-Dimethylaminopyridine 
DMAPO = 4-(Dimethylamino)pyridine N-oxide 
DMPI = Dess–Martin periodinane 
DMF = N,N-Dimethylformamide 
EDC/EDCI.HCl =  1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride 
EtOAc = Ethyl acetate 
Fmoc = Fluorenylmethyloxycarbonyl  
g = grams 
HATU =  N-[(Dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-
ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide 
h = hour 
HOBt = 1-Hydroxybenzotriazole 
HPLC = High-performance liquid chromatography 
IR = Infrared  
LC-MS = Liquid chromatography–mass spectrometry 
M = Molar 
MALDI = Matrix Assisted Laser Desorption/Ionization 
Me = methyl  
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MeCN = acetonitrile 
MeOH = methanol 
mg = milligrams 
mins = minutes 
mL = millilitres 
mmol = millimoles 
MNBA = 2-Methyl-6-nitrobenzoic anhydride 
MsCl = Methanesulfonyl chloride 
NBS = N-Bromosuccinimide 
NMR = Nuclear Magnetic Resonance 
O-NBS = 4-Nitrobenzenesulfonyl  
PDC = Pyridinium Dichromate   
Prenyl = 3-methyl-but-2-en-1-yl 
PyBop = Benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate 
rt = room temperature 
SAR = Structure activity relationship 
SPPS = solution phase peptide synthesis 
TBS = tert-Butyldimethylsilyl 
TFA = Trifluoroacetic acid 
THF = Tetrahydrofuran 
TIPS = Triisopropylsilane 
TLC = Thin layer chromatography 
TMSCl = Trimethylsilyl chloride 
TMSOTf = Trimethylsilyl trifluoromethanesulfonate 
Trt = Trityl 
 
 
 
Amino acid abbreviations 
Ala = alanine 
Arg = arginine 
Asn = asparagine 
Asp = aspartic acid 
Gln = glutamine 
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Gly = glycine 
Ile = isoleucine 
Leu = leucine 
Lys = lysine 
Phe = phenylalanine 
Pro = proline 
Ser = serine 
Thr = Threonine 
Trp = Tryptophan 
Val = valine 
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Appendix 1  
NMRs from important stages of Chapter 2. 
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Hunanamycin A 
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Appendix 2 
Example data from peptides in Chapter 3.  
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Depsipeptide 3.2.6 
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 Peptide 3.2.3 
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 Depsipeptide 3.2.11 
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Peptide 3.2.43 
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Appendix 3 
HPLC and MALDI data from Chapter 4. 
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Peptide 4.14a  
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Peptide 4.17a 
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Peptide 4.18a 
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Peptide 4.13b 
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 (Peptide 4.10 precursor) 
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Peptide 4.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
